The adaptive immune response to Epstein-Barr virus by Rist, Melissa
 
 
 
 
 
 
The adaptive immune response to Epstein-Barr virus 
Melissa Jane Rist (nee Bell)  
B. App. Sc. (Hons) 
 
 
 
 
 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy at 
The University of Queensland in 2015 
School of Medicine 
ii 
 
Major histocompatibility complex (MHC) class I molecules form medleys with peptide 
antigens which are expressed on the cell surface for recognition by CD8+ T cells.  Derived from 
antigens synthesized in the cytoplasm, these peptides are generally 8-10 amino acids in length.  For 
most MHC alleles two of the pockets within the peptide binding groove display a marked 
preference for one or two amino acids at certain anchor positions within the peptide. This was the 
breakthrough discovery that enabled more efficient CTL epitope mapping.  Dependent on this 
information, web-based algorithms used to predict CD8+ T cell epitopes were designed to include 
peptides limited to between 8 and 10 residues.  The apparent dominance of MHC class I peptides of 
8 to 10 amino acids in length may be misleading and result from this bias of widely used 
algorithms.  Several studies have clearly shown that some longer peptides are naturally processed 
and presented for recognition by CD8+ T cells.  A number of these noncanonical epitopes have been 
identified in Epstein-Barr virus (EBV).  In order to ascertain the role of long peptides in CD8+ T 
cell responses, studies were required which utilise overlapping peptide screening and not web-based 
algorithms to predict peptides.  The latent herpes virus Epstein-Barr virus is a superb model to 
determine the relative prevalence of noncanonical T cell epitopes.    
Abstract 
A number of highly immunogenic antigens of EBV were the focus of this study.  Many 
novel class I EBV epitopes were identified with a significant proportion arising from the BZLF1 
antigen.  Overall, 28 latent epitopes from EBNA3A, EBNA3B, EBNA3C and EBNA1 and 13 lytic 
epitopes from BRLF1, BMLF1 and BMRF1 were identified in addition to novel epitopes from 
BZLF1, including five noncanonical CD8+ T cell epitopes.  The EBV BZLF1 protein demonstrated 
a propensity for epitope clustering.  In total, I have defined 13 novel epitopes from this EBV protein 
which are restricted to a number of HLA alleles and appear to be clustered and in many instances 
overlapping.  These included two overlapping epitopes of different length that nevertheless conform 
to the binding motif of the large and abundant HLA-B*44 supertype. While HLA-B*18:01+ 
individuals responded strongly and exclusively to an octamer peptide 173SELEIKRY180, HLA-
B*44:03+ individuals responded to the atypically large dodecamer peptide 169EECDSELEIKRY180 
that encompasses the octamer peptide. Moreover, the octamer peptide bound more stably to HLA-
B*18:01 than the dodecamer peptide while conversely, HLA-B*44:03 bound only the longer 
peptide.  Furthermore, crystal structures of these viral peptide-HLA complexes showed that the 
antigen-binding cleft of HLA-B*18:01 was more ideally suited to bind shorter peptides, while 
HLA-B*44:03 exhibited characteristics that favoured the presentation of longer peptides.  Mass 
spectrometric identification of over a thousand naturally-presented ligands revealed that HLA-
B*18:01 was more biased towards presenting shorter peptides than HLA-B*44:03. Collectively, 
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these data highlight a mechanism through which polymorphism within an HLA class I supertype 
can diversify determinant selection and immune responses by varying peptide length preferences.   
Interestingly, a human protein sequence (DELEIK
 
AY) was identified with sequence 
homology to the octamer EBV epitope.  The peptide was shown to bind stably to HLA-B*1801, and 
peptide elution/mass spectrometric studies showed it is presented by this HLA molecule on the 
surface of human cells.  A significant proportion of T cells raised against the SELEIKRY EBV 
epitope cross-reacted with this HLA-B*1801-binding self-peptide.  Of note, only a limited number 
of HLA-B*1801+ healthy individuals showing strong IFN-γ responses to SELEIKRY had a 
detectable response to DELEIKAY.  These cross-reactive T cells were shown to express a diverse 
array of T cell receptors.  The potential for self-reactivity by these CTLs is presumably kept under 
rigorous control by normal self-tolerance mechanisms.  However, these EBV/self cross-reactive T 
cells could pose an autoimmune threat if HLA-B*1801-DELEIKAY levels increased or the T cell 
activation threshold is reduced as a result of cytokine release during inflammation and tissue 
damage.  These cross-reactive T cell populations should be considered for their potential role in 
self-reactivity following viral infection. 
iv 
 
 
Declaration by author 
This thesis is composed of my original work, and contains no material previously published or 
written by another person except where due reference has been made in the text. I have clearly 
stated the contribution by others to jointly-authored works that I have included in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional editorial 
advice, and any other original research work used or reported in my thesis. The content of my thesis 
is the result of work I have carried out since the commencement of my research higher degree 
candidature and does not include a substantial part of work that has been submitted to qualify for 
the award of any other degree or diploma in any university or other tertiary institution. I have 
clearly stated which parts of my thesis, if any, have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the policy and procedures of The University of Queensland, the thesis be made available 
for research and study in accordance with the Copyright Act 1968 unless a period of embargo has 
been approved by the Dean of the Graduate School.  
 
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the 
copyright holder to reproduce material in this thesis. 
 
v 
 
 
Publications during candidature 
Original research articles (peer-reviewed) 
Rist MJ, Hibbert KM, Croft NP, Smith C, Neller MA, Burrows JM, Miles JJ, Purcell AW, 
Rossjohn J, Gras S, Burrows SR.  T cell cross-reactivity between a highly immunogenic Epstein-
Barr virus epitope and a self-peptide naturally presented by HLA-B*18:01+ cells. The Journal of 
Immunology.  2015 May; 194: 4668-4675. 
 
Rist MJ, Neller MA, Burrows JM, Burrows SR.  T Cell Epitope Clustering in the Highly 
Immunogenic BZLF1 Antigen of Epstein-Barr virus.  Journal of Virology. 2015 Jan; 89 (1):703-
712.   
  
Rist MJ, Theodossis A, Croft NP, Neller MA, Welland A, Chen Z, Sullivan LC, Burrows JM, 
Miles JJ, Brennan RM, Gras S, Khanna R, Brooks AG, McCluskey J, Purcell AW, Rossjohn J, 
Burrows SR.  HLA Peptide Length Preferences Control CD8+ T Cell Responses.  The Journal of 
Immunology. 2013 June; 191 561-571. 
 
Neller MA, Burrows JM, Rist MJ, Miles JJ, Burrows SR.  High frequency of herpesvirus-specific 
clonotypes in the human T cell repertoire can remain stable over decades with minimal turnover.  
Journal of Virology.  2013 87 (1) 697-700. 
 
Horst D, Burrows SR, Gatherer D, van Wilgenburg B, Bell MJ, Boer IG, Ressing ME, and Wiertz 
EJ.  Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a 
despite extensive sequence variation.  Journal of Virology.  2012 86 (1):572-7. 
 
 
Conference abstracts (peer-reviewed) 
Rist MJ, Theodossis A, Croft NP, Neller MA, Welland A, Chen Z, Sullivan LC, Burrows JM, 
Miles JJ, Brennan RM, Gras S, Khanna R, Brooks AG, McCluskey J, Purcell AW, Rossjohn J, 
Burrows SR.  HLA Peptide Length Preferences Control CD8+ T Cell Responses.   
Australasian Society of Immunology Annual Meeting. December 2013. Wellington, New Zealand.  
(oral) 
 
Rist MJ, Theodossis A, Croft NP, Neller MA, Welland A, Chen Z, Sullivan LC, Burrows JM, 
Miles JJ, Brennan RM, Gras S, Khanna R, Brooks AG, McCluskey J, Purcell AW, Rossjohn J, 
Burrows SR.  HLA Peptide Length Preferences Control CD8+ T Cell Responses.   
Brisbane Immunology Group Annual Meeting. August 2013. Gold Coast, Australia. (oral) 
 
Rist MJ, Theodossis A, Croft NP, Neller MA, Welland A, Chen Z, Sullivan LC, Burrows JM, 
Miles JJ, Brennan RM, Gras S, Khanna R, Brooks AG, McCluskey J, Purcell AW, Rossjohn J, 
Burrows SR.  HLA Peptide Length Preferences Control CD8+ T Cell Responses.   
Frontiers in Immunology Research Network Conference. July 2013. Monte Carlo, Monaco. (oral) 
 
Rist MJ, Theodossis A, Croft NP, Neller MA, Welland A, Chen Z, Sullivan LC, Burrows JM, 
Miles JJ, Brennan RM, Gras S, Khanna R, Brooks AG, McCluskey J, Purcell AW, Rossjohn J, 
Burrows SR.  HLA Peptide Length Preferences Control CD8+ T Cell Responses.   
Australasian Society of Immunology Annual Meeting.  December 2012. Melbourne, Australia.  
(poster, Three minute mini-oral) 
 
 
vi 
 
Chapter 4: 
Publications included in this thesis 
Rist MJ, Neller MA, Burrows JM, Burrows SR.  T Cell Epitope Clustering in the Highly 
Immunogenic BZLF1 Antigen of Epstein-Barr virus.  Journal of Virology. 2015 Jan; 89 (1):703-
712   
Contributor Statement of contribution 
Rist MJ (Candidate) Experiment design (80%) 
Sample collection and processing (100%) 
Data acquisition/lab work (90%) 
Analysis and interpretation of data (80%)  
Manuscript preparation (80%) 
Neller MA Data acquisition/lab work (5%) 
Reviewed and edited manuscript  
Burrows JM Data acquisition/lab work (5%) 
Reviewed and edited manuscript 
Burrows SR Project conception (100%) 
Experiment design (20%) 
Analysis and interpretation of data (20%)  
Manuscript preparation (20%) 
 
Chapter 5: 
Rist MJ, Theodossis A, Croft NP, Neller MA, Welland A, Chen Z, Sullivan LC, Burrows JM, 
Miles JJ, Brennan RM, Gras S, Khanna R, Brooks AG, McCluskey J, Purcell AW, Rossjohn J, 
Burrows SR.  HLA Peptide Length Preferences Control CD8+ T Cell Responses.  The Journal of 
Immunology. 2013 June; 191:561-571. 
Contributor Statement of contribution 
Rist MJ (Candidate) Experiment design (30%) 
Sample collection and processing (60%) 
Data acquisition/lab work (35%) 
Analysis and interpretation of data (30%)  
Manuscript preparation (50%) 
Theodossis A Experiment design (20%) 
Sample collection and processing (15%) 
Data acquisition/lab work (25%) 
Analysis and interpretation of data (15%)  
Manuscript preparation (15%)  
Croft NP Experiment design (20%) 
vii 
 
Sample collection and processing (15%) 
Data acquisition/lab work (25%) 
Analysis and interpretation of data (15%)  
Manuscript preparation (15%) 
Neller MA Data acquisition/lab work (5%) 
Reviewed and edited manuscript 
Welland A Data acquisition/lab work (5%) 
Reviewed and edited manuscript 
Chen Z Sample collection and processing (5%) 
Reviewed and edited manuscript 
Sullivan LC Made reagents (tetramers) 
Reviewed and edited manuscript 
Burrows JM Data acquisition/lab work (5%) 
Reviewed and edited manuscript 
Miles JJ Analysis and interpretation of data (5%)  
Reviewed and edited manuscript 
Brennan RM Sample collection and processing (5%) 
Reviewed and edited manuscript 
Gras S Analysis and interpretation of data (10%)  
Reviewed and edited manuscript 
Khanna R Analysis and interpretation of data (5%)  
Reviewed and edited manuscript 
Brooks AG Made reagents (tetramers) 
Reviewed and edited manuscript 
McCluskey J Experiment design (10%) 
Reviewed and edited manuscript 
Purcell AW Experiment design (10%) 
Reviewed and edited manuscript 
Rossjohn J Project conception (20%) 
Reviewed and edited manuscript 
Burrows SR Project conception (80%) 
Experiment design (10%) 
Analysis and interpretation of data (20%)  
Manuscript preparation (20%) 
viii 
 
Chapter 6: 
Rist MJ, Hibbert KM, Croft NP, Smith C, Neller MA, Burrows JM, Miles JJ, Purcell AW, 
Rossjohn J, Gras S, Burrows SR.   T cell cross-reactivity between a highly immunogenic Epstein-
Barr virus epitope and a self-peptide naturally presented by HLA-B*18:01+ cells.  The Journal of 
Immunology.  2015 May; 194: 4668-4675. 
Contributor Statement of contribution 
Rist MJ (Candidate) Experiment design (40%) 
Sample collection and processing (95%) 
Data acquisition/lab work (55%) 
Analysis and interpretation of data (70%)  
Manuscript preparation (70%) 
Hibbert KM Experiment design (20%) 
Sample collection and processing (5%) 
Data acquisition/lab work (25%) 
Reviewed and edited manuscript  
Croft NP Experiment design (10%) 
Data acquisition/lab work (10%) 
Analysis and interpretation of data (10%)  
Reviewed and edited manuscript 
Smith C Experiment design (5%) 
Reviewed and edited manuscript 
Neller MA Data acquisition/lab work (5%) 
Reviewed and edited manuscript 
Burrows JM Experiment design (5%) 
Data acquisition/lab work (5%) 
Reviewed and edited manuscript 
Miles JJ Project conception (10%) 
Reviewed and edited manuscript 
Purcell AW Project conception (10%) 
Reviewed and edited manuscript 
Rossjohn J Project conception (20%) 
Reviewed and edited manuscript 
Gras S Experiment design (10%) 
Manuscript preparation (10%) 
Burrows SR Project conception (60%) 
Experiment design (10%) 
ix 
 
Analysis and interpretation of data (20%)  
Manuscript preparation (20%) 
x 
 
 
Contributions by others to the thesis  
My supervisor, Professor Scott Burrows, contributed significantly to the conception and design of 
the projects described in this thesis.  No other significant contributions were made. 
 
 
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
 None 
 
 
xi 
 
 First and foremost, I would like to thank my supervisor, Professor Scott Burrows.  His 
constant support and guidance has been instrumental during my PhD and instilled in me the 
confidence to grow as a scientist.  I genuinely appreciate the opportunities he has given to me and 
could not imagine a more patient supervisor.  He has been an outstanding mentor and will continue 
to be.  I would like to thank my associate supervisor Professor Rajiv Khanna for his support and 
guidance.  Many thanks to Dr Corey Smith who has been a constant source of knowledge and 
patience and I greatly appreciate his invaluable friendship and advice, Mrs Jacqueline Burrows has 
been an unwavering support both in and out of the lab and a wealth of molecular knowledge and Dr 
Viviana Lutzky for her advice, friendship and support.  Thank you to Professor Denis Moss for his 
guidance and advice.  Thank you to Cellular Immunology lab member Dr Rebekah Brennan for her 
advice.  I would also like to acknowledge collaborative efforts from Professor Jamie Rossjohn, Dr 
Stephanie Gras and Professor James McCluskey. 
Acknowledgements 
 My family and friends have been an invaluable source of encouragement and support.  
Especially my parents whose love, support and unwavering belief that I am capable of achieving 
anything is instrumental in all that I do and my husband Michael, for your constant love, support 
and our two feline distractions.  
 Finally, I am extremely grateful for the funding sources that supported this project.  My PhD 
scholarship was funded by the National Health and Medical Research Council and travel grant by 
the Australasian Society of Immunology.   
    
  
xii 
 
T Cell immunity, epitope, Epstein-Barr virus, T cell receptor repertoire, adaptive immunity, 
sequence polymorphism, major histocompatibilty complex 
Keywords 
 
ANZSRC code: 110704, Cellular Immunology, 80% 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
ANZSRC code: 110309, Infectious Diseases, 10% 
ANZSRC code: 110804, Medical Virology, 10% 
 
FoR code: 1107, Immunology, 80% 
Fields of Research (FoR) Classification 
FoR code: 1103, Clinical Sciences, 10% 
FoR code: 1108, Medical Microbiology, 10% 
 
xiii 
 
Table of Contents 
List of Abbreviations           1 
Chapter 1: Introduction and Literature Review       4 
1.1 The Immune System          5
 1.1.1 Introduction          5                
 1.1.2 Innate Immunity         5 
 1.1.3 Adaptive Immunity         6 
 1.1.4 Introduction to T cell immunity       6 
 1.1.5 Antigen Processing and Presentation                  7
  1.1.5a Structure of MHC Class I molecules      7 
                1.1.5b MHC Class I pathway        7 
  1.1.5c Cross Presentation        8 
  1.1.5d MHC Class II pathway       8 
  1.1.5e Immunodominance           9 
1.2 Antigen Presentation and Recognition        11 
 1.2.1 Introduction to the T Cell Receptor       11 
 1.2.2 αβ T cells, γδ T cells and coreceptor molecules      11 
 1.2.3 T Cell Receptor V(D)J recombination       12 
 1.2.4 Thymic selection         14 
 1.2.5 TCR bias          15 
 1.2.6 The human TCR in Immune Responses        16 
 1.2.7 TCR/pMHC Structures         17 
1.3 Immune response to a herpes virus        19 
 1.3.1 Herpesviridae          19 
 1.3.2 A brief overview of EBV        20 
 1.3.3 Structure of EBV         21 
 1.3.4 Lytic EBV Proteins of interest        21 
 1.3.5 Latent EBV Proteins of interest        22 
 1.3.6 Cellular Immune Responses to EBV       23 
 1.3.7 Unusually long EBV CTL epitopes       25 
1.4 Scope of Thesis: Aims and Hypotheses        30
           
 Chapter 2: Methods            31 
2.1 Cell culture           32 
xiv 
 
 2.1.1 Ficoll-Paque Density Gradient-lymphocyte isolation     32 
 2.1.2 Cryopreservation and thawing of cells       32 
 2.1.3 Generating Phytohaemagglutinin blasts      33 
 2.1.4 Generating Lymphoblastoid cell lines (LCL)      33 
 2.1.5 Generating LCL-stimulated T cell lines      33 
 2.1.6 Generating peptide-stimulated T cell lines      34 
2.2 Cell surface staining and functional assays       34 
 2.2.1 Flow cytometric multimer staining       34 
 2.2.2 Intracellular Cytokine Staining (ICS)       35 
 2.2.3 Flow cytometric analysis of TRBV usage      35 
 2.2.4 Flow cytometric analysis of TRBV usage with ICS     35 
 2.2.5 Interferon-γ ELISpot assay        36 
2.3 Flow cytometry reagents         37 
 2.3.1 Antibodies          37 
 2.3.2 Multimers          37 
 
Chapter 3: Determine the relative prevalence of peptide epitopes of over 10 amino acids 38 
in length in CD8+ T Cell recognition of Epstein-Barr virus (EBV) 
 
 3.1 Introduction          39 
 3.2 Results           42 
 3.3 Discussion           59 
  
Chapter 4: T Cell Epitope Clustering in the Highly Immunogenic BZLF1 Antigen of  65 
Epstein-Barr Virus 
Published research article: Journal of Virology. 2015 Jan; 89 (1):703-712 
 
Chapter 5: HLA Peptide Length Preferences Control CD8+ T Cell Responses   76 
Published research article: The Journal of Immunology. 2013 Jun; 191:561-571 
Supplementary data                    144 
 
Chapter 6: T cell cross-reactivity between a highly immunogenic Epstein-Barr virus  88  
epitope and a self-peptide naturally presented by HLA-B*18:01+ cells.        
Published research article: The Journal of Immunology.  2015 May 194:4668-4675. 
 
Chapter 7: Discussion                   116 
 7.1 Overview                    117 
 7.2 Determine the relative prevalence of peptide epitopes of over 10 amino acids             117 
 in length in CD8+ T Cell recognition of EBV  
 7.3 Determine if the highly immunogenic BZLF1 antigen of EBV includes novel             121  
 CD8+ T Cell epitopes 
xv 
 
 7.4 Determine if the peptide length preferences of class I human leukocyte antigens        122  
 influence epitope selection in the EBV-specific T cell response 
 7.5 T cell cross-reactivity between an EBV epitope and an abundant self-peptide             124 
 presented by HLA-B18:01+ cells 
 7.6 Conclusions                   126 
 7.7 Reference List                   130 
     
 1 
 
List of Abbreviations 
α  alpha 
β beta 
δ delta 
ε epsilon 
γ gamma 
ζ zeta 
APC antigen presenting cell 
APC  allophycocyanin 
BCIP/NBT 5’bromo-4 chloro-3 indole and inorganic phosphate/ nitro blue tetrazolium chloride 
BL Burkitt’s lymphoma 
CCL2 chemokine (C-C motif) ligand 2 
cDNA complementary DNA 
CDR complementarity determining region 
CLIP class II-associated invariant chain peptide 
cTEC cortical thymic epithelial cell 
CTL  cytotoxic T lymphocyte 
CTLp  CD8+ T cell precursor  
DC dendritic cell  
DMSO dimethyl sulfoxide 
DN double negative 
DNA deoxyribonucleic acid 
DP double positive 
EBNA Epstein-Barr virus nucleic acid 
EBV Epstein-Barr virus 
ELISpot enzyme linked immunospot assay 
ER endoplasmic reticulum 
FACS fluorescence activated cell sorter 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
HC heavy chain 
HCMV Human Cytomegalovirus 
HHV Human herpes virus 
HIV Human Immunodeficiency Virus 
HL Hodgkin’s lymphoma 
2 
 
HLA human leukocyte antigen 
HSV Herpes Simplex virus 
ICS intracellular cytokine staining 
IDDM Insulin-dependent diabetes mellitus 
IFN interferon 
Ig immunoglobulin 
Ii invariant chain 
IL interleukin 
IM infectious mononucleosis 
ITAM immunoreceptor tyrosine based activation motif 
kb kilobase 
KSHV Kaposi’s Sarcoma-associated herpesvirus 
LCL lymhoblastoid cell line 
LMP latent membrane protein 
LPS lipopolysaccharide  
mAb monoclonal antibody 
MFI mean fluorescence intensity 
MHC major histocompatibility complex 
mg milligram 
µg microgram 
mM millimolar 
µM micromolar 
MS Multiple Sclerosis 
NK natural killer cells  
NPC Nasopharyngeal Carcinoma 
PAMPs pathogen-associated molecular patterns 
PBMC peripheral blood mononuclear cell 
PBS  phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PerCP peridinin-chlorophyll proteins 
PerCP-Cy5.5 PerCP with a cyanine dye (Cy5.5) 
PFA paraformaldehyde 
PHA phytohemagglutinin 
p-HLA peptide-Human Leukocyte Antigen 
3 
 
pMHC peptide-MHC complex 
PRR pattern recognition receptors 
PTLD post transplant lymphoproliferative disorder 
RAG recombinase-activating gene 
RBC  red blood cell 
RNA ribonucleic acid 
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute medium 
RT room temperature 
SIV simian immunodeficiency virus 
SLE systemic lupus erythematosus 
SP single positive 
TAP transporter associated with antigen processing 
TCGF T cell growth factor 
TCM T cell media 
TCR T cell receptor 
TNFα tumour necrosis factor-alpha 
TR tandom repeat 
Vα variable region of the T cell receptor alpha chain 
Vβ variable region of the T cell receptor beta chain 
VZV Varicella-Zoster virus 
WT wild type 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
Chapter 1 
 
 
 
 Introduction and Literature Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
1.1 The Immune System 
 
1.1.1   Introduction 
The immune system is an interesting and complex network of biological sentinels that 
defend the body from foreign invaders.  Although, the human body has many levels of defence 
including skin, mucous membranes and stomach acids it is ultimately the immune system that 
detects invasion by bacterial, parasitic and viral agents distinguishing and eliminating these 
organisms without causing damage to self.  Traditionally the immune system is divided into two 
streams, innate and adaptive. 
 
1.1.2  Innate Immunity  
It is believed that during evolution the innate immune system appeared prior to the adaptive 
immune system.  Innate immunity is activated immediately following infection to control 
replication of the infecting pathogen.  Mediated by germ-line-encoded receptors, innate immune 
recognition is genetically predetermined. These receptors have defined specificities for infectious 
microorganisms and are expressed on the surface of the professional antigen-presenting cells (APC) 
of the innate immune system including macrophages, dendritic cells (DC) and B cells (Medzhitov 
and Janeway Jr 2000).  
As there is a limit to the number of genes that can be encoded by a host’s genome, relatively 
few germ-line encoded molecules bear the task of detecting a vast array of molecular structures, or 
patterns associated with infectious microorganisms.  This role is fulfilled by pattern- recognition 
receptors (PRRs) expressed on APCs focused on detecting a selection of highly conserved patterns, 
pathogen-associated molecular patterns (PAMPs), shared by a large group of pathogens.  PAMPs 
include conserved features of microbial pathogens such as bacterial and fungal cell-wall 
components and viral nucleic acids  (Janeway Jnr 1989).  Importantly, none of these structures are 
produced by the host organism and are therefore distinct from self-antigens presenting the innate 
immune system with the ability to discriminate between self and non-self (Medzhitov and Janeway 
Jr 1997). 
For example, synthesized only by bacteria, lipopolysaccharides (LPS) are recognized by 
PRRs on macrophages alerting the host to the presence of an infecting organism.  Upon activation 
macrophages secrete cytokines (e.g. interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-α)) 
and chemokines (e.g. chemokine (C-C motif) ligand 2 (CCL2)) directing monocytes and neutrophils 
to exit the bloodstream and enter the surrounding tissue at the site of infection, initiating the process 
of inflammation (Janeway Jnr, Travers et al. 2001).  Ultimately, the sensing of microbes by cells of 
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the innate immune system initiate the adaptive immune response by instructing the direction of the 
adaptive immune system (Medzhitov and Janeway Jr 1997).      
 
1.1.3  Adaptive Immunity           
The adaptive immune system provides long-lasting antimicrobial protection and is mediated 
by T and B lymphocytes.  Formed in the bone marrow, B cells secrete microbial-specific antibodies 
upon proliferation and activation, whilst following maturation in the thymus, T cells recognize 
foreign antigens derived from pathogens and protect the host from infection (Janeway Jnr, Travers 
et al. 2001).  These lymphocytes bear antigen receptors generated somatically.  Each lymphocyte 
displays a structurally unique receptor, as these receptors are not predestined and generated 
randomly this results is an extremely diverse repertoire of receptors.   
Lymphocytes recognizing antigens specific for pathogens are subsequently selected for 
clonal expansion, however, the receptor repertoire contains binding sites that have the capacity to 
react not only with pathogens and environmental antigens but also with self.  This diverse repertoire 
of antigen receptors of the adaptive immune system is almost infinite as there are approximately 
1014 and 1018 different somatically generated immunoglobulin (Ig) receptors and T cell receptors, 
respectively (Medzhitov and Janeway Jr 2000).   
 
1.1.4 Introduction to T-cell immunity 
There are two distinct subsets of naïve T cells, those expressing the co-receptor CD8 or T 
cells expressing the co-receptor CD4.  These T cells bear the αβ T cell receptor (TCR).  Following 
activation of a naïve CD4+ T cell, it differentiates into one of four further subsets: Th1, Th2, Th17 
and regulator T cells (Treg).  Once the naïve CD8+ T cells are activated they develop into cytotoxic 
T cells (CTL).  T cells committed to the CD8 lineage depend on the binding of the αβ TCR to major 
histocompatibility complex (MHC) class I molecules, where as the commitment of the T cells of the 
CD4 lineage is to MHC class II molecules (Borgulya, Kishi et al. 1991).   
In 1974, Rolf Zinkernagel and Peter Doherty published in Nature the biological significance 
of MHC Class I molecules, showing that TCRs are designed to recognise the presented antigen in 
addition to the MHC, i.e. CTLs, induced by viral infection recognise cells in a virus specific, class 
I-restricted manner.  (Zinkernagel and Doherty 1974).  CD4+ helper T cells contribute to the 
expansion of CD8+ T cells and provide specific cytokines such as IL-2 as well as assisting B cells in 
proliferation and differentiation and switching the class of antibody they produce, whilst CTLs kill 
infected target cells.    
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1.1.5 Antigen Processing and Presentation 
 
1.1.5a Structure of MHC Class I molecules 
A mature MHC I complex consists of three noncovalently associated sections, a heavy chain 
(45kDa), a light chain (12kDa) also called β2-microglobulin and a short peptide antigen.  In 
humans, there are three class Ia loci, HLA-A, B and C.  Both alleles of the loci are codominantly 
expressed, indicating that an individual may express up to six different class Ia molecules (Parham, 
Adams et al. 1995).  The heavy chain (HC) consists of a cytoplasmic region, a transmembrane 
region, and an extracellular region composed of three α domains (α1, α2 and α3) with one to three 
N-linked glycosylation sites.  It is the α3 region of the HC that contains the binding site for the CD8 
receptor on CTL.  The α1 and α2 domains interact with the TCR on CTL and fold together to form 
a groove that binds and displays the antigenic peptides. The base of the cleft is formed by a beta-
pleated sheet and the walls are comprised of two alpha helices.  It is primarily in these residues in 
and around the cleft of the HC where allelic polymorphisms occur and allow an alteration of 
peptide-binding specificity of the MHC I molecules (Parham, Adams et al. 1995) (Bjorkman, Saper 
et al. 1987). 
 
1.1.5b MHC Class I pathway 
MHC class I molecules display fragments of intracellular expressed antigens from 
pathogens or self for monitoring by the immune system.  Generally these proteins are in the form of 
small peptides around 9 amino acids in length (Rock and Goldberg 1999).  CTLs can identify 
peptide-MHC complexes (pMHC) and distinguish between infected and uninfected cells.  This 
presentation pathway is the result of a number of biochemical processes from proteolysis to the 
transportation of fragments to the plasma membrane.  Predominantly it is endogenous proteins that 
are presented to the MHC I molecule following ubiquitination in the cytosol and delivered to the 
proteasome to initiate fragmentation.  An adenosine triphosphate (ATP)-dependent multisubunit 
protease, the proteasome is considered the main machinery behind the generation of antigenic 
peptides (usually 8-10 residues in length) (Rock, Gramm et al. 1994).   
Class I peptides are then transported into the lumen of the endoplasmic reticulum (ER) by 
the transporter associated with antigen presentation (TAP) complex.  Peptides are required to be 7 
residues or longer for transportation by TAP, with the reduced efficiency with peptides longer than 
12 residues (Shepherd, Schumacher et al. 1993).  Following transportation to the ER, peptides are 
loaded onto the MHC class I molecule. This sequence of events involves a partially folded MHC 
class I α chain binding to calnexin until β2-microglobin (β2:M) binds and the calnexin dissociates.  
Additional molecules join the complex including the transmembrane glycoprotein, tapasin (which 
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links TAP to peptide free MHC class I molecules) and the chaperones calreticulin and ERp57 
(Wright, Kozik et al. 2004).   Within the ER, peptides bind to the MHC class I-β2m heterodimer that 
is released from the peptide loading complex.  The fully assembled peptide loaded MHC molecules 
are translocated from the ER through the Golgi apparatus onto the cell surface to be scrutinised by 
the TCR of CD8+ T cells (Kloetzel 2001, Cresswell, Ackerman et al. 2005). 
 
1.1.5c Cross Presentation  
In some instances it is antigens from the extracellular environment that are presented on the 
cell surface in association with MHC class I molecules and stimulate CD8+ T-cell immunity.  This 
process is referred to as cross-presentation.  Now known as a major mechanism of the immune 
system, cross-presentation is the only pathway the immune system can utilise to detect and advance 
on viral infection and mutations that occur predominantly in the parenchymal cells.  These viral 
antigens are processed and presented by specialised APCs which acquire the viral antigen from the 
infected cells, in most cases by phagocytosis and occasionally using fluid-phase endocytosis (Watts 
and Amigorena 2001).  The principal cell which cross presents antigens is the DC (Mellman and 
Steinman 2001).  Internalised antigens may then be processed through one of two known pathways. 
The phagosome-to-cytosol pathway and the vacuolar pathway are the two current pathways 
attributed with cross-presentation.  The dominant of these mechanisms is the TAP dependent 
phagosome-to-cytosol pathway.  In this pathway the antigen is internalised into phagosomes or 
micropinosomes and transferred into the cytosol.  Once in the cytosol, proteosomes hydrolyse the 
antigen into oligopeptides which are transported by TAP to the MHC class I molecules in the ER or 
“ER-phagosome” vesicles (Kovacsovics-Bankowswki and Rock 1995).  The second and less 
understood mechanism, the vacuolar pathway is TAP independent, however, requires endosomal 
protease, cathepsin S.  Phagosomes internalise antigens to be degraded into oligopeptides, 
predominantly by cathepsin S.   The resulting peptides are then presumably loaded onto the MHC 
class I molecules that have arrived into the vesicle from the plasma membrane or ER (Rock and 
Shen 2005).  
 
1.1.5d MHC Class II pathway 
MHC Class II processing pathway focuses MHC class II-antigen complex transporting to 
the cell surface for presentation to CD4+ T cells.  Although predominantly associated with peptides 
derived from exogenous proteins, studies have shown that endogenous proteins too come into play.  
MHC class II proteins are expressed on professional APCs including DCs, B cells and 
macrophages, also cortical and medullary thymic epithelial cells have been shown to be involved.  
There are two MHC class II pathways, the classical, MHC Class II-mediated exogenous antigen 
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processing pathway and the less understood, non-classical, cytoplasmic antigen presentation 
pathway.   
In the exogenous pathway, exogenous proteins are degraded by acidic proteases located 
within endosomes and lysosomes, MHC class II molecules are assembled in the ER with the 
chaperone invariant chain (Ii).  The Ii targets the Ii-MHC class II complex to the endosomal 
pathway, where once entered into the endosomal/lyosomal compartments, Ii is degraded into 
fragments, one of these small fragments, class II–associated invariant chain peptide (CLIP) is 
retained and involved with the MHC class II binding groove.  An MHC-encoded molecule human 
leukocyte antigen HLA-DM is required for the removal of CLIP and capture of antigenic peptides 
by the MHC class II molecules.  The resulting peptide-MHC class II complexes are subsequently 
transported to the cell surface for scrutiny by CD4+ T cells (Bryant and Ploegh 2004, Li, Gregg et 
al. 2005).  MHC class II molecules are also capable of binding peptides that are derived from 
endogenous proteins and cytoplasmic proteins, via the cytoplasmic antigen presentation pathway.  It 
remains unknown how peptides from cytoplasmic antigens gain access to MHC class II molecules, 
but one possibility is that they are acquired exogenously by bystander APCs and then follow the 
classical MHC class II pathway.             
 
1.1.5e Immunodominance 
Immunodominance primarily refers to the phenomenon by which only a small fraction of 
the possible thousands of peptides encoded by complex foreign (especially viral) antigens are 
selected for presentation on the surface of MHC class I alleles and induce measurable responses.  
Limitations of the CD8+ T cell repertoire play a major role in the resultant non-immunogenic status 
of peptides as does inefficient antigen processing.  
Only ~ 1/2000 of foreign antigen peptides achieve immunodominant status within a given 
class I allele, with roughly the equivalent number of peptides acquiring subdominant status, 
inducing a weak to non-detectable CD8+ T cell response (Yewdell and Bennink 1999).  A central 
feature of the CD8+ T cell response,  immunodominance has been observed in relation to a number 
of viruses including influenza (Turner, Kedzierska et al. 2005) and Epstein-Barr virus (EBV) 
(Argaet, Schmidt et al. 1994).  There are a number of determinants which may influence the 
immunogenicity of a peptide including the pMHC complexes’ abundance on the surface of APCs, 
the peptide binding preferences of the MHC class I molecules and the ability to suppress 
subdominant epitope responses (Yewdell and Bennink 1999) (Tynan, Elhassen et al. 2005).   
Although an abundance of particular CTL epitopes presented on the surface of APCs does 
account for immundominance in some instances, the correlation between abundance and 
immunodominance is not always the case (Crotzer, Christian et al. 2000).  An example of this has 
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been demonstrated in the T cell response to EBV.   Crotzer and colleagues characterized the 
expression of four epitopes from the latent proteins EBNA3B (RRARSLSAERY), EBNA3C 
(RRIYDLIEL and FRKAQIQGL) and LMP2 (RRRWRRLTV).   These epitopes are recognized by 
HLA-B27 subtypes HLA-B*2702, B*2704 or B*2705.  RRIYDLIEL the immunodominant epitope 
was recognized in the context of all three B27 subtypes, whilst the remaining three epitopes induced 
a response in only one subtype, in the following combinations RRARSLSAERY/B*2702, 
RRRWRRLTV/B*2704 and FRKAQIQGL/B*2705.  The apparent immunodominance of 
RRIYDLIEL did not correlate with the abundance of this epitope and showed an inverse 
relationship.  The immunodominant epitope was least abundant with less than or equal to the 
abundance of the nonimmunogenic epitopes and their respective HLA-B27 subtypes (Crotzer, 
Christian et al. 2000).  This phenomenon may be the result of factors such as the T cell repertoire or 
T cell affinity influencing the degree of the T cell response. 
Another influential element on immunodominance involves CTLs specific for dominant 
peptides suppressing responses to other competing peptides (immunodomination).  A number of 
mechanisms may play a role in the suppression of subdominant peptides including a rapid response 
by CD8+ T cells specific for immunodominant peptides cascading towards a reduction in antigenic 
load and suboptimal expression of subimmunodominant peptides for CTL activation.  Suppression 
of a subdominant peptide by an immunodominant peptide has been repeatedly observed (Deng, 
Yewdell et al. 1997) (Mylin, Bonneau et al. 1995).  Additionally, competition at the APC level for 
CD8+ T cell activation or systemic suppression of subimmunodominant peptides by  CD8+ T cells 
specific for the immunodominant peptides (Zinkernagel, Althage et al. 1978, Yewdell and Bennink 
1999).  This form of suppression results in enhanced responses to subimmunodominant peptides 
under conditions when responses to immunodominant peptides are eliminated by changes or 
removal of the determinant, its MHC class I restriction element or by removal of the 
immunodominant peptide-specific CD8+ T cell response (Doherty, Biddison et al. 1978, 
Zinkernagel, Althage et al. 1978).  Tynan et al, demonstrated with their investigation into EBV 
BZLF1 epitope APQPAPENAY, that peptide conformation can have a dramatic impact on the 
immunogenicity of an MHC-peptide complex and play a role in controlling immunodominance in T 
cell responses (Tynan, Elhassen et al. 2005).   
A further key predictor of immunodominance is supported by findings of La Gruta et al.  
This work suggests that CD8+ T cell precursor (CTLp) frequency and epitope density are the prime 
determinants of immundominance hierarchy after influenza A virus infection in mice (La Gruta, 
Kedzierska et al. 2006).  Other studies have also shown a relationship between naïve CTLp 
frequencies and the magnitude of the CTL immune response for a variety of both viral and nonviral 
epitopes (Moon, Chu et al. 2007, Kotturi, Scott et al. 2008, Obar, Khanna et al. 2008).  However, 
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demonstrating the complexity of this field La Gruta and colleagues have reported a differential 
contribution of CTLp frequency to immunodominance.  Recent work by this group suggests that for 
subdominant epitopes there is no correlation between the CTLp frequency and the 
immunodominance hierarchy following intranasal infection of mice with influenza A virus (La 
Gruta, Rothwell et al. 2010).   
In another study that was focused on the role of viral coinfection on the inter and intra-
individual immunodominance of CTL responses against known HIV and EBV-derived, HLA-class I 
restricted epitopes, the impact of HLA-allele usage, functional avidity and HLA binding affinity 
were compared.  Observations show the two major aspects of immunodominance, the magnitude 
and frequency of recognition, are related to each other, whilst the functional avidity appears to be of 
more importance to the magnitude of responses than peptide binding affinity to HLA molecules 
(Bihl, Frahm et al. 2006).     
Recent reports by Hansen and colleagues portray a shift in the current immunodominant 
hierarchy paradigm.  Their findings show simian immunodeficiency virus (SIV)-specific CD8+ T 
cells recognize highly promiscuous epitopes that interestingly include dominant responses to 
epitopes restricted by MHC class II molecules.  These data reveal flexibility in CD8+ T cell 
recognition determining that the established rules of epitope recognition and immunodominance are 
not absolute, as well as uncovering unconventional CD8+ T cell responses (Hansen, Sacha et al. 
2013).  What remains unclear is how these various factors balance out and influence 
immunodominance in a normal immune response.     
 
1.2 Antigen Presentation and Recognition  
 
1.2.1 Introduction to the T cell Receptor 
T cell antigen receptors (TCR) are expressed on the surface of T lymphocytes in order to 
recognize antigens.  These exceptional proteins detect foreign antigens that have been captured and 
presented by MHC molecules.  TCRs have unique binding specificity determined by unique 
antigen-binding site, a result of variation in amino acid sequence.  In order to respond to an infinite 
number of pathogens, humans possess a predicted 1012 lymphocytes with the theoretical number of 
an estimated 1018 receptors.  This extraordinary complex system plays a critical role in the immune 
system.  
 
1.2.2 αβ T cells, γδ T cells and coreceptor molecules 
T cells fall into one of two lineages depending on whether the TCR is comprised of an α-
chain paired with a β-chain or a γ-chain combined with a δ-chain.  The vast majority of the body’s 
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circulating T cells are of the αβ lineage, whilst γδ TCRs are less abundant and represent around 5% 
of T cells in the circulating lymphocyte population (De Rosa, Andrus et al. 2004).  The γδ T cells 
are mainly located in the epithelial sites of the body such as the gut and the skin.  These cells appear 
to form the first line of defence, recognising structures such as lipids and heat shock proteins, and 
are therefore an integral part of the innate immune system (Taghon and Rothenberg 2008).  The 
precise details of the γδ lineage are not well understood. 
      αβ TCRs are expressed on the surface of around 95% of all T lymphocytes.  These TCRs 
interact with peptide antigens in association with MHC molecules (pMHC) and are divided into two 
classes determined by their effector functions and accessory molecules.  T cells bearing the CD8 
coreceptors recognize MHC class I molecules and are referred to as CTLs or killer T cells, whilst 
those bearing CD4 coreceptors bind MHC class II molecules on APCs including DCs and 
macrophages and are called helper T cells (Wilson and Garcia 1997).  It has been postulated 
whether the role of the coreceptors is to increase affinity of the TCR for MHC molecules or to 
recruit sufficient intracellular protein tyrosine kinase, p56lck (Lck) (Zamoyska 1998).   One of the 
primary events which occur immediately upon TCR engagement with pMHC is the recruitment of 
T-cell-specific Lck via CD4 or CD8 coreceptors, activating the T cell response (Wange and 
Samelson 1996). 
 The CD3 complex consists of CD3δ, CD3ε, and CD3γ.  The presence of  the CD3 complex 
is required for stable cell surface expression and normal development of αβ TCRs in addition to the 
signalling transduction cascade initiated by the TCR binding to the pMHC (Rudolph, Stanfield et al. 
2006).  The intracytoplasmic homodimer CD3ζζ signals to the interior of the cell upon antigen 
binding.   Activated Lck phosphorylates the immunoreceptor tyrosine based activation motifs 
(ITAMs), present on the cytoplasmic tails of the CD3 chains, which play a critical role in the 
transmitting of signals onward.  The TCR complex is issued with ten ITAMs, which may offer 
flexibility to signalling (Janeway Jnr, Travers et al. 2001).   
 
1.2.3 T Cell Receptor V (D) J recombination          
  At the centre of the adaptive immune response is the recognition of antigenic peptides bound 
to MHC molecules by TCRs.  Generated somatically through site specific DNA recombination 
reactions, TCR diversity is a result of the random assembly of variable (V), diversity (D) and 
joining (J) gene segments.  The four TCR polypeptides (α, β, γ and δ) each have a V, J and C 
region, however, β and δ also have D regions.  The thymus is the site where TCR genes are initially 
rearranged and expressed during the earliest stages of T cell differentiation.  Undergoing 
rearrangement first is TCR β,  γ and δ genes followed by TCR α (Davis and Bjorkman 1988).  V 
gene segments are carried in the germline of humans (and mice) and encode around the first 90 
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residues of mature TCR α and TCR β chains.  These are assembled in the double negative (DN) 
stage (CD4-CD8-) of T cell development of the TCR β chain gene.  TCR β gene assembly involves 
a short D gene segment which is juxtaposed to a short J segment.  V segment rearrangement follows 
and is assembled downstream to the DJ segment.  In contrast, the TCR α chain is rearranged last at 
the double positive (DP) stage (CD4+CD8+) of T cell development and contains no D region 
(Goldrath and Bevan 1999).  The human TCR β locus comprises 42 Vβ gene segments, 2Dβ gene 
segments and 12 Jβ gene segments and the human TCR α locus has 43 Vα gene segments and 58 Jα 
gene segments (Turner, Doherty et al. 2006). 
 
Figure 1. Schematic representation of TCR V(D)J Recombination.   a) αβ TCR heterodimers 
consist of an α-chain and a β-chain generated by somatic gene recombination.  b) Complimentarity-
determining regions (CDRs) are regions of hypervariability encoded in the V gene segments. 
(Turner, Doherty et al. 2006).  
 
V gene segments encode the regions of hypervariability known as complimentarity-
determining regions (CDRs).  The immunoglobulin-like fold results in three loops or CDRs.  CDR 
loops 1 and 2 are encoded by the V gene segments and have a limited diversity resulting from the 
germline V gene segments (Goldrath and Bevan 1999).  The CDR3 loop, however, is comprised of 
both germline residues from the V (D) J segments and nongermline components derived from N 
nucleotides that are added at the V (D) J joints during recombination  (Davis and Bjorkman 1988).  
The CDR3 region is a critical component of the TCR as it can mediate contact with the antigenic 
peptide-MHC complex (Davis and Bjorkman 1988, Shortman, Egerton et al. 1990).  Diversity 
within the CDR3 arises as a result of random nucleotide additions and DNA splicing by 
recombinase activating genes (RAG1 and RAG2).  V (D) J recombination requires the coordinated 
14 
 
activity of both RAG1 and RAG2.  These genes are only expressed in developing lymphocytes and 
determine irreversible T cell lineage commitment (Yui and Rothenberg 2014).  The mathematical 
estimation of potential TCR diversity is around 1018 unique αβ TCRs, although after considering 
thymic positive and negative selection events the size of the naïve TCR αβ repertoire is estimated to 
be around 2 x 107 TCRs for each human (Arstila, Casrouge et al. 1999).  Following translation, a 
functional TCR heterodimer comprised of a folded α-chain and β-chain, fused via a cysteine-
cysteine linker is transported to the membrane surface. 
 
1.2.4 Thymic Selection 
The thymus is the site where positive and negative selection of T lymphocytes occurs.  Their 
fate is determined by their surface receptors interaction with self-pMHC complexes displayed by 
thymic APCs (Klein, Kyewski et al. 2014). This process begins when DN (CD4-CD8-) progenitors 
are transmitted signals for positive selection from a pre-TCRβ complex generating immature DP 
(CD4+CD8+) thymocytes (Guidos 1996).  Expressing a vast array of TCRαβ complexes for 
interactions with self-pMHC complexes on cortical thymic epithelial cells (cTECs), DP thymocytes 
will die by neglect if they fail to positively engage with self-pMHC complexes within the first 3-4 
days.  Negative selection (or clonal deletion) eliminates DP or single positive (SP) thymocytes that 
express TCR with high affinity for self antigens or due to excessive interactions (Guidos 1996, 
Starr, Jameson et al. 2003, Klein, Kyewski et al. 2014).  Both these events of selection occur in 
discrete thymic microenvironments (cortex and medulla, respectively) composed of different types 
of APCs. 
DP precursors bearing low densities of self MHC TCRαβ are positively selected and 
induced to differentiate into TCRhi CD4 or CD8 SP thymocytes (Guidos 1996, Klein, Kyewski et al. 
2014).   Less than 5% of DP progenitors proceed to downregulate one of the coreceptors and 
become mature SP thymocytes (Goldrath and Bevan 1999).  This process of “mainstream” αβ T cell 
positive selection occurs with a single APC type, the cTECs   These specialized APCs are 
structurally arranged to support intimate interactions with DN and DP thymocytes (Klein, Kyewski 
et al. 2014).  The intricate mechanisms involved in development and timing determining the 
commitment of TCR to either CD4 or CD8 lineage still remains to be completely understood.  The 
process of commitment to either CD4 or CD8, however, has been affiliated with positive selection.  
Generally, DP precursors bearing class I MHC-specific TCRαβ will retain the expression of CD8, 
whilst those bearing the class II MHC-specific TCRαβ will retain CD4 expression (Fowlkes and 
Schweighoffer 1995, Guidos 1996).  The affinity model proposed by Klein and colleagues 
envisages positive selection of T cells with a range of affinities for self peptides including T cells 
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with high affinity for self providing rapid, short lived immune responses balanced by T cells with a 
low affinity for self providing a sustained response (Klein, Kyewski et al. 2014). 
 
1.2.5 TCR Bias 
TCR diversity peaks in the naïve compartment, however, throughout an individuals’ lifetime 
the antigen-experienced repertoire becomes skewed depending on antigen exposure and is often 
characterised by biases in the TCR repertoire.  In addition individuals sharing the same HLA types 
display TCR biases with public clonotypes dominating the immune response.  The extent of the bias 
may be one of three classifications depending on the degree of bias in the Vα/Vβ and CDR3 usage.  
TCR bias type 1 is characterised by the bias of at least one V region selection (generally, Vβ 
region), however, there is no display of CDR3 conservation.  In contrast to type 1, type 2 TCR bias 
does involve sequence conservation within CDR3, often characterised by “motifs” within the CDR3 
of the TCR Vα or Vβ chains.  The least common form of TCR bias, type 3, is defined by conserved 
Vα and/or Vβ usage in combination with conservation within the CDR3 sequence and J region 
(Turner, Doherty et al. 2006, Gras, Kjer-Nielsen et al. 2008).  As with TCR diversity, examples of 
TCR bias have been observed in persistent viral infections including EBV (Miles, Borg et al. 2006) 
and HIV (Stewart-Jones, Gillespie et al. 2005) as well as autoimmunity (Babbe, Roers et al. 2000) 
and lipid-based immunity (Borg, Wun et al. 2007).   
The degree of antigen-driven TCR bias both within and between individuals appears to be 
determined by multiple factors including continuous antigenic stimulation, convergent 
recombination and structural constraints (Turner, Doherty et al. 2006, Gras, Kjer-Nielsen et al. 
2008, Li, Ye et al. 2012).  Such structural constraints playing a role in the emergence of TCR biases 
arise from the need to recognize atypical MHC landscapes including featureless and bulged 
epitopes (Gras, Kjer-Nielsen et al. 2008).  In an effort to understand TCR bias structural studies 
have investigated features of immunodominant responses and unearthed fundamental elements of 
the basis of TCR bias and TCR-MHC interactions.  Patterns of recognition between TCR and MHC 
have been identified indicating that a minimum of three positions on the MHC are contacted as a 
base requirement for MHC restriction (Tynan, Burrows et al. 2005).  The adaptability of TCRs is 
highlighted by the capacity to recognize peptide-based or lipid-based antigens through various 
docking strategies ranging from parallel to orthogonal (Gras, Kjer-Nielsen et al. 2008).   
Finite changes in the peptide ligand may result in viral escape as well as impact profoundly 
on the TCR repertoire. Thus, the TCR repertoire is a complex system determined by numerous 
factors including genetics and antigen exposure and further studies are required to unlock the 
mechanisms involved which may shed light on ways to optimize immunotherapeutic development.   
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1.2.6 The human TCR in Immune Responses 
As mentioned previously epitope-specific TCR repertoires are selected from a pool of naïve 
TCRαβ heterodimers in the range of around 2 x 107 (Arstila, Casrouge et al. 1999).  The adaptive 
immune system relies on T cells patrolling the blood stream to generate receptors with the ability to 
recognize and destroy virtually any pathogen.  TCR diversity is provided by gene rearrangement 
within the variable regions (CDR loops) resulting from the V (D) J recombination process (Attaf, 
Huseby et al. 2015).  Viral control, viral escape prevention and enhanced recognition of 
heterologous viruses are associated advantages of the utilization of highly diverse epitope-specific 
TCRs in response to viral infection (Charini, Kuroda et al. 2001, Messaoudi, Guevara Patino et al. 
2002, Cornberg, Chen et al. 2006, Wang, Dash et al. 2012).  In addition, TCR diversity has been 
shown to play a critical role towards homeostasis of Treg cells and suppressor function (Fohse, 
Suffner et al. 2011).  Of these 2 x 107 human TCRs, some clonotypes may be referred to as either 
“public” when found in different, unrelated individuals, or “private” when unique to the individual.  
This tendency of the clonotype appears to be encoded by the naïve repertoires (Thomas, Handel et 
al. 2013). Many studies have demonstrated distinct TCR repertoires in response to acute or 
persistent viral infections including influenza (Lehner, Wang et al. 1995), EBV (Argaet, Schmidt et 
al. 1994, Lim, Trautmann et al. 2000), human cytomegalovirus (HCMV) (Trautmann, Rimbert et al. 
2005) and Human Immunodeficiency Virus (HIV) (Kalams, Johnson et al. 1994). 
In one example, following acute influenza A virus infection, the CD8+ T cell response in 
HLA-A2+ individuals generally is directed predominantly towards a dominant influenza virus 
matrix protein epitope, MP58-66.  This HLA-A2 specific public response is characterised by CD8+ T 
cells specific for MP58-66 with a restricted TCR repertoire.  These epitope specific CD8+ T cells  
express a bias for Vβ17, and the highly conserved CDR3β sequences that contain the IRSSY motif 
(Moss, Moots et al. 1991, Lehner, Wang et al. 1995).   
Lim et al performed extensive TCR analysis on the dominant HLA-A2 restricted EBV 
epitope GLCTLVAML derived from the BMLF1 lytic protein.  Their findings showed several T 
cell clonotypes with recurrent Vβ subsets expressing Vβ2, Vβ4 or Vβ16 and highly conserved 
CDR3β motifs in epitope specific T cell lines derived from several unrelated individuals.  
Additionally, as the TCR α chains comprised the same TRAV region it is suggested that there is a 
hierarchical contribution of the TCR α-chain compared to the TCR β-chain CDR in the context of 
this particular pMHC complex (Lim, Trautmann et al. 2000).   
Another example of an EBV public TCR clonotype is prominent in HLA-B8+ individuals.  
This CD8+ T cell response is directed at the epitope FLRGRAYGL, derived from the EBNA3A 
protein.  Virtually all individuals select a particular T cell sequence denoted as the clonotype LC13 
(Argaet, Schmidt et al. 1994).  These CTL nearly all use the same TCRα and TCRβ chains derived 
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from identical Vα and Jα (TRAV 26-2*01, TRAJ52*01) and N region sequences and identical TCR 
Vβ, Dβ, and Jβ (TRBV7-8*03, TRBD1/D2, TRBJ2-7*01) sequences (Argaet, Schmidt et al. 1994).  
This highly conserved clonotype LC13 is the TCR used in the CD8+ T cell response to the 
FLRGRAYGL epitope by most HLA-B8+ individuals.  CD8+ T cells expressing this TCR are cross-
reactive with the alloantigen HLA-B*4402.  EBV+ individuals expressing both HLA-B*8 and 
HLA-B*4402 demonstrate a reduced B8-restricted CTL response to the FLRGRAYGL epitope.  Of 
most interest, is that these CD8+ T cells recognise neither HLA-B*4402 nor express the LC13 TCR 
seen in the HLA-B8 response (Burrows, Silins et al. 1995).   
An assessment of clonal diversity of CTL responses against HCMV by Trautmann and 
colleagues demonstrates a dramatic clonal focussing of CD8+ T cells specific for the HLA-A2-
restricted, pp65 epitope NLVPMVATV (NLV/A2).  These NLV/A2 specific T cells derived from 
distinct individuals displayed public TCR features in immunodepressed or chronic inflammatory 
disease patients.  In some instances, full conservation of the TCR Vα junctional region was 
observed. The NLV/A2 response in healthy individuals, however, was heterogenous with the CD8+ 
T cell response comprising a number of Vβ regions.  These findings suggest that the driving force 
behind this repertoire focusing in situations of repeated antigenic stimulation in the case of chronic 
inflammation and HCMV reactivation is TCR affinity/avidity (Trautmann, Rimbert et al. 2005).  It 
remains to be determined if clonal focussing is linked to a high frequency in the preimmune 
repertoire, an improved immune response or a requirement to optimize interactions with the TCR.   
 
1.2.7 TCR/pMHC Structures 
In 1996 Garboczi and colleagues reported the original description of the crystal structure of 
a mouse TCR, providing some insight on the structure of the TCR/pMHC complex (Garboczi, 
Ghosh et al. 1996). Since then over thirty unique structures for TCR/pMHC class I complex 
structures and twenty unique TCR/pMHC class II complex structures have been solved broadening 
our knowledge of these significant interactions (Rossjohn, Gras et al. 2015).  Generally, MHC 
molecules bind with peptides via a series of pockets within the peptide-binding groove.  These 
pockets are referred to as either A-F or P1-P9 in the case of MHC class I and MHC class II, 
respectively (Adams and Luoma 2013).  Predominantly, these are residues P5, P7 and P8 for 
nonamer peptides and P4, P6 and P7 for octamer peptides.  Due to the extensive backbone 
interactions in the MHC class II binding groove, MHC class II peptides demonstrate a more 
uniform dispersal of key side chain contributions which are predominantly seen at P-1, P2, P3, P5 
and P8 (Rudolph and Wilson 2002).  Polymorphism within the MHC is centred around the antigen-
binding cleft and is key in determining how and which peptides bind to any MHC molecule 
(Theodossis, Guillonneau et al. 2010).    
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Structural investigations showing docking geometry of TCR/pMHC complexes offers some 
insights as to how foreign peptides are recognised in the context of the same MHC and the role this 
may play in positive selection.  Generally, it is a diagonal orientation that the TCR adopts above the 
pMHC complex.  This orientation aligns the CDR1 and CDR2 loops over the α1 and α2 helices, or 
β1 helices of the MHC class I and MHC class II molecules, respectively (Rudolph and Wilson 
2002).  The basic affinity of the TCR for the generic MHC allele is provided by the interaction with 
the conserved germline CDR1 and CDR2 loops, whilst the CDR3 loop interacts with the peptide.  
In this context, the CDR1 and CDR2 loops are likely to play a role in positive selection, whereas the 
CDR3 loop’s role lies within negative selection (Rudolph and Wilson 2002).       
The structure of the TCR is comprised of an α- and a β- chain and resembles the overall 
scaffold of an Fab antibody fragment.  The assembly of the germline-encoded regions within the 
complex indicates the CDR1 and CDR2 regions mostly contact the helices of the MHC, whereas the 
CDR3 region is in contact with the peptide (Wilson and Garcia 1997).  Cradled within the MHC-Ag 
binding cleft, the peptide is positioned to enable the CDR3 loops of the TCR to sit above the MHC, 
permitting direct contact with the up-pointing peptide side chains.  It is the regions of the peptide 
outwardly oriented that can directly contact the TCR, whilst buried regions of the peptide may have 
an indirect effect on TCR binding (Theodossis, Guillonneau et al. 2010).  The interaction between 
the TCR and the pMHC occurs approximately in a diagonal orientation (Rudolph and Wilson 
2002). This docking method permits the TCR binding surface to fit between the high areas that are 
situated near the amino termini of each of the two MHC α helices, maximising the few peptide 
residues that are exposed to the TCR (Mazza and Malissen 2007).  The ability of the CDR3 loops to 
undergo conformational changes upon interaction with the pMHC underpins its role in TCR cross-
reactivity (Rudolph, Stanfield et al. 2006). 
The structural characteristics of the determined TCR/pMHC interactions have been 
compared and show that many closely related complexes vary in terms of the bound peptide, minor 
differences in MHC structure and subtle changes in TCR gene usage.  Interestingly, what appears to 
be common to all TCR/pMHC I complexes solved to date is the docking topology, whereby, the V 
α-chain sits over the  α2-helix and the V β-chain is positioned over the  α1-helix of the MHC class I 
molecule (Rossjohn, Gras et al. 2015).   
An elegant example is the archetypical LC13 TCR-HLA-B*0801-FLRGRAYGL structure 
(Figure 2).  Following antigen recognition, this immunodominant TCR undergoes extensive 
conformational change in the CDRs, including disruption of the CDR1α and CDR2α loops resulting 
in an enhanced fit with the pMHC complex.  With the focus on the long axis of the HLA-B8 peptide 
binding groove, the LC13 TCR binds in an approximate diagonal (60°) orientation.  Of note, the 
usage of the variable domains Vα (58%) and Vβ (42%) is approximately equal which is consistent 
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with public TCRα and TCRβ selection (Kjer-Nielsen, Clements et al. 2003).  The CDR3 loops were 
shown to be the driving force behind the interaction in a somewhat “peg and notch” manner with 
the P7-Tyr (peg) protruding into the central cavity (notch) of the LC13 TCR (Kjer-Nielsen, 
Clements et al. 2002, Kjer-Nielsen, Clements et al. 2003). 
 
Figure 2.  LC13 TCR Complexed to HLA-
B8/FLRGRAYGL. 
Ribbon representation of the LC13-HLA-B8-FLRGRAYGL 
complex.  The bound EBV peptide is shown in yellow.  The α-
chain and β-chain of the LC13 TCR are shown in green and 
grey, respectively.  The HLA-B*0801 molecule is shown in 
purple and the blue ribbons represent the β2-microglobulin 
domain (Kjer-Nielsen, Clements et al. 2003). 
 
 
Crystal structures of TCR/pMHC have demonstrated how the peptide contacts the 
TCR/MHC interface.  With the determining of more than 50 unique TCR-pMHC structures the field 
has seen a progression in knowledge in the area, however, there still remains fundamentals of T cell 
biology to be explored.    
   
1.3 Immune response to a herpes virus 
 
1.3.1 Herpesviridae 
In 2008 the International Committee on Taxonomy of Viruses updated the former family 
Herpesviridae by splitting members into three families and incorporating them into a new order 
Herpesvirales.  The family Herpesviridae retains mammal, bird and reptile viruses, while the new 
families Alloherpesviridae and Malacoherpesviridae incorporate fish and frog viruses and bivalve 
viruses, respectively (Davison, Eberle et al. 2009).  Herpesviruses have distinct morphology from 
20 
 
all other viruses.  A T = 16 icosahedral capsid contains a linear, double-stranded DNA genome of 
125-290 kbp.  This capsid is surrounded by a proteinaceous matrix dubbed the tegument and then 
by a lipid envelope containing membrane-associated proteins (Pellet and Roizman 2006). 
The family Herpesviridae is divided into subfamilies Alphaherpesviridae, 
Betaherpesviridae and Gammaherpesviridae.  A vast proportion of the human population is 
infected with one or more of the eight known human herpesviruses, including the 
alphaherpesviruses herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) and varicella-zoster virus 
(VZV), the betaherpesviruses human cytomegalovirus (HCMV) and human herpesviruses 6 and 7 
(HHV-6 and HHV-7) and the gammaherpesviruses Epstein-Barr virus (EBV) and Kaposi’s 
sarcoma-associated herpesvirus (KSHV) (Davison, Eberle et al. 2009).  Despite the presence of a 
powerful immune response directed against herpesviruses they have the ability to establish lifelong 
infections which have been associated with the development of several malignancies (Horst, 
Verweij et al. 2011). 
 
1.3.2 A Brief Overview of EBV 
EBV, a lymphotropic gamma-1 herpesvirus, is widespread in all human populations, 
infecting around 95% of the adult population worldwide.  The transmission of this lifelong 
persistent virus is via the oral route.  After close contact, viral particles present in the saliva of 
infected individuals enter into the oral cavity of the naïve individual, the virus is amplified by 
replicative (lytic) infection in permissive cells (probably epithelial) in the oropharynx.  This lytic 
infection results in vast amounts of virus shedding into the throat.  Simultaneously, the infection of 
the mucosal B cells occurs and the virus initiates latent, persistent infection of the B cell pool 
(Kutok and Wang 2006, Hislop, Taylor et al. 2007, Long, Taylor et al. 2011).  In developing 
countries, EBV is associated with an asymptomatic infection occurring usually in infancy or early 
childhood.  In developed countries, however, acute infection is often delayed until adolescence or 
early adulthood and in around 25% of cases can result in the self-limiting lymphoproliferative 
disorder, infectious mononucleosis (IM).  IM was etiologically linked to EBV in 1968 by Henle et 
al, symptoms associated with IM range from fever and sore throat to lymphadenopathy and 
splenomegaly (Henle, Henle et al. 1968, Kutok and Wang 2006, Rickinson and Kieff 2007).   
EBV types 1 and 2 (also denoted as types A and B) circulate in most populations.  These 
viral types differ largely in nuclear protein genes that encode EBNA-LP, EBNA2, EBNA3A, 
EBNA3B and EBNA3C, which are expressed in the latency III stage, with up to 47% amino acid 
sequence difference between types 1 and 2 for EBNA 2 alone.  Type 1 is predominantly seen in 
developed countries, whereas type 2 is prevalent in equatorial Africa and New Guinea populations 
(Kieff and Rickinson 2007).  Although EBV infection is generally benign and uneventful it is 
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currently associated with a number of malignancies.  Diseases of the immunocompetent host 
associated with EBV include Burkitt’s Lymphoma (BL), Hodgkin’s Lymphoma (HL) and 
nasopharyngeal carcinoma (NPC) and those of the immunocompromised host include post-
transplantation lymphoproliferative disorder (PTLD), AIDS associated B cell lymphomas, Wiskott-
Aldrich syndrome-associated B cell lymphomas and Leiomyosarcoma (Kutok and Wang 2006).   
There are a number of forms of EBV latency, apart from Latency 0 infection in which all 
antigen expression is suppressed, all forms express EBER1 and EBER2 RNAs and the Bam HIA 
rightward transcripts.  During Latency I infection EBNA-1 is also expressed.  In Latency II 
infection EBNA-1 is expressed as well as LMP from promoters in the Bam HIN region of the 
genome.  Latency III infection sees the full spectrum of latent proteins expressed, including EBNA-
1, 2, 3A, 3B, 3C and –LP (Rickinson and Kieff 2007).  Some five decades on since the discovery of 
EBV by Epstein and colleagues (Epstein, Achong et al. 1964) and a vaccine continues to elude 
immunologists the world over. 
 
1.3.3 Structure of EBV 
EBV, as with other herpesviruses, has a toroid-shaped DNA core in a nucleocapsid with 162 
capsomeres, a protein tegument lies between the nucleocapsid and an outer envelope with external 
glycoprotein spikes.  The virus contains a linear, double stranded, 184kb DNA genome, features of 
which include short and long unique sequence domains, internal (IR1) and terminal (TR) tandem 
repeat and direct repeats, as well as perfect and imperfect DNA repeats, most of which are within 
the open reading frame (ORF).  The linear termini of the genome join intracellularly to form 
circular, episomal DNA.  The number of TR in any given linear genome is highly variable, a result 
of the random TR cleavage that creates full length genomes.  A signature number of TRs is created 
when the linear genome circularises into the viral episome (Figure 3a).  This signature remains 
during episomal replication in dividing cells and all subsequent daughter cells derived from the 
single infected cell share this signature which can be used to determine clonal populations of EBV-
infected cells (Kutok and Wang 2006, Kieff and Rickinson 2007).   
 
1.3.4 Lytic EBV Proteins of interest  
Around 80 EBV proteins are expressed during lytic viral replication, which involves the 
sequential expression of immediate early, early and late proteins.  Lytic cycle activation is initiated 
by the expression of two immediate early proteins BZLF1 (Zta) and BRLF1 (Rta).  Cox et al noted 
that Rta and Zta appeared to regulate gene expression at the level of transcription and that these 
transactivators work in concert to facilitate reactivation (Cox, Leahy et al. 1990).  BZLF1 is a 
member of the basic leucine zipper family which binds to the AP1-like Z response elements in EBV 
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early promoters (Zalani, Holley-Guthrie et al. 1996).   BRLF1 has distant homology to c-myb 
which interacts with BZLF1 transactivating the BMRF1 promoter (Kenney, Holly-Guthrie et al. 
1992).  BMRF1, an early protein has proved to be essential for the production of infectious EBV 
progeny as well as being associated with enhanced expression of BHLF1 (Neuhierl and Delecluse 
2006).  The early transactivator protein, BMLF1 is activated by the expression of BZLF1 and 
BRLF1(Lieberman, O'Hare et al. 1986). 
 
1.3.5 Latent EBV Proteins of interest 
During latent infection, EBV genes hijack normal B cell mechanisms leading to the 
establishment of lymphoblastoid cell lines (LCLs).  At least nine latency-associated viral antigens 
are expressed by LCLs and include the six nuclear antigens, EBV nuclear antigen 1 (EBNA1), 
EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNA leader protein (LP) and latent membrane 
proteins LMP1, LMP2A and LMP2B (Figure 3b).  As discussed earlier when all nine of these 
antigens are expressed it is referred to as latency III form of EBV infection (Kutok and Wang 2006, 
Rickinson and Kieff 2007).  The focus will now shift to EBNA1 and the three EBNA3 genes, 
EBNA3A, -3B and -3C.  EBNA1 is essential for the persistence and maintenance of the EBV 
episome and enhancing genome expression.  A unique feature of EBNA1 is the glycine-alanine 
repeat (GAr) domain which inhibits MHC class I presentation of cis-linked epitopes.  Also of great 
importance, EBNA1 is the only viral protein that is expressed in all forms of latency and in all 
EBV-associated malignancies (Rickinson and Kieff 2007, Long, Taylor et al. 2011).   
Tandemly placed in the EBV genome, EBNA3A, -3B and -3C share a similar gene 
structure.  These three stable proteins can interact with cellular proteins involved in transcription 
regulation and bind to the cellular repressor-binding protein (RBP)-Jκ (Le Roux, Kerdiles et al. 
1994, Young and Rickinson 2004).  EBNA3A and EBNA3C are both critical for B-lymphocyte 
growth transformation and survival.  Interestingly, EBNA3B is not essential for latent infection of 
B lymphocytes and cell survival, although its presence in EBV isolates of healthy carriers indicates 
that it plays a part in natural infection (Kieff and Rickinson 2007).  Recent observations from White 
and colleagues investigating viruses lacking this gene in both a humanized mouse model and 
patients with aggressive lymphomas suggest that EBNA3B behaves as a tumour suppressor.  This 
appears to apply across all EBV strains, not just the B95-8 strain and may play a role in minimizing 
an oncogenic risk to the host (White, Ramer et al. 2012).      
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Figure 3. Epstein-Barr virus genome. a) Electron micrograph of the EBV virion.  b) 
Diagramatic representation of the location and transcription of the EBV latent genes on the 
double-stranded viral DNA episome (Young and Rickinson 2004).   
 
1.3.6 Cellular Immune Responses to EBV         
CD8+ T cells recognise peptides derived from viral proteins associated with MHC 
molecules.  The adaptive immune response, in particular T cells, is vital in controlling EBV infected 
B-cell proliferation and is of immense importance during persistent infection (Hislop, Taylor et al. 
2007).  Studies focusing on the CD8+ T cell response during IM portray a pattern of reactivity that 
to an extent mirrors the EBV infection cycle.  Individual lytic epitopes have been shown to 
constitute up to 50% of the CD8+ T cell population.  EBV epitope-specific reactivities are typically 
seen at a higher frequency towards epitopes from immediate early (BZLF1 and BRLF1) antigens or 
a subset of early antigens (including BMRF1 and BMLF1).  Delayed early and in particular late 
lytic antigens have a tendency for less frequent or smaller responses (Hislop, Taylor et al. 2007, 
Abbott, Quinn et al. 2013).  Indeed this hierarchy correlates with the varying levels at which 
epitopes from these lytic proteins are presented on the surface of infected cells and portrays a 
system whereby the virus’s array of immune evasion proteins seeks to impair the cell’s antigen 
processing capacity (Rowe and Zuo 2010).   
Responses to latent epitopes are present at a vastly reduced frequency in IM compared to 
lytic epitope responses, with individual epitope specificities contributing up to only 5% of CD8+ T 
cells (Hislop, Kuo et al. 2005).  The largest focus of responses is towards epitopes in the EBNA3 
family of proteins (EBNA3A, EBNA3B and EBNA3C), which appears to likely reflect this group 
of proteins accounting for around 60% of the latent genes coding capacity.  Responses towards 
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other latent antigens including EBNA1, EBNA2, EBNA-LP and LMP2 have also been seen at an 
equal intensity (Hislop, Taylor et al. 2007, Taylor, Long et al. 2015).  Qualitative changes in the 
content of EBV-specific CD8+ T cell responses have been noted over time following infection.  A 
lytic epitope restricted by HLA-A2 with reactivties equal to other sustained epitopes has been 
shown to disappear post-IM, whilst responses to latent epitopes may not be detectable until 3-4 
months post primary infection (Hislop, Annels et al. 2002).  These changes result in a complex 
distribution of EBV-specific reactivities whereby CD8+ T cell responses for one individual may 
present quite differently when at the post-IM state compared to at the height of acute infection 
(Hislop, Taylor et al. 2007).     
A number of CD8+ T cell responses to EBV latent and lytic proteins of interest have been 
previously described and are shown in Table 1 and Table 2, respectively.  Lytic proteins BRLF1 
and BZLF1 have a number of defined CD8+ T cell epitopes presented by HLA-A, B and C.  For 
example,  Pepperl et al defined several BRLF1 epitopes including the HLA-A24-restricted decamer 
epitope DYCNVLNKEF, and ATIGTAMYK restricted to HLA-A11, as well as the HLA-Cw4-
restricted ERPIFPHPSKPTFLP epitope and HLA-B61 restricted QKEEAAICGQMDLS epitope 
(Pepperl, Benninger-Doring et al. 1998).  Examples of BZLF1 epitopes are HLA-B8-restricted 
RAKFKQLL (Bogedain, Wolf et al. 1995) and the HLA-B*3501-restricted EPLPQGQLTAY 
epitope (Saulquin, Ibisch et al. 2000).  
There are less known epitopes from the early lytic proteins BMLF1 and BMRF1.  Steven et 
al have however defined a number of epitopes from both these proteins.  These include the HLA-
A2-restricted GLCTLVAML and HLA-B18-restricted DEVEFLGHY epitopes which are both from 
the BMLF1 protein (Steven, Annels et al. 1997).  BMRF1 epitopes include the HLA-Cw6 
YRSGIIAVV peptide which has also been found to be restricted by HLA-B39 by Pudney et al and 
the FRNLAYGRTCVLGKE epitope with HLA-Cw3 restriction, for which the minimal active 
sequence has not been precisely mapped (Steven, Annels et al. 1997, Pudney, Leese et al. 2005).  
Results from Pudney and colleagues suggest a focusing of CD8+ T cell responses toward epitopes 
from immediate early and early proteins and a hierarchy of immunodominance amongst the EBV 
lytic cycle antigens (Pudney, Leese et al. 2005).     
The elusive search for an EBNA1 CTL epitope came to fruition in 1997 when Blake et al 
showed that CD8+ T cell responses to EBNA1 epitopes were in fact detectable in humans with the 
discovery of two EBNA1 epitopes HPVGEADYFEY restricted to HLA-B*3501 and the HLA-
A*0203-restricted VLKDAIKDL (Blake, Lee et al. 1997).  In addition to this previous work, in 
2000 Blake and colleagues mapped another three EBNA1 epitopes, two HLA-B7-restricted epitopes 
RPQKRPSCI and IPQCRLTPL and the HLA-B53-restricted epitope HPVGEADYF, which lies 
within the HLA-B*3501 HPVGEADYFEY sequence (Blake, Haigh et al. 2000).   
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There are a number of immunodominant epitopes attributed to the EBNA3 proteins.  One 
particular immunodominant EBNA3A epitope is HLA-B8-restricted FLRGRAYGL (FLR) which 
dominates over another HLA-B8-restricted epitope, QAKWRLQTL (Burrows, Sculley et al. 1990) 
(Burrows, Gardner et al. 1994).  FLR may be considered the most effective of CTL epitopes as this 
domination by a single TCR has been shown during acute primary infection (Callan, Annels et al. 
1998) as well as the major clonotype for at least 18 years (Miles, Silins et al. 2005). This 
immunodominance phenomena is also seen in the response to the EBNA3B HLA-A11-restricted 
epitopes, where IVTDFSVIK is dominant over AVFDRKSDAK (Gavioli, Kurilla et al. 1993).  
Interestingly, most of the known EBNA3C epitopes are HLA-B restricted including the HLA-
B*2705-restricted LRGKWQRRYR and FRKAQIQGL epitopes.  Some epitopes are restricted by 
multiple class I HLA alleles such as the immunodominant RRIYDLIEL epitope which is presented 
by the HLA-B27 subtypes –B*2702, -B*2704 and –B*2705  (Brooks, Murray et al. 1993, Hill, 
Worth et al. 1995).   
 
1.3.7 Unusually long EBV CTL Epitopes 
Generally peptide epitopes presented by MHC class I molecules are 8 to 10 residues in 
length.  For most MHC class I alleles two pockets within the peptide binding groove display a 
marked preference for two or three amino acids at certain anchor positions within the peptide 
(Rammensee, Falk et al. 1993).  Although most peptides naturally presented for recognition by 
MHC class I molecules conform to this canonical length (8-10 residues), it has been demonstrated 
by several groups investigating a diverse range of viruses and several melanoma antigens that 
peptides of 11-14 residues can bind to particular MHC class I molecules (Burrows, Rossjohn et al. 
2006).  Indeed, earlier findings from our group demonstrate unusually long peptides binding to 
MHC class I molecules (Green, Miles et al. 2004, Burrows, Bell et al. 2008), (M. J. Rist, J. M. 
Burrows and S. R. Burrows, unpublished data).  
Based on information including proteasome fragment length preference (Wenzel, 
Eckerskorn et al. 1994), class I antigen processing machinery (Pamer and Cresswell 1998) and TAP 
peptide length preferences (Momburg, Roelse et al. 1994), web-based algorithms have been 
designed to predict MHC class I peptides between 8-10 residues (Rammensee, Bachmann et al. 
1999, Nussbaum, Kuttler et al. 2003).  Despite these limitations and using alternate approaches to 
these web-based algorithms, there are numerous reports defining unusually long CD8+ T cell 
epitopes over 10 residues in length presented by MHC class I molecules (Burrows, Rossjohn et al. 
2006).  Twenty-six CTL epitopes greater than 10 amino acids in length have been reported in 
viruses including HIV (Sipsas, Kalams et al. 1997), HCMV (Weekes, Wills et al. 1999), hepatitis B 
virus (Schirmbeck, Melber et al. 1994) and melanoma antigens (Aarnoudse, van den Doel et al. 
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1999, Kawakami, Wang et al. 2001).  Of note, is the 14mer epitope derived from an alternate 
opening reading frame of the macrophage colony stimulating factor gene.  This CTL epitope is 
naturally presented by HLA-B*3501 (Probst-Kepper, Stroobant et al. 2001, Probst-Kepper, Hecht et 
al. 2004).      
Several MHC class I bound, immunogenic peptides that are longer than 10 residues have 
undergone structural characterisation that has shown in each case, the peptide adopts a bulging 
confirmation whereby the extra length “inserts” between the primary anchor residues.  This 
adaptation maintains the hydrogen bonding with the peptide N- and C- termini (Probst-Kepper, 
Hecht et al. 2004, Tynan, Borg et al. 2005, Miles, Borg et al. 2006).  Six of these defined unusually 
long CTL epitopes are derived from EBV antigens (Blake, Lee et al. 1997, Rickinson and Moss 
1997, Green, Miles et al. 2004, Pudney, Leese et al. 2005, Burrows, Bell et al. 2008).  For example, 
the highly immunogenic 13-mer epitope, 52LPEPLPQGQLTAY64 (LPEP) from the BZLF1 antigen 
of EBV that is presented by HLA-B*3508 (Green, Miles et al. 2004).  Also from BZLF1 and 
completely overlapped by the 13mer is the 11mer 54EPLPQGQLTAY64 naturally presented by the 
HLA-B*3501 allele (Miles, Elhassen et al. 2005).  116RPQGGSRPEFVKL128 is a 13mer epitope that 
binds to HLA-B*0702 from the lytic EBV antigen BMRF1 (Pudney, Leese et al. 2005).  Another 
example of a noncanonical epitope is the 11-mer 407HPVGEADYFEY417 (HPV), derived from the 
EBNA1 protein of EBV (Blake, Lee et al. 1997).  HPV has been found to be highly immunogenic 
and binds promiscuously to two HLAs and may be recognised by individuals expressing either 
HLA-B*3501 or HLA-B*3508.  Structural studies indicate HPV bulges out of the MHC molecule, 
in HLA-B*3501 the bulged section was disordered, whereas the bulged epitope adopts an ordered 
confirmation in relation to HLA-B*3508 (Miles, Borg et al. 2006).   
A number of these unusually long CTL epitopes completely overlap with shorter sequences 
within the peptides that conform to the conventional binding length and score well using the 
binding algorithms, however, have not been found to be immunogenic.  Both HPV and LPEP are 
such examples.  HPV has been shown to be immundominant over shorter peptides HPVGEADY 
and HPVGEADYF that both conform to the peptide binding motif of HLA-B*3501 (Blake, Lee et 
al. 1997).  Additionally, LPEP has been shown to bind with a higher affinity to HLA-B*3508 
compared to the shorter sequences EPLPQGQLTAY and LPQGQLTAY which both conform to the 
binding motif of the HLA-B*3508 allele (Green, Miles et al. 2004). 
A number of MHC class I molecules have demonstrated the ability to present unusually long 
CTL epitopes (Burrows, Rossjohn et al. 2006).  Interestingly, five of the six EBV noncanonical 
epitopes are presented by members of the HLA-B7 supertype family.  These alleles include HLA-
B*0702, HLA-B*3501 and HLA-B*3508 which prefer peptides with a Proline at position 2.  It has 
been postulated by Burrows and colleagues that members of this supertype present a high number 
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of long peptides due to a unique feature of the class I antigen processing pathway (Burrows, 
Rossjohn et al. 2006).  As a result of the ER-associated aminopeptidases inability to cleave the bond 
at the N- side of Proline, an accumulation of peptides with x-Pro-xn sequence is likely to occur 
(Serwold, Gaw et al. 2001), with many of these peptides likely to be long.  As the HLA-B7 
supertype has a preference for Prolines at position 2 these alleles are more likely to have unusually 
long CTL epitopes available for presentation within the ER compared to other HLA alleles that are 
not members of this supertype (Burrows, Bell et al. 2008). 
Four out of the six unusually long EBV CTL epitopes are located in lytic antigens BZLF1 
and BMRF1, with the remaining two epitopes from the latent antigens EBNA1 and EBNA3B.  With 
such numbers it is difficult to ascertain if this is representative of a pattern or disproportionate lean 
towards the lytic antigens containing a majority of the noncanonical epitopes.  It may reflect the 
individual epitope-specific populations that are typically 0.2-2% and 0.05-1% of the CTL 
population for lytic and latent epitopes, respectively (Bihl, Frahm et al. 2006).  In addition, this 
observation mirrors to an extent the relative immunodominance of CTL responses of the lytic and 
latent cycle antigens (Hislop, Taylor et al. 2007).  What remains to be determined is the frequency 
with which unusually long CTL epitopes are recognized by CD8+ T cells and if there are other 
MHC class I alleles capable of naturally presenting such epitopes. 
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Table 1 Latent EBV CD8+ T cell epitopes (adapted from Hislop et al, 2007) 
EBV Antigen Epitope 
Coordinates 
Epitope Sequence HLA Restriction Reference 
Latent     
EBNA1 72-80 RPQKRPSCI B7 Blake et al, 2000 
 407-415 HPVGEADYF B53 Blake et al, 2000 
 407-417 HPVGEADYFEY B35.01 Blake et al, 1997 
 528-536 IPQCRLTPL B7 Blake et al, 2000 
 574-582 VLKDAIKDL A2.03 Blake et al, 1997 
 566-574 LQTHIFAEV A2 (Marescotti, Destro 
et al. 2009) 
EBNA3A 158-166 QAKWRLQTL   B8 (Burrows, Gardner 
et al. 1994) 
 176-184 AYSSWMYSY A30.02 (Steven, Leese et al. 
1996) 
 246-253 RYSIFFDY A24 Burrows et al, 1994 
 325-333 FLRGRAYGL   B8 (Burrows, Sculley et 
al. 1990) 
 378-387 KRPPIFIRRL   B27 Brooks J, unpub 
 379-387 RPPIFIRRL   B7 Hill et al, 1995 
 406-414 LEKARGSTY B62 Rickinson and 
Moss, 1997 
 450-458 HLAAQGMAY ? Burrows et al, 1994 
 458-466 YPLHEQHGM   B35.01 Burrows et al, 1994 
 491-499 VFSDGRVAC A29 Rickinson and 
Moss, 1997 
 502-510 VPAPAGPIV B7 Rickinson and 
Moss, 1997 
 596-604 SVRDRLARL A2 Burrows et al, 1994 
 603-611 RLRAEAQVK A3 (Hill, Lee et al. 
1995) 
 617-625 VQPPQLTLQV   B46 (Whitney, Chan et 
al. 2002) 
EBNA3B 149-157 HRCQAIRKK   B27.05 Rickinson and 
Moss, 1997 
 217-225 TYSAGIVQI A24.02 Rickinson and 
Moss, 1997 
 244-254 RRARSLSAERY B27.02 Brooks et al, 1993 
 279-287 VSFIEFVGW   B58 (Lee, Chan et al. 
2000) 
 399-408 AVFDRKSDAK   A11 (Gavioli, Kurilla et 
al. 1993) 
 416-424 IVTDFSVIK   A11 Gavioli et al, 1993 
 488-496 AVLLHEESM B35.01 Rickinson and 
Moss, 1997 
 657-666 VEITPYKPTW   B44 Rickinson and 
Moss, 1997 
EBNA3C 163-171 EGGVGWRHW   B44.03 (Morgan, Wilkinson 
et al. 1996) 
 213-222 QNGALAINTF B62 (Kerr, Kienzle et al. 
1996) 
 249-258 LRGKWQRRYR B27.05 Brooks et al, 1993 
 258-266 RRIYDLIEL   B27.02/.04/.05 Brooks et al, 1993 
 271-278 HHIWQNLL B39 Rickinson and 
Moss, 1997 
 281-290 EENLLDFVRF   B44.02 (Burrows, Misko et 
al. 1990) 
 284-293 LLDFVRFMGV A2.01 Kerr et al, 1996 
 285-293 LDFVRFMGV B37 (Shi, Smith et al. 
1997) 
 335-343 KEHVIQNAF B44.02 (Khanna, Burrows et 
al. 1992) 
 343-351 FRKAQIQGL B27.05 Brooks et al, 1993 
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Table 2 Lytic EBV CD8+ T cell epitopes (adapted from Hislop et al, 2007) 
EBV Antigen Epitope 
Coordinates 
Epitope Sequence HLA Restriction Reference 
Lytic     
BRLF1 25-39 LVSDYCNVLNKEFT B18 Pepperl et al, 1998 
 25-33 LVSDYCNVL A2.05 Annels NE, unpub 
 28-37 DYCNVLNKEF A24 Pepperl et al, 1998 
 91-99 AENAGNDAC B45 Pudney et al, 2005 
 101-115‡ IACPIVMRYVLDHLI A24/Cw2 Pudney et al, 2005 
 109-117 YVLDHLIVV A2.01 Saulquin et al, 
2000 
 121-135 FFIQAPSNRVMIPAT Unknown Pepperl et al, 1998 
 134-142 ATIGTAMYK A11 Pepperl et al, 1998 
 148-156 RVRAYTYSK A3 Benninger-Doring 
et al, 1999 
 225-239 RALIKTLPRASYSSH A2 Pepperl et al, 1998 
 393-407 ERPIFPHPSKPTFLP Cw4 Pepperl et al, 1998 
 441-455 EVCQPKRIRPFHPPG Unknown Pepperl et al, 1998 
 529-543 QKEEAAICGQMDLS B61 Pepperl et al, 1998 
     
BZLF1 52-63 LPEPLPQGQLTAY B35.08 Green et al, 2004 
 
54-63 EPLPQGQLTAY B35.01 
Saulquin et al, 
2000 
 77-86 APQPAPENAY B35.08 Tynan et al, 2005  
 
79-89 QPAPENAYQAY B35.01/08 
(Burrows, Bell et 
al. 2008) 
 
172-183 DSELEIKRYKNR B18 
(Saulquin, Ibisch et 
al. 2000) 
 
190-197 RAKFKQLL B8 
Bogedain et al, 
1995 
 197-205 LQHYREVAA Cw8 Pudney et al, 2005 
 
209-217 SENDRLRLL B60 
(Scotet, David-
Ameline et al. 
1996) 
     
BMLF1 265-273 KDTWLDARM Unknown Steven et al, 1997 
 259-267 GLCTLVAML A2.01 Steven et al, 1997 
 397-405 DEVEFKGHY B18 Steven et al, 1997 
 435-444 SRLVRAILSP B14 Annels NE, unpub 
     
BMRF1 20-28 CYDHAQTHL A24 Pudney et al, 2005 
 86-100‡ FRNLAYGRTCVLGKE Cw3/10 Steven et al, 1997 
 116-128 RPQGGSRPEFVKL B7 Pudney et al, 2005 
 208-216 TLDYKPLSV A2.01 (Hislop, Annels et 
al. 2002) 
 268-276 YRSGIIAVV Cw6 Steven et al, 1997 
 268-276 YRSGIIAVV B39 Pudney et al, 2005 
 286-295 LPLDLSVILF B53 Annels NE, unpub 
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1.4  Scope of Thesis: Aims and Hypotheses 
The primary aim of this study was to explore highly immunogenic antigens of Epstein-Barr virus to 
identify novel epitopes.  This was conducted in an unbiased investigation of both epitope length and 
HLA involvement. 
 
Aim One: Determine the relative prevalence of peptide epitopes of over 10 amino acids in length in 
CD8+ T cell recognition of EBV. 
 
Hypothesis One:  Peptide epitopes of over 10 amino acids in length are abundant in antiviral 
CD8+ T cell responses. 
 
Aim Two:  Determine if the highly immunogenic BZLF1 antigen of EBV includes novel CD8+ T 
cell epitopes.  
 
Hypothesis Two: There are many unidentified CD8+ T cell epitopes to be defined in the 
BZLF1 antigen.  
 
Aim Three: Determine if the peptide length preferences of class I human leukocyte antigens 
influence epitope selection in the EBV-specific T cell response. 
 
Hypothesis Three: Different class I human leukocyte antigens have distinct peptide length 
preferences, and this influences epitope selection in the EBV-specific T cell response. 
 
Aim Four: Characterise a cross-reactive T cell response to an EBV epitope and self-peptide 
presented by HLA-B*1801. 
 
Hypothesis Four: The T cell receptor repertoire that cross-reacts with an EBV epitope and a 
self-peptide are identical between individuals. 
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2.1 Cell Culture 
 
2.1.1 Ficoll-Paque Density Gradient – lymphocyte isolation 
Blood (obtained with informed consent and approval from the QIMR Berghofer Medical 
Research Institute Human Research Ethics Committee, Brisbane, Queensland, Australia) was 
diluted 1:1 with warmed RPMI1640 medium (37°C) and mixed.  10mL of Ficoll-Paque (StemCell 
Technologies, USA) was aliquoted into a 30ml flat bottom tube and slowly overlayed with up to 
20ml of blood/RPMI1640 mixture.  These tubes were centrifuged at 500 x g for 20 minutes without 
the brake.  Separation of the blood results in a number of defined layers.  The top layer consists of 
plasma, the middle layer is lymphocyte rich, including monocytes, followed by the layer of Ficoll 
and the base layer of red blood cells (RBC) and granulocytes.  The central, lymphocyte-rich layer 
made up of peripheral blood mononuclear cells (PBMCs) was harvested into 10mL tubes containing 
6mL of RPMI1640.  PBMCs were pelleted by centrifugation at 244 x g for 10 minutes with brake.  
The supernatant was aspirated using a vacuum pipette and the PBMCs were again pelleted by 
centrifugation at 244 x g for 10 minutes with brake.  If RBC contamination was apparent, 
subsequent washes were performed.  Following the final wash, PBMCs were resuspended into 5mL 
of RPMI1640 supplemented with 10% fetal calf serum (FCS).  PBMC concentration was 
determined by counting the cells using a haemocytometer and microscope.       
 
2.1.2 Cryopreservation and thawing of cells 
Cryopreservation of cells in a 1ml cryovial routinely consists of a 50/50 ratio of 500μL cells 
resuspended in RPMI1640 with 10%FCS (R10) and 500μL of cryoprotectant solution, R10 
containing 20% dimethyl sulfoxide (DMSO) (Sigma, USA).  Tubes containing the required 
resuspension of cells and appropriate volume of cryoprotectant solution were placed in a beaker of 
chilled water maintained at 4°C for at least 30 minutes.  500μL of cells was mixed thoroughly with 
500μL of the R10/DMSO solution (final DMSO concentration of 10%) and aliquoted into cryovials 
(Nunc, USA).  These cryovials were placed in a Mr Frosty cooling container (Nalgene, USA) and 
immediately stored in the -80°C freezer.  The Mr Frosty container consists of an isopropanol-
containing wall that enables the cooling rate of -1°C/minute rate essential for successful 
cryopreservation.  After 24 hours cyrovials of cells may be moved into liquid nitrogen for long term 
storage. 
 Following removal from liquid nitrogen tanks, cells were thawed by placing the cryovial in 
beakers of heated water (37°C).  These thawed cells were transferred into 10mL tubes containing 
9mL of warmed R10.  Cells were centrifuged at 244 x g for 10 minutes and resuspended in fresh 
R10 to ensure residual DMSO removal. 
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2.1.3 Generating Phytohaemagglutinin blasts 
A mitogen for T cells, phytohaemagglutinin (PHA), rapidly causes T cells to divide and 
remain viable for 6-8 weeks.  Leucoagglutinin (PHA-L) was added at a concentration of 10μg/mL 
to 2x106 PBMCs in 10ml of R10, aliquoted into a T75 flask (Nunc, Denmark).  On day 4, T cell 
media (TCM) was added to the culture.  TCM consists of RPMI1640 supplemented with 10% FCS, 
30% T cell growth factor (TCGF) (supernatant from Gibbon lymphosarcoma T cell line, MLA-144) 
and 20 units/mL of interleukin-2 (IL-2) (Hoffman-LaRoche, USA).  The PHA blasts were 
maintained with addition of fresh TCM bi-weekly. 
 
2.1.4 Generating Lymphoblastoid Cell Lines 
Lymphoblastoid cell lines (LCLs) were generated by the exogenous transformation of B 
cells with EBV derived from B95-8 or QIMR-Wil cell lines.  2x106 PBMCs were pelleted in a 
10mL tube and 1mL of filtered (0.65μM) supernatant from the B95-8 cell line was added and 
lightly vortexed.  This was then incubated for 1 hour at 37°C.  A final volume of 10mL R10 was 
added to the tube and the cells were centrifuged at 244 x g for 10 minutes.  The cell pellet was 
resuspended in 5mL CSA media, consisting of RPMI1640 medium with 10% FCS and cyclosporin 
A (0.1 mg/ml) (Sigma-Aldrich, USA).  Dilutions of these cells were added to 6 wells of a 24 well 
tissue culture plate.  2mls was added to the first well, 1ml to the second well, adding a lesser 
volume of cells across the remaining 4 wells with the last well containing 300μL of cells.  All wells 
were made up to a final volume of 2mLs with CSA media and incubated in a 37°C, 5%CO2/95% air 
humidified incubator.  Bi-weekly addition of CSA media for 4 weeks enabled EBV-infected, 
transformed B cells to divide and establish into an immortal lymphoblastoid cell line.  Mature LCLs 
can be subcultured indefinitely with R10 media. 
 Spontaneous LCLs were also established without the exogenous addition of EBV.  These 
LCLs arise from the spontaneous outgrowth from PBMCs of EBV sero-positive donors.  This 
involved culturing the PBMCs in 96 well flat-bottom plates at various cell densities for 2 months in 
CSA media (RPMI1640 medium with 10% FCS and cyclosporin A (0.1 mg/ml).       
 
2.1.5 Generating LCL-stimulated T cell lines 
EBV-specific CTL cultures were raised by culturing PBMCs (2x106/2mL well) with 
autologous lymphoblastoid cell lines (LCLs) (2x105/2mL well) (responder/stimulator = 10:1).  
LCLs were γ-irradiated (8000 rad) in 10mL tubes.  R10 media was added to the tubes of irradiated 
LCLs to a final volume of 10mL and centrifuged at 244 x g for 10 minutes.   The responders and 
stimulators were combined at a 10:1 ratio in 24 well plates and incubated for 3 days. Cultures were 
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supplemented with TCM on day 3, split on day 7, and subcultured for up to 18 days.  There was no 
HLA preference in the production of CTL cultures, only EBV sero-positive status. 
 
2.1.6 Generating peptide-stimulated T cell lines 
CTL bulk cultures were raised by culturing PBMCs (2x106/2mL well) with autologous 
PBMCs that were precoated with the required peptide (0.1μM for 1 hour, responder/stimulator = 
2:1).  The peptide-coated stimulators were washed 3 times (final volume of 10mL R10, centrifuged 
at 244 x g for 10 minutes, supernatant aspirated) following the one hour incubation to remove 
unbound peptide.  The responders and stimulators were combined in 24 well plates and incubated 
for 3 days.  Cultures were supplemented with TCM on day 3, split on day 7 and subcultured for up 
to 18 days. 
 
2.2 Cell surface staining and functional assays  
 
2.2.1 Flow cytometric multimer staining 
PBMCs or CTLs were stained with pHLA multimers by incubation for 30 minutes at 4°C 
with an allophycocyanin-labelled (APC) HLA-Cw*06-CRAKFKQLL (National Institute of Health, 
USA) or APC-labelled HLA-B*1801-SELEIKRY or a phycoerythrin-labelled (PE) HLA-B*4403-
EECDSELEIKRY multimer (Manufactured by collaborator Lucy Sullivan, University of 
Melbourne, Australia) (Briefly, recombinant HLA B1801 or HLA B4403 and human b2 
microglobulin, produced in Escherichia coli, were solubilised in urea and injected together with 
SELEIKRY or EECDSELEIKRY, respectively into a refolding buffer consisting of 100mM Tris 
(pH 8.0), 400mM arginine, 2mM EDTA, 5mM reduced glutathione, and 0.5mM oxidized 
glutathione.  Refolded complexes were purified by anion exchange chromatography using DE52 
resin (Whatman, Tewksbury, USA) followed by gel filtration through a Superdex 75 column 
(Amersham Pharmacia Biotech, Piscataway, USA).  The refolded HLA-B1801-SELEIKRY and 
HLA-B4403-EECDSELEIKRY complexes were biotinylated by incubation for 16 hours at 30°C 
with the BirA enzyme (Avidity, USA).  Multimeric HLA-peptide complexes were produced by the 
stepwise addition of extravidin-conjugated PE (Sigma, USA) or APC (Sigma, USA) to achieve a 
1:4 molar ratio (extravidin-PE or APC:biotinylated class I)). Cells were then washed and incubated 
with peridinin-chlorophyll protein with a cyanine dye (PerCP-Cy5.5) –conjugated anti-human CD8 
mAb (BioLegend), PE with a cyanine dye (PE-Cy7)-conjugated anti-human CD3 mAb 
(eBioscience) and Alexa Fluor 700-conjugated anti-human CD4 (BD Pharmingen) for 30 minutes at 
4°C.  Cells were washed twice in FACS buffer (2% FCS in phosphate buffered saline (PBS)), 
centrifuging at 1000 x g for 2 minutes and pouring off the supernatant between washes.  These 
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samples were then analysed on a FACS LSR Fortessa flow cytometer using FACSDiva software 
(BD Biosciences).  If the samples were not analysed immediately, they were fixed in 1% 
paraformaldehyde (PFA) in PBS.        
 
2.2.2 Intracellular Cytokine Staining (ICS) 
PBMCs or T cells were incubated for 4-5 hours at 37°C with various synthetic peptides 
(1μg/ml) in R10 supplemented with 5μg/ml Brefeldin A (BioLegend).  These cells were then 
washed and incubated with PerCP-Cy5.5-conjugated anti-CD8 and Alexa flour 488-conjugated 
anti-human CD4 at 4°C for 30 minutes.  Cells were washed, then fixed and permeabilised with 
Cytofix/Cytoperm (BD Pharmingen) at 4°C for 20 minutes.  Cells were then washed in perm/wash 
(BD Pharmingen), incubated with PE-conjugated anti-Interferon (IFN)-γ (BD Pharmingen) at 4°C 
for 30 minutes, washed with perm/wash, resuspended in PBS and analysed on a FACS LSR 
Fortessa (BD Biosciences). 
 
2.2.3 Flow cytometric analysis of TRBV usage  
PBMCs or T cell lines (LCL-stimulated and/or peptide-stimulated) were incubated for 30 
minutes at 4°C with an SELEIKRY-HLA-B*1801 allophycocyanin (APC-labelled) multimer 
(Melbourne).  Cells were then washed and incubated with peridinin-chlorophyll protein-Cy5.5 
(PerCP-Cy5.5)-labelled anti-human CD8 mAb (BioLegend), and one of the following 
phycoerythrin (PE) or fluorescein isothiocyanate (FITC)-labelled TCR β-chain-specific mAbs 
(Beckman Coulter): Vβ1 (TRBV9), Vβ2 (TRBV20-1), Vβ3 (TRBV28), Vβ4 (TRBV29), Vβ5.1 
(TRBV5-1), Vβ5.2 (TRBV5-6), Vβ5.3 (TRBV5-5), Vβ6.7 (TRBV7-1), Vβ7 (TRBV4), Vβ7.2 
(TRBV4-3), Vβ8 (TRBV12), Vβ9 (TRBV3), Vβ11 (TRBV25-1), Vβ12 (TRBV10), Vβ13.1 
(TRBV6-5), Vβ13.2 (TRBV6-2), Vβ13.6 (TRBV6-6), Vβ14 (TRBV27), Vβ16 (TRBV14), Vβ17 
(TRBV19), Vβ18 (TRBV18), Vβ20 (TRBV30), Vβ21.3 (TRBV11-1), Vβ22 (TRBV2) or Vβ23 
(TRBV13).  Cells were washed twice in FACS buffer (2% FCS in phosphate buffered saline 
(PBS)), centrifuging and tipping off the supernatant between washes.  These samples were analysed 
on a FACS LSR Fortessa flow cytometer using FACSDiva software (BD Biosciences).  If samples 
were not analysed immediately, they were fixed in 1% paraformaldehyde (PFA) in PBS. 
 
2.2.4 Flow cytometric analysis of TRBV usage with ICS 
In the absence of a multimer for TRBV usage assays, an ICS was required with the desired 
synthetic peptide followed by TRBV usage assay.  PBMCs or T cells were incubated for 4-5 hours 
at 37°C with various synthetic peptides (1μg/ml) in R10 supplemented with 5μg/ml Brefeldin A 
(BioLegend).  Cells were centrifuged at 1000g for 2 minutes and supernatant discarded.  Cells were 
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resuspended in 25μl PBS and 1μl of one of the following phycoerythrin (PE) or fluorescein 
isothiocyanate (FITC)-labelled TCR β-chain-specific mAbs (Beckman Coulter): Vβ1 (TRBV9), 
Vβ2 (TRBV20-1), Vβ3 (TRBV28), Vβ4 (TRBV29), Vβ5.1 (TRBV5-1), Vβ5.2 (TRBV5-6), Vβ5.3 
(TRBV5-5), Vβ6.7 (TRBV7-1), Vβ7 (TRBV4), Vβ7.2 (TRBV4-3), Vβ8 (TRBV12), Vβ9 (TRBV3), 
Vβ11 (TRBV25-1), Vβ12 (TRBV10), Vβ13.1 (TRBV6-5), Vβ13.2 (TRBV6-2), Vβ13.6 (TRBV6-
6), Vβ14 (TRBV27), Vβ16 (TRBV14), Vβ17 (TRBV19), Vβ18 (TRBV18), Vβ20 (TRBV30), 
Vβ21.3 (TRBV11-1), Vβ22 (TRBV2) or Vβ23 (TRBV13) and incubated at room temperature for 
20 minutes.  Cells were then incubated with PerCP-Cy5.5-conjugated anti-CD8 mAb at 4°C for 20 
minutes. Cells were washed, then fixed and permeabilised with Cytofix/Cytoperm (BD 
Pharmingen) at 4°C for 20 minutes.  Cells were then washed in perm/wash (BD Pharmingen), 
incubated with APC-conjugated anti-Interferon (IFN)-γ (BD Pharmingen) at 4°C for 30 minutes, 
washed with perm/wash, resuspended in PBS and analysed on a FACS LSR Fortessa (BD 
Biosciences). 
       
2.2.5 Interferon-γ ELISpot assay 
Interferon (IFN)-γ ELISpot assays were performed using cytokine capture and detection 
reagents according to manufacturer’s instructions (ELISpot PRO for Human IFN-γ, Mabtech).  
Briefly, 96-well nitrocellulose plates pre-coated with anti-IFN-γ Abs were seeded with 
approximately 50 000 autologous LCL T cells or PBMCs or peptide-stimulated CTL cultures and 
the appropriate peptide at various concentrations (10µM and 1µM or 10-fold dilutions from 10μM- 
0.000001μM).  After incubation for 16 hours at 37°C in 5% CO2, the cells were discarded and 
captured IFN-γ was detected with a biotinylated anti-IFNγ Ab, followed by development with an 
alkaline phosphatase substrate solution (BCIP/NBT-plus).  Spots were counted using an automated 
plate counter (AID). 
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2.3 Flow cytometry reagents 
 
2.3.1 Antibodies 
 
Recognises Conjugate Isotype Species Raised in Clone Company 
CD3 PE-Cy7 IgG1 Human Mouse SK7 BD Pharmingen 
CD4 Alexa Flour 
488 
IgG1 Human Mouse RPA-
T4 
BioLegend 
CD4 Alexa Fluor 
700 
IgG1 Human Mouse RPA-
T4 
BD Pharmingen 
CD4 FITC IgG1 Human Mouse RPA-
T4 
BD Pharmingen 
CD4 PE IgG1 Human Mouse L120 BD Pharmingen 
CD8 PerCP-
Cy5.5 
IgG1 Human Mouse RPA-
T8 
BioLegend 
CD14 Pacific Blue IgG1 Human Mouse M5E2 BD Pharmingen 
CD19 eFluor 450 
(Pacific 
Blue) 
IgG1 Human Mouse HIB19 eBioscience 
IFN-γ APC IgG1 Human Mouse B27 BD Pharmingen 
IFN-γ PE IgG1 Human Mouse B27 BD Pharmingen 
 
 
2.3.2 Multimers 
 
Sequence HLA 
Restriction 
Conjugate Company 
CRAKFKQLL Cw*0602 APC NIH 
EECDSELEIKRY B*4403 PE Melbourne 
SELEIKRY B*1801 APC Melbourne 
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Chapter 3: 
 
 
Aim One: 
Determine the relative prevalence of peptide epitopes of over 10 amino acids in length in CD8+ T 
cell recognition of EBV. 
 
Hypothesis One:   
Peptide epitopes of over 10 amino acids in length are abundant in antiviral CD8+ T cell responses. 
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3.1 Introduction 
Class I major histocompatibility complex (MHC) molecules form medleys with peptide 
antigens which are expressed on the cell surface for recognition by CD8+ T cells.  Derived from 
antigens synthesized in the cytoplasm, these peptides are generally 8-10 amino acids in length.  For 
most MHC alleles two of the pockets within the peptide binding groove display a marked 
preference for one or two amino acids at certain anchor positions within the peptide (Falk, 
Rotzschke et al. 1991). This was the breakthrough discovery that enabled more efficient CTL 
epitope mapping.  Dependent on this information, web-based algorithms used to predict CD8+ T cell 
epitopes were designed to include peptides limited to between 8 and 10 residues.  The apparent 
dominance of MHC class I-presented epitopes of 8 to 10 amino acids in length may be misleading 
and result from this bias of widely used algorithms.  Indeed, many predicted epitopes have been 
shown to be nonimmunogenic failing to be processed and presented on APCs or as a result of 
limitations in the TCR (Eisenlohr, Yewdell et al. 1992).   
It has been demonstrated by several groups investigating viruses as well as melanoma 
antigens that peptides between 11-14 amino acids in length can bind to particular MHC class I 
molecules (Burrows, Rossjohn et al. 2006).  Of the 27 CD8+ T cell epitopes greater than 10 residues 
in length that have been reported in viruses including HIV (Sipsas, Kalams et al. 1997), HCMV 
(Weekes, Wills et al. 1999), and hepatitis B virus (Schirmbeck, Melber et al. 1994), seven unusually 
long CD8+ T cell epitopes are derived from EBV antigens (Blake, Lee et al. 1997, Rickinson and 
Moss 1997, Green, Miles et al. 2004, Pudney, Leese et al. 2005, Burrows, Bell et al. 2008, Rist, 
Theodossis et al. 2013).  The most dramatic example is the 14mer epitope, 
4LPAVVGLSPGEQEY17, derived from an alternative open reading frame of the macrophage 
colony-stimulating factor gene.  This extreme epitope is naturally presented by HLA-B*3501 and is 
recognised by tumour-infiltrating CD8+ T cells (Probst-Kepper, Stroobant et al. 2001, Probst-
Kepper, Hecht et al. 2004).    
Several MHC class I bound, immunogenic peptides that are longer than ten residues have 
been characterized structurally and shown that, in each case, the peptide adopts a bulging 
confirmation whereby the extra length “inserts” between the primary anchor residues (Tynan, Borg 
et al. 2005, Miles, Borg et al. 2006).  For example, the highly immunogenic 13-mer epitope 
52LPEPLPQGQLTAY64 (LPEP) from the BZLF1 antigen of EBV that is the target of a CD8+ T cell 
response by HLA-B*3508+ EBV+ individuals (Green, Miles et al. 2004).  Another example of a 
noncanonical epitope is the 11-mer 407HPVGEADYFEY417(HPV), derived from the EBNA1 protein 
of EBV (Miles, Borg et al. 2006).  In addition, our recent findings of the BZLF1 dodecamer 
169EECDSELEIKRY180, restricted to HLA-B*4403, also showed a bulged conformation (Rist, 
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Theodossis et al. 2013).  Both LPEP and HPV share another characteristic in that these epitopes 
completely overlap with shorter sequence peptides that conform to the binding motif of their 
respective HLA allele and score well using predictive web-based algorithms but have proven to be 
nonimmunogenic.  These unusually long CTL epitopes not only bind MHC class I molecules 
sufficiently to stimulate CD8+ T cell responses they also show a superior immunodominance in 
comparison to the shorter peptides (Blake, Lee et al. 1997, Green, Miles et al. 2004, Burrows, 
Rossjohn et al. 2006).   
Interestingly, many of the unusually long CTL epitopes are presented in the context of 
HLA-B*0702, HLA-B*3501 or HLA-B*3508.  These HLA alleles are all members of the HLA-B7 
supertype family which share primary anchor residues at position 2 and the C-terminus (Burrows, 
Rossjohn et al. 2006, Burrows, Bell et al. 2008).  Burrows and colleagues have previously proposed 
that members of this supertype present a high number of long peptides due to a unique feature of the 
class I antigen processing pathway (Burrows, Rossjohn et al. 2006).  As a result of the ER-
associated aminopeptidases inability to cleave the bond at the N- side of Proline, an accumulation of 
peptides with x-Pro-xn sequence is likely to occur (Serwold, Gaw et al. 2001), with many of these 
peptides likely to be long.  As the HLA-B7 supertype has a preference for Prolines at position 2 
these alleles are more likely to have unusually long CTL epitopes available for presentation within 
the ER compared to other HLA alleles that are not members of this supertype (Burrows, Bell et al. 
2008).  Indeed around half of the defined noncanonical CTL epitopes have a Proline at position 2 
and this may continue as a characteristic with newly identified unusually long CTL epitopes.   
In determining the presence of noncanonical CD8+ T cell epitopes, the latent herpes virus 
EBV is a superb model due to the strong responses detected in healthy virus carriers.  A number of 
highly immunogenic antigens of EBV were the focus of this study, including the lytic antigens 
BRLF1, BMLF1 and BMRF1 and the latent antigens EBNA3A, EBNA3B, EBNA3C and EBNA1.  
Immediate early (IE), early (E) and late (L) proteins are sequentially expressed during lytic viral 
replication.  Incorporating around 80 EBV proteins the lytic cycle is activated by the expression of 
two immediate early proteins BZLF1 (Zta) and BRLF1 (Rta) (Zalani, Holley-Guthrie et al. 1996).  
Feederle and colleagues have demonstrated that both transactivators, BZLF1 and BRLF1 are 
required for early and late EBV gene expression as well as for viral DNA expression.  The 
expression of late protein gp350 appears to require BRLF1 but does seem to be directly influenced 
by BZLF1 (Feederle, Kost et al. 2000).  Early protein BMRF1 has proved to be essential for the 
production of infectious EBV progeny as well as being associated with enhanced expression of 
BHLF1 (Neuhierl and Delecluse 2006).   
During latent infection, EBV genes hijack normal B cell mechanisms leading to the 
establishment of lymphoblastoid cell lines (LCLs).  At least nine latency-associated viral antigens 
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are expressed by LCLs and include the six nuclear antigens, EBV nuclear antigen 1 (EBNA1), 
EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNA leader protein (LP) and latent membrane 
proteins LMP1, LMP2A and LMP2B.  When these nine antigens are expressed it is referred to as a 
latency III form of EBV infection (Kutok and Wang 2006, Rickinson and Kieff 2007).  The 
essential antigen required for the persistence and maintenance of the EBV episome and enhancing 
genome expression is EBNA1.  A unique feature of EBNA1 is the glycine-alanine repeat (GAr) 
domain which inhibits MHC class I presentation of cis-linked epitopes.  Also of great importance, 
EBNA1 is the only viral protein that is expressed in all forms of latency and in all EBV-associated 
malignancies (Rickinson and Kieff 2007, Long, Taylor et al. 2011).   
Tandemly placed in the EBV genome, EBNA3A, -3B and -3C share a similar gene 
structure.  These three stable proteins can interact with cellular proteins involved in transcription 
regulation and bind to the cellular repressor-binding protein (RBP)-Jκ (Le Roux, Kerdiles et al. 
1994, Young and Rickinson 2004).  EBNA3A and EBNA3C are both critical for B-lymphocyte 
growth transformation and survival.  Interestingly, EBNA3B is not essential for latent infection of 
B lymphocytes and cell survival, although its presence in EBV isolates of healthy carriers indicates 
that it plays a part in natural infection (Kieff and Rickinson 2007).  Maruo and colleagues showed 
that EBNA3C plays an essential role in maintaining LCL growth and that this role cannot be filled 
by EBNA3A or EBNA3B (Maruo, Wu et al. 2006). 
In order to determine the relative prevalence of peptide epitopes of over 10 amino acids in 
length in CD8+ T cell recognition of EBV, this study utilised overlapping peptides, not web-based 
algorithms to predict peptides.  This approach removes any bias towards peptide length and 
proposed HLA allele restriction.  Many novel CD8+ T cell epitopes were identified with examples 
from all EBV antigens investigated, including four unusually long CD8+ T cell epitopes.  As the 
vast majority of CD8+ T cell epitopes that have been defined to date are 8 to 10 residues in length, it 
is unlikely that the wider immunology community accepts that longer peptides play a significant 
role.  However, this apparent dominance may be misleading and due to the bias of widely used 
algorithms to predict class-I binding peptides no longer than 10 amino acids in length.  
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3.2 Results 
IFN-γ ELISpot assays were used to test overlapping 20-amino acid (aa) peptides 
corresponding to the lytic antigens BRLF1, BMLF1 and BMRF1 and the latent antigens EBNA3A, 
EBNA3B, EBNA3C and EBNA1.  These overlapping peptide sets were screened for recognition by 
T cell lines.  These T cell lines were raised by in vitro stimulation of PBMCs from 41 healthy EBV-
seropositive individuals with their autologous LCLs (Table 1).  Results for a number of individuals 
screened with the overlapping peptide sets of the EBV antigens EBNA3A, BMLF1, BRLF1, 
EBNA3C, BMRF1, EBNA3B and EBNA1 are shown in Fig. 1 A to G, respectively. 
                         
                       TABLE 1 Class I HLA types of donors used in this study 
Donor ID HLA-A HLA-B HLA-C 
B33 24, 29 1801, 4403 5, 16 
B9 1, 30 8, 18 5, 7 
JC33 3, 25 18, 4403 Unknown 
DP55 2 15, 18 1, 5 
CG59 2, 3 7, 18 7, 12 
B16 2, 11 15, 44 3, 5 
HB49 3, 32 7, 8 7 
MR67 2 15, 57 3, 6 
AO83 2, 24 18, 44 5, 7 
B28 2, 23 4402, 53 5, 6 
B20 3, 24 7 7 
B5 11, 24 15, 35 3, 4 
B22 3, 23 41, 47 6, 17 
B2 1, 11 40, 52 3, 12 
B3 1, 3 8, 40 2, 7 
B39 26, 68 27, 4402 2, 5 
DM42 24, 29 4403, 4405 2 
KK68 1, 29 8, 4403 7, 16 
B4 26, 32 40, 4402 1, 3 
B17 1, 2 7, 8 7 
B21 32, 68 7, 14 7, 8 
B23 3, 11 35, 4402 3, 5 
B36 3, 24 7, 4402 5, 7 
B32 2, 68 7, 39 7 
B34 1, 32 7 7 
B8 2, 66 4402, 49 7 
B15 1, 26 27, 62 1, 3 
B25 1, 2 35, 51 4, 14 
B26 2, 11 35, 58 4, 7 
MW65 1, 3 8, 3501 4 
LC50 1 8, 18 7 
SB60 2 35, 57 4, 6 
B7 2, 3 7, 37 6, 7 
B13 1, 2 27, 57 2, 6 
B38 2, 3 7, 57 6, 7 
B10 11, 31 7, 51 7, 15 
B11 11, 24 50, 62 4, 6 
B14 2, 11 51 15, 16 
B19 1, 3 8, 4403 4, 7 
B21 32, 68 7, 14 7, 8 
B24      2 40 3 
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With nearly 1000 peptides screened for each of the 41 healthy EBV carriers it is not possible 
to show the results of each individual to all peptides.  Figure 1 A to G shows examples of results 
with these overlapping peptides for 25 of the 41 individuals screened (Table 1).    The results are 
indicative of those attained for all of the EBV antigens tested, with a portion of the peptides 
eliciting an IFN-γ response whilst the majority of screened peptides gave a negative result.  Collated 
from the results of all individuals tested, is the list of novel epitopes defined in this study (Table 2).   
The greatest number of epitopes defined in the antigens investigated was 12 novel epitopes 
within EBNA3A.  There was a degree of epitope clustering and overlapping in this antigen (Table 2 
& Fig.1A).  Depicted in Fig. 1A are the initial results for the three highly immunogenic overlapping 
peptides 116DQFFGSQISNTEMYIMYAMA135, 121SQISNTEMYIMYAMAIRQAI140 and 
126TEMYIMYAMAIRQAIRDRRR145.  All of the responders were HLA-B*18 positive and all had 
the strongest IFN-γ response to peptide 126-145.  HLA-B*18 negative donors (MR67 and HB49) 
displayed no IFN-γ response to these peptides (Fig. 1A).  The peptides TEMYIMYAMA, 
TEMYIMYAM and TEMYIMYA, which have sequences included within these 20mer peptides, 
were screened to map the EBNA3A epitope.  The peptides were titrated from 10μg/ml to 
0.000001μg/ml and tested with HLA-B18+ donors B9 and B33 (Fig. 2A and 2B, respectively).  The 
nonamer 131TEMYIMYAM139 was determined to be the minimal epitope titrating out to a final 
peptide concentration of 0.0001μg/ml with B9 and 0.000001μg/ml with B33.  It is notable that this 
nonamer peptide conforms to the HLA-B*1801 binding motif (Hillen, Mester et al. 2008).  
Another EBNA3A epitope which overlaps TEMYIMYAM is 126SQISNTEMY134.  Figure 
2C displays results from donor B16 and peptides FGSQISNTEMY, SQISNTEMY and QISNTEMY 
tested with IFN-γ ELISpot titrations from 10μg/ml to 0.000001μg/ml, showing SQISNTEMY and 
QISNTEMY as equally active epitopes.  The nonamer conforms to the HLA-B*1501 binding motif 
with a Glutamine at position 2 and Tyrosine at the C terminus (Falk, Rotzschke et al. 1995).  
However, it cannot be ruled out that both the nonamer SQISNTEMY and octamer QISNTEMY are 
epitopes in this donor as the dose response curves for these two peptides are very similar.  
Figure 2D demonstrates results indicating that another novel epitope from EBNA3A is 
34WENVLIEL41.  Donors B3 and B4 show significant IFN-γ responses to a number of peptides in 
this truncated peptide set.  All peptides that included the nonamer sequence 34WENVLIEL41 were 
recognized by the T cells.  As HLA-B*40 is shared by both donors B3 and B4 and the nonamer 
conforms to the published binding motif  of HLA-B*40 with anchor residues Glutamic acid at 
position 2 and Leucine at the C-terminus (Falk, Rotzschke et al. 1995) it is likely that this epitope is 
restricted by HLA-B*40.   
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Protein Epitope 
Coordinates 
Epitope Sequence Epitope Length 
(AA) 
Likely HLA 
Restriction 
Lytic     
IE      BRLF1  64-73 REWGGLMATL 10 B40 
(605AA) 101-109 IACPIVMRY 9 A29 and Cw2/3 
 198-206 TYPVLEEMF 9 A24 
 260-268 KAVETPILV 9 B51 
 293-301 SESGQFHAF 9 B44 
     
E       BMLF1 209-218 VAAHPEIGAW 10 B57/58 
(438AA) 244-252 KDTWLDARM 9 B47 
 320-328 DYNFVKQLF 9 A24/23 
 376-384 DEVEFLGHY 9 Cw6 
     
E        BMRF1 116-125 RPQGGSRPEF 10 B7 
(404AA) 146-156 MPYMPPASDRL 11 B53 
 286-293 LPLDLSVILF 10 B35 
 369-377 LERPLAVQL 9 B40 
Latent     
EBNA3A 34-41 WENVLIEL 8 B40 (B60/61) 
(944AA) 126-134 SQISNTEMY 9 B1501(62) 
 131-139 TEMYIMYAM 9 B18 
 133-141 MYIMYAMAI 9 A23 
 137-145 YAMAIRQAI 9 B51 
 170-180 WPMGYQAYSSW 11 B53 
 187-196 HQTTPTFVHL 10 B52 or Cw3 
 283-290 LQRTDLSY 8 B1501(62) 
 509-517 IVRPWEPSL 9 Unknown 
 631-640 MEGPLVPEQQ 10 B18 
 639-647 QQMFPGAPF 9 B18 
 642-650 FPGAPFSQV 9 B51 
     
EBNA3B 168-176 KLLSSCRSW 9 A32 
(938AA) 178-186 MGYRTHNLK 9 A3 
 198-206 HPVLVTATL 9 B3501 
 279-287 VSFIEFVGW 9 B57 
 416-424 IVTDFSVIK 9 A68 
 888-898 SHSPVVILENV 11 B52 
     
EBNA3C 90-98 TEDNVPPWL 9 B40 
(992AA) 160-168 LVAEGGVGW 9 A25 
 162-170 AEGGVGWRHW 10 B4402 
 180-189 WPMGYRTATL 10 B7 
 244-253 AEVRFLRGKW 10 B4402/03 
 335-343 KEHVIQNAF 9 B40 
 343-351 FRKAQIQGL 9 Cw6 
 650-658 WEMRAGREI 9 B4901 
 740-750 QPAPQAPYQGY 11 B3501 
     
EBNA1     
(641AA) 499-508 DEGTWVAGVF 10 B18 
 
TABLE 2 Summary of Novel EBV CD8+ T cell epitopes defined in this study 
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FIGURE 2. Novel epitopes from the latent EBV antigen EBNA3A.  EBV-specific T cell lines from 
donors (A) B9, (B) B33 and (C) B16 were tested with IFN-γ ELISpot assays to precisely map the 
minimal epitopes.  Cells were tested with various concentrations of the indicated peptides.  (D)  
EBV-specific T cell lines, raised by in vitro stimulation with irradiated autologous LCLs from 
donors B3 and B4 were tested in IFN-γ ELISpot assays for recognition of overlapping peptides 
(10μg/ml) corresponding to a region of the EBNA3A protein sequence. 
A 
B 
C 
D 
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Four novel epitopes were defined from the lytic antigen BMLF1 (Table 2).  Abbott et al 
recently noted 205SMLAVAAHPEIGAWQ219 as a novel epitope (Abbott, Quinn et al. 2013) and, 
from results in this study (Fig. 3A), the decamer  209VAAHPEIGAW218 appears to be the minimal 
epitope with  HLA-B*57/58 the likely restricting allele, based on the published motif of these two 
alleles (Falk, Rotzschke et al. 1995).  Concurring with the findings of Abbott et al, the responding 
donor in those studies was also HLA-B*58 positive.   
 
 
 
FIGURE 3. Mapping epitopes from the BMLF1 protein.  (A) EBV-specific T cell lines from two 
HLA-B57+ individuals MR67 and B38 were tested with the overlapping peptides as shown by IFN-
γ ELISpot assays at a final concentration of 10μg/ml.  Various concentrations of the indicated 
peptides were tested with EBV-specific T cell lines from (B) an HLA-A23+ donor B22 and (C) an 
HLA-A24+ donor B5 identifying the minimal epitope. 
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In 1997, Steven et al described 244KDTWLDARM252 (included within peptides 
236EFFTKSTNKDTWLDARMQAI255 and 241STNKDTWLDARMQAIQNAGL260, Fig. 1B) as a 
new epitope, however no HLA-restriction was noted (Steven, Annels et al. 1997).  Based on the 
previously described binding motif for HLA-B47 (Hillen, Mester et al. 2008) and the HLA typing 
of the responding donor in our study (Donor B22), it is likely that this epitope is restricted by HLA-
B47.   
Another newly defined BMLF1 epitope mapped from several donors is 320DYNFVKQLF328 
(included within peptides 311APCFLPNTRDYNFVKQLFYI330 and 
316PNTRDYNFVKQLFYITCATA335, Fig. 1B).  Three peptides were designed to map this new 
BMLF1 epitope: DYNFVKQL, DYNFVKQLFY and DYNFVKQLF.  These peptides were titrated 
from 10μg/ml to 0.0001μg/ml and tested with donors B22 (HLA-A*23-Fig. 3B) and B5 (HLA-
A*24-Fig. 3C).   The minimal epitope was found to be the nonamer 320DYNFVKQLF328 which 
titrated out to a final peptide concentration of 0.0001μg/ml.  Of most interest was that 
DYNFVKQLF had a significant response in both the HLA-A*23 and HLA-A*24 donor.  
Degeneracy in HLA restriction has been shown previously for other EBV epitopes (Burrows, 
Elkington et al. 2003, Frahm, Yusim et al. 2007).  Such epitopes could be particularly valuable for 
EBV vaccine development allowing one epitope to deliver protection through more than one HLA 
allele. 
Five novel epitopes were defined from the lytic antigen BRLF1 (Table 2).  Figure 1C shows 
a selection of donors with significant IFN-γ responses to a number of the BRLF1 overlapping 
peptides.  Peptides 91AENAGNDACSIACPIVMRYV110, 96NDACSIACPIVMRYVLDHLI115 
and/or 101IACPIVMRYVLDHLIVVTDR120 (Fig. 1C) elicited IFN-γ responses in donors B2, B3 
and B39, DM42 and KK68. The results from donors B2, B3 and B39 tested with a truncated peptide 
set are shown in Fig. 4 A to C.  The minimal epitope with maximum activity in all three donors is 
the nonamer, 101IACPIVMRY109.  Interestingly, this epitope appears to be presented by a number of 
HLA alleles including HLA-Cw2 and HLA-Cw3 (shared by donors B2, B3 and B39).  Previous 
studies have noted a longer version of this epitope 101IACPIVMRYVLDHLI115  (Pudney, Leese et 
al. 2005) (Abbott, Quinn et al. 2013), concluding that the epitope was HLA-A*2402 and Cw*0202 
restricted in the case of Pudney et al and HLA-B*58 restricted in the Abbott et al study although the 
responding donor was also HLA-Cw3.   
BRLF1 overlapping peptides 56INEAKAHGREWGGLMATLNI75, 
61AHGREWGGLMATLNICNFWA80 and 66WGGLMATLNICNFWAILRNN85 (Fig. 1C) induced 
significant IFN-γ responses from donor B2.  Figure 4D depicts the results of a truncated peptide set 
to determine the minimal epitope in this donor.  The decamer 64REWGGLMATL73 is the minimal 
epitope with maximum activity, with a likely HLA-restriction of HLA-B*40 based on the published  
 55 
 
 
 
 
 
 
FIGURE 4. Identification of epitopes mapped from the BRLF1 antigen of EBV.  EBV-specific T 
cell lines from (A) an HLA-Cw3+ individual, (B) and (C) two HLA-Cw2+ individuals and (D) an 
HLA-B40+ individual, raised by in vitro stimulation with irradiated autologous LCLs, tested in IFN-
γ ELISpot assays for recognition of indicated peptides corresponding to regions of the BRLF1 
protein sequence.  Cells were tested with various concentrations of the indicated peptides. 
A 
B 
C 
D 
Sp
ot
s p
er
 m
ill
io
n 
ce
lls
 
Sp
ot
s p
er
 m
ill
io
n 
ce
lls
 
Sp
ot
s p
er
 m
ill
io
n 
ce
lls
 
 56 
 
 
binding motif with anchor residues Glutamic acid at position 2 and Leucine at the C-terminus (Falk, 
Rotzschke et al. 1995).  Abbott et al also noted that a longer version of this peptide 
61AHGREWGGLMATLNI75 stimulated T cell responses in their study, with an unknown HLA 
restriction (Abbott, Quinn et al. 2013).  The responding donor in the Abbott et al study is noted as 
HLA-B*60 which is a split antigen that recognizes certain B40 serotypes. 
Latent antigen EBNA3C was the source of the second largest number of novel epitopes, 
with nine defined in this study (Table 2).  Figure 1D displays a number of donors that responded to 
peptides 236EQERYAREAEVRFLRGKWQR255 and 241AREAEVRFLRGKWQRRYRRI260.  Data 
from a truncated peptide set corresponding to the overlapping region of these two peptides, tested 
with donors B23 and B28 are shown in Fig. 5A and 5B demonstrating the novel decamer 
244AEVRFLRGKW 253 as the minimal epitope with maximum activity.  This sequence conforms to 
the HLA-B*4402/03 binding motif (Hillen, Mester et al. 2008), an allele shared by donors B23 and 
B28.  This epitope overlaps with the previously mapped HLA-B*2705-restricted epitope 
249LRGKWQRRYR258 (Brooks, Murray et al. 1993).  It is also possible that the 12mer peptide 
242REAEVRFLRGKW253 is an epitope presented by HLA-B44 since it also conforms to the binding 
motif of this HLA molecule (Hillen, Mester et al. 2008). 
A second novel decamer from EBNA3C was mapped from donor B32.  Significant IFN-γ 
responses were observed from this donor to peptides 171WLLTSPSQSWPMGYRTATLR190 and 
176PSQSWPMGYRTATLRTLTPV195 (Fig. 1D).  Results from a truncated peptide set with donor 
B32 demonstrate that the minimal epitope with maximum activity was 180WPMGYRTATL189 (Fig. 
5C) which conforms to the HLA-B7 binding motif (Maier, Falk et al. 1994 ).  Also shown in Fig. 
1D is the response to peptides 326NPYHARRGIKEHVIQNAFRK345 and 
331RRGIKEHVIQNAFRKAQIQG350 from donor B3.  These overlapping peptides incorporate the 
nonamer 335KEHVIQNAF343 that was previously mapped as a HLA-B*4402 restricted epitope 
(Khanna, Burrows et al. 1992).  Although donor B3 is not HLA-B*4402+, another member of the 
HLA-B44 supertype, HLA-B40 is expressed, suggesting that the 335KEHVIQNAF343 epitope is 
presented by this allele as well as HLA-B*4402.      
As with the other lytic antigens included in this study, BMRF1 was found to include several 
novel epitopes.   Pudney et al mapped the unusually long HLA-B*0702-restricted epitope   
116RPQGGSRPEFVKL128 in a 2005 study (Pudney, Leese et al. 2005).  Figure 1E shows IFN-γ 
responses to the overlapping peptides 106VEQASLQFYKRPQGGSRPEF125 and 
111LQFYKRPQGGSRPEFVKLTM130 from donors B17, B20 and B36.  Figure 6A depicts results 
from donor B20 screened for recognition of a truncated peptide set corresponding to the 
overlapping region.  The minimal epitope with maximum activity was found to be the decamer, 
116RPQGGSRPEF125.  Interestingly, another HLA-B7+ donor, B21, only responded to the longer  
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FIGURE 5. Defining two decamer EBNA3C epitopes.  IFN-γ ELISpot assays were used to define 
minimal epitopes, by screening EBV-specific T cell lines from two HLA-B*4402+ individuals (A) 
donor B23 and (B) donor B28 with truncated peptides at10μg/ml and 1μg/ml and (C) a T cell line 
from the HLA-B7+ individual, donor B32, against various concentrations of the indicated peptides. 
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FIGURE 6.   Identification of minimal epitopes from the EBNA3C antigen of EBV.  EBV-specific 
T cell lines from HLA-B7+ individual (A) donor B20 and HLA-B35+ individual (B) donor B23 were 
screened with various concentrations of the indicated peptides by IFN-γ ELISpot assays.   
 
13mer peptide as described by Pudney et al (data not shown).  A novel epitope was also mapped 
from donor B23.  As shown in Fig. 6B, the decamer 286LPLDLSVILF295 was recognised at 
relatively low peptide concentrations, and this peptide conforms to the HLA-B*35 binding motif 
(Falk, Rotzschke et al. 1993).  Interestingly, this epitope was previously noted as HLA-B*53 
restricted (Chapter 1, Table 2, Annels, NE unpublished) and both HLA-B*35 and HLA-B*53 are 
members of the HLA-B7 supertype (Sidney, Peters et al. 2008).  Together these findings provide a 
significant list of novel epitopes from a number of EBV lytic and latent antigens restricted to 
various HLA -A, -B and -C alleles.  In order to definitively determine the HLA restricting elements 
A 
B 
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of these novel epitopes future studies could focus on culturing CD8+ T cell clones specific for each 
novel peptide.  These cloned populations can be tested for recognition of peptide-loaded target cells, 
either autologous donors or allogeneic donors partially matched specific for either HLA-A, -B or -C 
alleles.  Results from such studies will identify the epitope’s restricting allele (Feederle, Kost et al. 
2000). 
3.3 Discussion 
The initial aim of this study was to address the relative prevalence of noncanonical CD8+ T 
cell epitopes of over 10 amino acids in length in selected lytic and latent antigens of EBV.  During 
the investigation it became apparent that the system is very complex, with various factors 
influencing epitope selection. The “big picture” view needs to incorporate, the virus’s interaction 
with the host and the role that each antigen plays in that, and the HLA allele with respect to anchor 
residue preferences in addition to what length of epitope each allele prefers. Noncanonical epitopes 
were identified albeit in very limited number.  However, an expansive list of new EBV CTL 
epitopes have been defined, allowing an assessment of the hierarchy of immunodominance between 
the EBV antigens and highlighting the highly immunogenic regions within several of the antigens 
where epitope clustering has been observed.  
Considering the immunodominance between the EBV antigens included in this study of 
healthy individuals, as assessed by the total number of CD8+ T cell epitopes, the latent antigen 
EBNA3A contains the greatest number of epitopes.  Supporting our observations Ning et al showed 
immunodominance of EBNA3 proteins over other latent proteins including EBNA1 in CD8+ T cell 
responses (Ning, Xu et al. 2011).  Hislop et al, having compared the relative immunodominance of 
lytic and latent EBV antigens in healthy donors, showed a hierarchy which largely concurs with our 
findings (Hislop, Taylor et al. 2007).  The relative immunodominance hierarchy in this study (with 
the exclusion of BZLF1), based on the identification of 28 latent and 13 lytic epitopes, is EBNA3A, 
EBNA3C, EBNA3B, BRLF1, BMLF1 and BMRF1 and lastly EBNA1.  
Latent antigens EBNA3A, EBNA3B and EBNA3C all play an important role in the 
interaction with RBPJκ binding activity (Robertson, Lin et al. 1996).  This RBPJκ binding activity 
region in all three of the EBNA 3 proteins is the location of around half of the novel epitopes 
identified in this study.   It is interesting that, with a vast level of homology between these three 
antigens, that EBNA3A appears to have the most epitopes that are recognized by EBV-specific 
cytotoxic T lymphocytes.  Indeed it is the conserved region in these three EBNA3 proteins from 
amino acids 90-320 that account for the location of around half of the epitopes for these antigens.  
Only a handful of EBNA 3C epitopes are located outside of this conserved region.  EBNA3A also 
has regions of overlapping and clustered epitopes, albeit not to the extent of BZLF1, although this is 
 60 
 
 
probably influenced by antigen size as EBNA3A is 944aa compared to BZLF1’s 245aa  (refer to 
Table 2 and Chapter 1,Table 1). 
The EBNA 3 proteins contain many immunodominant CD8+ T cell epitopes.  Highlighted 
by Bihl and colleagues study with healthy virus carriers, six of the defined EBNA3A epitopes are 
immunodominant, as are seven epitopes for both EBNA 3B and EBNA3C (Bihl, Frahm et al. 2006).  
However, the frequency with which individuals respond to these immunodominant epitopes appears 
to be variable.  A study by Benninger-Doring et al with eight HLA-B8-positive EBV carriers, 
examined for reactivities to HLA-B8-restricted EBV epitopes, showed 50% of donors responded to 
the immunodominant EBNA3A-325FLRGRAYGL333 epitope while only 25% of donors reacted 
against 158QAKWRLQTL166, also from EBNA3A.  This is compared to all eight donors recognising 
the BZLF1 190RAKFKQLL197 epitope (Benninger-Doring, Pepperl et al. 1999).   
It has been suggested that differences in CD8+ T cell responses may be greatly influenced by 
the source of the EBV epitope (e.g. lytic or latent antigen) (Hislop, Annels et al. 2002).  The 
rationale for this being that high viral loads in acute infection may propel responses of low avidity 
against highly expressed lytic antigens, whilst during chronic infection the preference may lean to 
high avidity responses against latent antigens expressed during later infection stages (Woodberry, 
Suscovich et al. 2005).  Indeed, previous work has demonstrated a noticeable shift from lytic to 
latent antigen-specific responses between the acute and chronic stages of EBV infection (Hislop, 
Annels et al. 2002, Woodberry, Suscovich et al. 2005).  Furthermore, the reactivities towards CTL 
epitopes will reflect the donor cohort and may be quite variable between studies depending on the 
individual’s EBV status i.e. acute IM, memory IM or healthy carrier.     
The remaining latent antigen examined, EBNA1, is essential for the persistence and 
maintenance of the EBV episome and enhancing genome expression.  A unique feature of EBNA1 
is the GAr domain which inhibits MHC class I presentation of cis-linked epitopes.  Also of great 
importance, EBNA1 is the only viral protein that is expressed in all forms of latency and in all 
EBV-associated malignancies (Rickinson and Kieff 2007, Long, Taylor et al. 2011).   Supporting 
the notion that the GAr domain of EBNA1 reduces its immunogenicity, only one epitope was 
defined in this study (Table 2) compared to the large number of epitopes that were identified in the 
other EBV antigens investigated.  A number of donors did respond to known EBNA 1 epitopes, 
although not all defined epitopes elicited CTL reactivities (Fig.1G).  This is not the first study to 
describe little or no responses to EBNA1.  A study by Murray et al also noted no detection of CTL 
components to EBNA1 when testing 16 EBV-immune donors (Murray, Kurilla et al. 1992).  It is 
notable that the C-terminal half of this protein is a rich source of CD4+ T cell epitopes.  These 
epitopes covering a range of HLA class II alleles, have been recognised in Caucasian donors 
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(Steigerwald-Mullen, Kurilla et al. 2000) (Voo, Fu et al. 2002) (Leen, Meij et al. 2001) and Chinese 
donors (Tsang, Lin et al. 2006) . 
The results of this study confirm and extend the findings of the recent work of Abbott et al 
on immunodominance among EBV lytic cycle antigens.  These authors found a number of new 
epitopes in EBV antigens BZLF1, BRLF1, BMLF1 and BMRF1 (among other lytic antigens not 
examined in this study).  Not all epitopes identified in the Abbott et al work elicited CTL responses 
in the donors in this study.  We have mapped several new epitopes from these antigens while 
additionally identifying the likely HLA-restriction.  An example is the novel BRLF1 epitope 
101IACPIVMRY109 which overlaps with the previously defined HLA-A*0201-restricted epitope 
109YVLDHLIVV117.  Initially defined by Pudney et al as 101IACPIVMRYVLDHLI115 with HLA- 
A24 or HLA-Cw2 restriction, Abbott et al also noted this 15-mer to be HLA-B58 restricted.  We 
have shown that the minimal epitope 101IACPIVMRY109 appears to be presented by a number of 
HLA alleles including HLA-A*29 and possibly HLA-Cw2 and HLA-Cw3 (shared by donors B2, 
B3 and B39).  It cannot be ruled out that this nonamer epitope is unusually promiscuous with 
regards to HLA restriction and can also elicit responses from other HLA alleles including HLA-B58 
and HLA-A24.  
  The pattern of EBV lytic antigen immunodominance described by Hislop et al in healthy 
virus carriers (Hislop, Taylor et al. 2007) with immediate early (IE) proteins being 
immunodominant over early (E) proteins, is maintained in our study, with the IE BRLF1 antigen 
demonstrating five novel epitopes and the E antigens BMLF1 and BMRF1 each containing four 
novel epitopes (Table 2).  When the IE antigen BZLF1 is considered (refer to Chapter 4 and 
Chapter 5) this pattern becomes more evident, with a total of 13 novel epitopes arising from this 
antigen.  The role of transcription factor BRLF1 in concert with BZLF1 is the initiation of the lytic 
cycle from the latent state (Ragoczy, Heston et al. 1998), and full expression of both these antigens 
is required during the lytic phase (Feederle, Kost et al. 2000).  Previously defined BRLF1 epitopes 
are found in all domains of this antigen ranging from the DNA binding domain (aa 1-320), the 
dimerization domain (aa 1-232) to the transcriptional domain (aa 520-605) (Manet, Rigolet et al. 
1991), while the proline rich domains (aa 352-410 and aa 450-500) (Manet, Rigolet et al. 1991) 
contains only one.  However, novel BRLF1 epitopes defined in this study remained confined to the 
DNA binding domain.  Interestingly, sequence analysis of BRLF1 in various lymphoma patients 
shows that amino acid mutations do not occur in the sequence of any novel or already known 
epitopes (Yang, Jia et al. 2014). 
Early lytic antigen BMRF1 has recently been shown to play a pivotal role in nuclear 
translocalization when coexpressed with molecular chaperone Hsp90 (Kawashima, Kanda et al. 
2013).  This process is dependent on the nuclear localisation signal domain located at the C-
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terminal region of BMRF1 (aa 378-404) (Zhang, Holley-Guthrie et al. 1999) .  It is of note that no 
epitopes are contained within this region of BMRF1 and all previously defined and novel epitopes 
with the exception of 369LERPLAVQL377, are located in the DNA binding domains (aa 44-194 and 
aa 238-302).   An interesting observation from this antigen is that there appears to be a 13-mer 
epitope 116RPQGGSRPEFVKL128 with HLA-B*0702 restriction noted by Pudney et al in a 2005 
study (Pudney, Leese et al. 2005) which overlaps with the novel decamer epitope, 
116RPQGGSRPEF125 that also appears to be restricted by HLA-B*0702.  Interestingly, donor B21 
only responds to the longer 13-mer peptide as described by Pudney et al (data not shown).   This 
preference to respond to the longer epitope may be due to a subtle HLA subtype difference in this 
donor and may warrant further investigation.    
In contrast to other EBV antigens all of the BMLF1 epitopes are located in the C-terminal 
half of the antigen.  The results from this study confirmed a number of known BMLF1 epitopes, 
albeit with additional likely HLA allele restriction, as well as mapping a minimal epitope previously 
described by Abbott et al (Abbott, Quinn et al. 2013).  Furthermore, we have shown the novel 
epitope 320DYNFVKQLF328 to have HLA-restriction to both the HLA-A23 and HLA-A24 alleles.   
With the exception of BMLF1, there appears to be a trend that a great majority of the 
epitopes defined in this study were located in the N-terminal region of the EBV antigens examined 
indicating that this region is an important target for the T cell response.  If this observation indeed 
reflects the distribution of epitopes this information can be harnessed for many applications.  
Initially, the location of epitopes within an antigen can provide insight into the functional roles and 
importance of certain domains within an antigen.  For example, EBNA3C resiudes aa130-159 bind 
to IRF4 or IRF8 (Banerjee, Lu et al. 2013) in addition to coactivating the EBV LMP-1 promoter 
with EBNA-2 via an SPI1 site in the absence of RBPJ (Zhao and Sample 2000, Lin, Johannsen et 
al. 2002).  Interestingly, there are no EBNA3C epitopes located in this region.  These areas bereft of 
epitopes may play a role in immune evasion and host mechanisms for such.  This has been observed 
in relation to GAr region of EBNA1, whereby EBNA1 peptides are poorly presented in the context 
of MHC Class I molecules and somewhat protected from recognition by CTLs (Levitskaya, Shapiro 
et al. 1997, Fogg, Kaur et al. 2005).  This information can be further used to enhance epitope 
prediction algorithms by providing further parameters to increase peptide prediction success.  
Future studies could investigate these “epitope poor” regions of antigens in search of immune 
evasion mechanisms.       
A point of difference between this study and many previous investigations that have mapped 
EBV T cell epitopes is the samples which were utilised.  Previous work by many has focused on the 
CD8+ T cell responses from IM samples (Callan 2003) (Steven, Annels et al. 1997, Hislop, Annels 
et al. 2002, Pudney, Leese et al. 2005), whereas this study has used T cell lines raised by in vitro 
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stimulation of PBMCs from 41 healthy EBV-seropositive individuals with their autologous LCLs.  
IM samples, however, have been shown to have somewhat skewed reactivities towards a lytic 
response and possibly epitopes that are only apparent during the initial stages of infection that later 
become extinguished (Callan 2003).  Sample sizes and donor cohort differences, in addition to the 
overlapping peptide screening method may lead to variations in epitope detection.   
It is difficult to compare the findings of this study with those focused on IM samples as in 
some cases the HLA of the indivduals and scope of the study was limited to that of already defined 
epitopes (Hislop, Annels et al. 2002) or limited to lytic antigens (Steven, Annels et al. 1997, 
Pudney, Leese et al. 2005).  In this study a significant proportion of the epitopes defined are from 
latent antigens compared to the lytic antigens with 28 and 13 epitopes defined, respectively.  This 
observation in itself somewhat defies the notion of skewed reactivities towards lytic responses, 
however comparisons have not been made with respect to the number of CD8+ T cells specific for 
each of these newly defined epitopes.  Of note are some similarities between the work of Pudney 
and colleagues (Pudney, Leese et al. 2005) examining CD8+ T cell responses in IM donors and this 
study examining healthy carriers.  Both studies identified near identical epitopes in BRLF1 and 
BMRF1 (the minimal epitope was not determined in the Pudney study, refer to Table 2 and Chapter 
1, Table 2) demonstrating that near identical CTL responses can be seen in both IM and healthy 
donors.   
As this study utilised T cell lines that were generated by exposure to autologous LCLs, there 
remains a possibility of skewing epitope-specific responses towards the latent antigens of EBV.  
However,this does not appear to be the case since similar reactivities were observed when peptides 
were tested with PBMCs or T cell lines generated by peptide stimulation (data not shown, (Rist, 
Hibbert et al. 2015)).  Although a potential bias may exist for reactivities towards latent responses, 
LCLs typically have 1-5% of cells in the lytic cycle, and this appears to be sufficient to stimulate 
many large lytic antigen-specific responses. 
In order to ascertain the extent of the abundance of noncanonical epitopes the overall 
numbers of novel epitopes of this study were combineed as well as results from previous studies.  
Of the 41 novel epitopes that were defined in this study, 4 (~10%) were noncanonical 11mers 
(Table 2).  The distribution of these 11mer epitopes was in antigens BMRF1, EBNA3A, EBNA3B 
and EBNA3C.  Interestingly, three of these epitopes have a Proline at the second residue and are 
recognised by members of the HLA–B7 supertype family concurring with previous findings 
(Burrows, Rossjohn et al. 2006, Burrows, Bell et al. 2008).  To determine the percentage of 
noncanonical epitopes for each studied antigen the number of new epitopes defined in this study 
were added to the number of known epitopes to establish an overall number of epitopes.  For the 
latent antigens EBNA1, EBNA3A, EBNA3B and EBNA3C the percentage of noncanonical 
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epitopes is 11%, 4%, 14% and 5%, respectively.  As minimal epitopes have been determined for all 
of the epitopes within these latent antigens it is clear that epitopes of over 10 residues in length play 
a significant role in the CD8+ T cell response to these antigens.   
However, this is less clear for the lytic antigens as many of the known epitopes are not 
defined as minimal epitopes, although and there are a number for which the minimal epitope has 
been determined in this study.  For example, there are eight known BMRF1 epitopes including a 
defined 13mer and two 15mers which may or may not be the minimal epitope.  In addition four 
novel epitopes have been defined in this study, one of which is an 11mer.  The percentage of 
noncanonical epitopes in BMRF1 is therefore 16% if the 15mers are excluded.  There were no 
noncanonical epitopes found in BMLF1 or BRLF1 in this study.  
To determine if the 41 novel epitopes identified in this study would have been predicted 
using standard epitope prediction algorithms, each antigen was assessed with the web-based 
prediction tool, SYFPEITHI.  Interestingly, 15 of the 41 novel epitopes, including the four 11 mer 
epitopes were not predicted by this tool.  This failure to predict epitopes was due to a number of 
factors, including limitations with HLA coverage and epitope length.  There are no prediction 
parameters for HLA-A23, -A29, -A32, -B15, -B40, -B52, -B53 and the HLA-C alleles and although 
there appears to be an 11mer prediction function when this was chosen for all antigens the program 
came back with no search results.  These findings indicate that many parameters of standard epitope 
prediction algorithms require reassessment and updating in order to reflect accurate epitope length 
and wider HLA coverage.                   
Although it does appear that long CD8+ T cell epitopes are not as plentiful as we initially 
hypothesised, four 11-mer epitopes have been defined including one in each of the EBNA3 proteins 
and another in BMRF1 (Table 2).  Our recent studies have shown that epitope length preference is 
heavily influenced by structural features of different HLA molecules.  The noncanonical dodecamer 
that was defined in this study, 169EECDSELEIKRY180 from BZLF1 helped highlight that HLA-
B*4403 favours the presentation of longer peptides (Rist, Theodossis et al. 2013) (Chapter Five).  
Future work in this area is required to determine the peptide length preference of other HLA alleles 
which may be used to improve web-based algorithms for epitope prediction in addition to assisting 
strategies for peptide-based vaccine design.  However, the present investigation has revealed many 
new epitopes including some that are clustered together and overlapping with previously defined 
epitopes and some that are restricted by several HLA alleles. 
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Chapter 4: 
 
Aim Two: 
Determine if the highly immunogenic BZLF1 antigen of EBV includes novel CD8+ T cell epitopes. 
 
Hypothesis Two:   
There are many unidentified CD8+ T cell epitopes to be defined in the BZLF1 antigen. 
 
Publication: Original research article 
Rist MJ, Neller MA, Burrows JM, Burrows SR.  T Cell Epitope Clustering in the Highly 
Immunogenic BZLF1 Antigen of Epstein-Barr virus.  Journal of Virology. 2015 Jan; 89 (1):703-
712.   
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Chapter 5: 
 
Aim Three: 
Determine if the peptide length preferences of class I human leukocyte antigens influence epitope 
selection in the EBV-specific T cell response. 
 
Hypothesis Three: 
Different class I human leukocyte antigens have distinct peptide length preferences, and this 
influences epitope selection in the EBV-specific T cell response. 
 
Publication: Original research article 
Rist MJ, Theodossis A, Croft NP, Neller MA, Welland A, Chen Z, Sullivan LC, Burrows JM, 
Miles JJ, Brennan RM, Gras S, Khanna R, Brooks AG, McCluskey J, Purcell AW, Rossjohn J, 
Burrows SR.  HLA Peptide Length Preferences Control CD8+ T Cell Responses.  The Journal of 
Immunology. 2013 June; 191:561-571 
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Chapter 6: 
 
Aim Four:  
Characterise a cross-reactive T cell response to an EBV epitope and self–peptide presented by 
HLA-B*1801. 
 
Hypothesis Four: 
The T cell receptor repertoire that cross-reacts with an EBV epitope and a self-peptide are identical 
between individuals. 
 
Published research article: 
Rist MJ, Hibbert KM, Croft NP, Smith C, Neller MA, Burrows JM, Miles JJ, Purcell AW, 
Rossjohn J, Gras S, Burrows SR.  T cell cross-reactivity between a highly immunogenic Epstein-
Barr virus epitope and a self-peptide naturally presented by HLA-B*18:01+ cells.  The Journal of 
Immunology.  2015, May; 194: 4668-4675. 
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Abstract 
T cell cross-reactivity underpins the molecular mimicry hypothesis in which microbial peptides 
sharing structural features with host peptides stimulate T cells that cross-react with self-peptides, 
thereby initiating and/or perpetuating autoimmune disease. EBV represents a potentially important 
factor in the pathogenesis of several autoimmune disorders, with molecular mimicry a likely 
mechanism. Here we describe a human self-peptide (DELEIKAY) that is a homologue of a highly 
immunogenic EBV T cell epitope (SELEIKRY) presented by HLA-B*18:01. This self-peptide was 
shown to bind stably to HLA-B*18:01, and peptide elution/mass spectrometric studies showed it is 
naturally presented by this HLA molecule on the surface of human cells. A significant proportion of 
CD8+ T cells raised from some healthy individuals against this EBV epitope cross-reacted with the 
self-peptide. A diverse array of T cell receptors was expressed by the cross-reactive T cells, with 
variable functional avidity for the self-peptide, including some T cells that appeared to avoid 
autoreactivity by a narrow margin, with only 10-fold more of the self-peptide required for 
equivalent activation as compared to the EBV peptide. Structural studies revealed that the self-
peptide-HLA-B*18:01 complex is a structural mimic of the EBV peptide-HLA-B*18:01 complex, 
and that the strong antiviral T cell response is primarily dependent on the alanine/arginine mismatch 
at position 7.  To our knowledge, this is the first report confirming the natural presentation of a self-
peptide cross-recognized in the context of self-HLA by EBV-reactive CD8+ T cells. These results 
illustrate how aberrant immune responses and immunopathological diseases could be generated by 
EBV infection.   
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Introduction 
The vast majority of the body’s circulating CD8+ T cells express αβ T cell receptors (TCRs) on the 
cell surface and play an integral role in the adaptive immune response, recognizing peptides bound 
to major histocompatibility complex (MHC) class I molecules [1].  T cells undergo rigorous 
selection in the thymus, eliminating those that recognize self-peptides associated with MHC 
molecules, whilst positively selecting those with the potential to recognize antigenic peptide 
epitopes [2].  Importantly, self or autoreactive T cells with a very low affinity/avidity can escape 
negative selection in the thymus and, under certain circumstances, can facilitate a variety of 
autoimmune conditions in humans [3] [4]. 
 Generated somatically through site specific DNA recombination reactions, TCR diversity is 
a result of the random assembly of variable (V), diversity (D) and junctional (J) gene segments.  
The TCR α chain is comprised of V and J gene segments whilst V, D and J genes encode the TCR β 
chain [5].  Each chain has three CDRs that make the Ag-binding site of the TCR. The CDR3 loop is 
a critical component of the TCR, as it generally mediates contact with the antigenic peptide-MHC 
complex [6]. The mathematical estimation of potential TCR diversity is around 1015 different TCRs, 
although after considering thymic positive and negative selection events, the size of the naïve 
TCRαβ repertoire is estimated to be around 2 x 107 TCRs for each human [5]. 
 As the binding sites of TCRs arise from random genetic mechanisms, these sites have the 
capacity to react not only with pathogens and environmental antigens but also with self antigens. 
Indeed, autoimmune disease and allergies can occur when activation of the adaptive immune 
response is directed at antigens that are self or environmental.  Forming the basis of the molecular 
mimicry hypothesis is T cell cross-reactivity, whereby it is postulated that T cells stimulated by an 
epitope derived from an infectious agent can cross-react with a self antigen that may share sequence 
or structural homology with that epitope. This phenomenon may initiate and/or perpetuate 
autoimmune disease [7].  Consistent with this theory a number of animal studies have demonstrated 
that antigen mimicry can induce a T cell response in addition to autoimmune disease in the form of 
murine autoimmune oophoritis [8], and limited sequence homology can evoke a multiple sclerosis 
(MS)-like disease [9]. 
Epstein-Barr virus (EBV), a lymphotropic gamma-1 herpesvirus, is widespread in all human 
populations, infecting around 95% of the adult population worldwide [10] [11].  EBV infection is 
associated with several autoimmune conditions including MS, for which a molecular mimicry 
mechanism has been proposed [12].  Recently, we investigated the CD8+ T cell response to the 
immediate early, BZLF1 antigen of EBV and described an octamer peptide 173SELEIKRY180 
(termed SEL) that is recognized by HLA-B*18:01+ individuals [13].  In the present study, we have 
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identified a human protein sequence (DELEIK
 
AY; termed DEL) with sequence homology to the 
octamer EBV epitope. A peptide corresponding to this sequence from the cleavage and 
polyadenylation specific factor 3-like protein (CPSF3L) was shown by peptide elution/mass 
spectrometry be presented by the HLA-B*18:01 molecule on the surface of human cells. A 
significant proportion of T cells raised against the EBV epitope cross-reacted with this HLA-
B*18:01-binding synthetic self-peptide, and structural studies revealed the molecular basis of this 
cross-reactivity. These results underscore the exquisite specificity of the immune system but 
highlight the potential danger of self-reactivity by T cells expanded in response to common viral 
infection. 
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Materials and Methods 
Purification of MHC-bound peptides   
C1R-HLA-B*18:01 cell pellet (5 x 108 cells) were ground in a Retsch Mixer Mill MM 400 under 
cryogenic conditions, resuspended in 0.5 % IGEPAL, 50 mM Tris-HCl pH 8.0, 150 mM NaCl and 
protease inhibitors (Complete Protease Inhibitor Cocktail Tablet; Roche Molecular Biochemicals) at 
a density of 5 x 107 cells/mL and incubated with rotation for 1 h at 4 °C [14].  Lysates were cleared 
by ultracentrifugation (180,000 x g) and HLA-peptide complexes sequentially immunoaffinity 
purified using solid-phase bound anti-Bw6 (HB152-SRF) antibodies. Bound complexes were 
washed and peptides eluted by acidification with 10 % acetic acid, as described [15-17].  The 
mixture of peptides and HLA proteins was fractionated on a 4.6 mm internal diameter x 50 mm 
long monolithic reversed-phase C18 HPLC column (Chromolith Speed Rod, Merck) using an 
ÄKTAmicro™ HPLC system (GE Healthcare).  Peptide-containing fractions were resolved from 
β2-microglobulin and solubilized HLA heavy chain using a linear gradient of aqueous 0.1% 
trifluoroacetic acid (TFA) (buffer A) to 80% acetonitrile/0.1% TFA (buffer B) at a flow rate of 1 
mL/min.  
 
Identification of MHC-bound peptides using LC-MS/MS   
Peptide-containing RP-HPLC fractions were concentrated using a Labconco CentriVap 
concentrator and reconstituted in 15 µL of 0.1% formic acid in water. After sonication in a water 
bath for 10 min, the reconstituted fractions were centrifuged for 10 min at 18,000 × g and 
transferred to mass spectrometry vials for analysis by an AB SCIEX 5600 TripleTOF mass 
spectrometer equipped with a Nanospray III ion source and coupled on-line to an Eksigent 
NanoUltra cHiPLC system. [14,16].  Samples were loaded onto the microfluidic trap column 
packed with ChromXP C18-CL 3-μm particles (300 Å nominal pore size; equilibrated in 0.1% 
formic acid/5% acetonitrile) at 5 μl min−1. An analytical (15 cm × 75 μm ChromXP C18-CL 3) 
microfluidic column was then switched in line and peptides separated by linear gradient elution of 
0–80% acetonitrile over 90 min (300 nl min−1). Mass spectrometry conditions were set to 
accumulate up to 30 MS/MS spectra per second. Data were analysed with Protein Pilot software 
(AB SCIEX) and peptide identities were determined subject to strict bioinformatic criteria that 
included the use of a decoy database to calculate the false discovery rate (FDR). A FDR cut-off of 5 
% was applied consistent with the accepted cut off for non-tryptic peptides [18, 19], and the filtered 
data set was further analyzed manually to exclude redundant peptides, known contaminants and 
non-specific peptides (i.e. those identified in an anti-HLA-Bw4 control peptide elution experiment).  
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T cell cultures 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque centrifugation into 
RPMI 1640 medium supplemented with 10% FCS (R10 medium). Blood donors were healthy, 
EBV-seropositive individuals who had given written informed consent. Approval was obtained 
from the QIMR Berghofer Medical Research Institute Human Ethics Committee (Brisbane, QLD, 
Australia). T cell cultures were raised by culturing PBMCs (2x106 per 2ml well) with either 
irradiated autologous lymphoblastoid cell lines (LCLs) (2x105 per 2ml well) for EBV-specific 
cultures or PBMCs that had been pre-coated with the EBV-SEL peptide (1μM for 1h, 
responder:stimulator ratio 2:1) for SEL-specific cultures. Cultures were supplemented with rIL-2 
(20U/ml) from day 3 and analyzed on day 18. Synthetic EBV peptide SEL and self-peptide DEL 
were synthesized by use of the Merrifield solid-phase method and purchased from New England 
Peptides (SEL) (Gardner, MA) and Mimotopes (DEL) (Clayton, Australia).  
 
ELISPOT assays 
IFN-γ ELISPOT assays were performed using cytokine capture and detection reagents according to 
manufacturer’s instructions (ELISpotPRO for Human IFN-γ, Mabtech, Stockholm, Sweden).  Briefly, 
96-well nitrocellulose plates pre-coated with anti-IFN-γ mAb were seeded with approximately 5 x 
104 EBV-specific T cells and peptides SEL or DEL at various concentrations. After incubation for 
16 hours at 37°C in 5% CO2, the cells were discarded, and captured IFN-γ was detected with a 
biotinylated anti-IFNγ Ab, followed by development with an alkaline phosphatase substrate solution 
(BCIP/NBT-plus). Spots were counted using an automated plate counter. 
 
pMHC multimer and TRBV staining 
T cell cultures (LCL- or peptide-stimulated) from healthy virus carriers were incubated for 30 
minutes at 4°C with an SEL-HLA-B*18:01 allophycocyanin (APC)-labelled tetramer [13].  Cells 
were then washed and incubated with PerCP-Cy5.5 conjugated anti-human CD8 mAb (BioLegend, 
San Diego, CA), and one of the following phycoerythrin or fluorescein isothiocyanate-labeled TCR 
β-chain-specific mAbs (Beckman Coulter): Vβ1 (TRBV9), Vβ2 (TRBV20-1), Vβ3 (TRBV28), Vβ4 
(TRBV29), Vβ5.1 (TRBV5-1), Vβ5.2 (TRBV5-6), Vβ5.3 (TRBV5-5), Vβ6.7 (TRBV7-1), Vβ7 
(TRBV4), Vβ7.2 (TRBV4-3), Vβ8 (TRBV12), Vβ9 (TRBV3), Vβ11 (TRBV25-1), Vβ12 (TRBV10), 
Vβ13.1 (TRBV6-5), Vβ13.2 (TRBV6-2), Vβ13.6 (TRBV6-6), Vβ14 (TRBV27), Vβ16 (TRBV14), 
Vβ17 (TRBV19), Vβ18 (TRBV18), Vβ20 (TRBV30), Vβ21.3 (TRBV11-1), Vβ22 (TRBV2) or Vβ23 
(TRBV13).  Cells were washed twice and fixed in 1% paraformaldehyde (PFA) in PBS. These 
samples were analysed on a FACS LSR-Fortessa flow cytometer using FACSDiva software (BD 
Biosciences). 
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Intracellular cytokine staining assay 
T cell lines from EBV-seropositive, HLA-B*18:01+ donors, raised by stimulation of PBMCs with 
the SEL peptide, were incubated for 4 hours at 37°C with either SEL or DEL peptide (1μg/ml) in 
R10 medium supplemented with 5μg/ml Brefeldin A (BioLegend). These cells were then washed 
and incubated at 4°C for 30 min with fluorescently-labeled mAb specific for cell surface markers 
(CD8-PerCP-Cy5.5 (Biolegend) and CD4-Alexa flour 488 (Biolegend)). Cells were washed, then 
fixed and permeabilized with Cytofix/Cytoperm fixation/permeabilization solution (BD 
PharMingen) at 4°C for 20 min. Next, the cells were washed in Perm/Wash (BD PharMingen), 
incubated with IFN-γ-PE (BD PharMingen) at 4°C for 30 min, washed with Perm/Wash, 
resuspended in PBS and analysed on a FACS LSR-Fortessa (BD Biosciences). In experiments 
evaluating the TRBV staining of DEL-reactive T cells, TRBV staining was performed prior to the 
fixation and permeabilization steps.  
 
Protein expression, purification and crystallisation 
HLA-B*18:011-276 and β2m were transformed in BL21-RIL E.coli competent cells and isolated 
from inclusion bodies similarly as previously described [20].  Thirty milligrams of HLA-B*18:01 
h eavy ch ain  (hc),  2 0 mg of β2 m an d 1 0  mg of each  pep tid e (DEL o r SEL) were d isso lv ed in 
refolding buffer containing 100 mM Tris-HCl pH 8.0, 400 mM L-Arginine-HCl, 2 mM EDTA, 0.2 
mM phenylmethylsulfonyl fluoride, 0.5 mM oxidised glutathione and 5 mM reduced glutathione. 
Two further 30 mg aliquots of the hc were added to the refolding buffer, leaving at least 3 h 
between each injection. After 48 h, the protein was dialysed three times against 10 L of 10 mM 
Tris-HCl pH 8.0 over a period of 24 h. The refolded protein was then purified by elution over anion 
exchange chromatography. 
Crystals of the DEL-HLA-B*18:01 complex were grown by the hanging-drop, vapour-
diffusion method at 20°C with a protein/reservoir drop ratio of 1:1, at a concentration of 10 mg/mL 
in TBS (10 mM Tris-HCl pH 8.0, 150 mM NaCl) using 14- 20% PEG 4K, 0.2 M Amonium Acetate 
and 0.1 M Na-Citrate pH 5.6. 
 
Data collection and structure determination 
The DEL-HLA-B*18:01 crystals were soaked in a cryoprotectant solution containing mother liquor 
solution with a final PEG concentration of 30% (w/v) PEG 4K and then flash frozen in liquid 
nitrogen. The data were collected on the MX1 beamline at the Australian Synchrotron (Clayton, 
Vic) using the ADSC-Quantum 210 CCD detector (at 100K). Data were processed using 
iMOSFLM [21] and scaled using SCALA on CCP4 suite [22].  The structure was determined by 
molecular replacement using the Phaser molecular replacement program in PHENIX [23] with the 
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SEL-HLA-B*18:01 (Protein Data Bank accession number, 4JQV) [13] as a search model minus the 
peptide. The model was then refined using PHENIX [23] and manually built using COOT [24].  
The final model has been validated using the Protein Data Base validation web site and the final 
refinement statistics are summarized in Table 1. Coordinates have been submitted to PDB database, 
code: 4XXC. All molecular graphics representations were created using PyMol [25]. 
 
Thermal stability assay 
To assess the difference in stability between HLA-B*18:01 bound to the DEL self-peptide and SEL 
EBV peptide, a thermal shift assay was performed. The fluorescent dye Sypro orange was used to 
monitor the protein unfolding. The thermal stability assay was performed in the Real Time 
Detection system (Corbett RotorGene 3000), originally designed for PCR. Data was acquired for 
the two pHLA complexes at two concentrations (5 and 10 mM) in TBS buffer (10 mM Tris-HCl 
pH8, 150 mM NaCl) in duplicate and temperature was increased at a rate of 1°C/min over a range 
of 29 to 90°C. The fluorescence intensity was measured with excitation at 530 nm and Emission at 
555 nm. The thermal melt (Tm) point represents the temperature for which 50% of the protein is 
unfolded.  The raw data were processed using GraphPad prism software.  
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Results 
Self-peptide homology to an EBV epitope presented by HLA-B*18:01 
The BZLF1 antigen of EBV includes a highly immunogenic octamer epitope 173SELEIKRY180 that 
is recognized by CD8+ T cells from HLA-B*18:01+ individuals [13].  Database searches identified a 
human protein sequence (DELEIK
In order to determine whether this self-peptide is presented by cells bearing the HLA-
B*18:01 allele, we screened mass spectrometry spectra from peptides eluted from C1R cells 
engineered to express HLA-B*18:01 [13].  ProteinPilot™-based searches detected the octamer 
DELEIKAY, although the confidence level assigned (~74%) was below the stringent false-
discovery rate cut-off that would normally be applied to refine the data from such searches. We also 
identified the C-terminally extended nonamer peptide DELEIKAYY at a confidence of 99%. 
Reasoning that both peptides may be presented rather than just the nonamer, with the differential 
abundance potentially accounting for a higher confidence scoring of the nonamer, we manually 
interrogated the spectra for the presence of precursor MS1 ions from both peptides (Fig. 2). Doubly 
charged precursor ions were detected for both the octamer (theoretical m/z of 490.7514; Fig. 2A) 
and nonamer (theoretical m/z of 572.2821; Fig. 2C) sequences. MS2 fragmentation spectra (Fig. 2B 
and 2D) triggered from both of these precursors confirmed their correct sequence assignment and 
thus their presence on B*18:01+ve cells. It is worth noting that the signal intensity for the MS1 and 
MS2 spectra for the octamer was ~10-fold lower than that observed for the nonamer, and the 
relatively low level of the former was likely to account for the lower confidence scoring by the 
ProteinPilot™ algorithm. These data also suggested that the octamer is therefore presented at lower 
abundance than the nonamer, although without accounting for relative differences in ionisation 
efficiency between the two peptides it is not possible to state this conclusively without further 
investigation. We failed to detect either peptide from cells not expressing HLA-B*18:01 (data not 
shown).  These experiments therefore confirm the natural presentation of the DELEIKAY self-
peptide homologue of the HLA-B*18:01-restricted EBV T cell epitope on the surface of human 
cells. 
AY) with sequence homology to this EBV epitope. This 
sequence is from CPSF3L which is a component of the multiprotein integrator complex associated 
with the C-terminal domain of RNA polymerase II [26], as well as a member of a group of the zinc-
dependent hydrolases called the metallo-β-lactamase family [27]. To establish if a peptide 
corresponding to this sequence can bind to HLA-B*18:01, the stability of this HLA molecule bound 
to the EBV or self-peptide was compared using a thermal stability assay. The two amino acid 
difference between the two peptides had little effect on the overall stability of the p-HLA-B*18:01 
complexes, with the two peptides showing a similar Tm point of ~70°C (Fig. 1).  
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Cross-recognition by EBV-reactive CD8+ T cells of a self-peptide presented by HLA-B*18:01 
In order to determine whether the DEL self-peptide is cross-recognized by EBV-reactive T cells, 
polyclonal T cell lines were generated from the PBMCs of healthy EBV-exposed, HLA-B*18:01+ 
individuals by stimulation with either SEL peptide or autologous EBV-infected cells (LCLs), 
followed by screening for recognition of the SEL and DEL peptides. IFN-γ ELISPOT assays using 
various concentrations of each peptide were conducted. All donors showed strong IFN-γ responses 
to the SEL EBV peptide, while cross-recognition of the human peptide was variable (Fig. 3). Only 
donors 1 and 2 recognized the DEL self-peptide although, in both cases, higher concentrations of 
DEL were required for equivalent levels of recognition observed with the EBV peptide. 
Nonetheless, the EBV-reactive T cell repertoire of Donor 1 appears to avoid autoreactivity by a 
surprisingly narrow margin, with only 10-fold more of the self-peptide required for equivalent 
activation compared with the EBV peptide.  
To determine the proportion of CD8+ T cells within the SEL-reactive repertoire that cross-
recognizes the DEL self-peptide, T cell lines were raised from healthy EBV-exposed, HLA-
B*18:01+ individuals by stimulation with SEL peptide and screened by intracellular cytokine 
staining for recognition of SEL and DEL (Fig. 4). Results showed variability in the percentage of 
SEL-reactive T cells cross-recognizing DEL, ranging from 60% in Donor 1, 8% in Donor 2, and 
20% in Donor 5.  This experiment was repeated using a T cell culture from Donor 2 that was 
generated by using stimulation with the autologous LCL and, although the frequency of SEL 
(17.0%) and DEL (1.6%)-reactive T cells was lower, the percentage of SEL-reactive T cells cross-
recognizing DEL (9%) was very similar to that measured in the T cell line from Donor 2 generated 
by using SEL peptide stimulation (data not shown).  These data therefore demonstrate that T cells 
with significant avidity for a naturally-presented self-peptide are expanded and activated by EBV 
infection of some HLA-B*18:01+ individuals.  
 
TCR repertoire of cells cross-recognising the self-peptide and EBV epitope 
To determine if SEL/DEL cross-reactivity is mediated by a monoclonal, oligoclonal or polyclonal 
population of T cells, the next set of experiments analyzed TCR ß-chain variable (TRBV) gene 
usage of the cross-reactive T cells from Donors 1, 2 and 5. Before examining the cross-reactive 
subset, we firstly analyzed the total SEL-reactive population using flow cytometry with monoclonal 
TRBV antibodies in combination with an SEL-HLA-B*18:01 tetramer (Fig. 5A). Although the 
constraints imposed by tolerance to a self-peptide homologue could be expected to restrict the 
diversity of a T cell response, relatively diverse TRBV gene usage was observed. Bias towards 
particular TRBV genes was noted, however, with strong selection of TRBV10 in all three donors, 
TRBV4 in Donors 2 and 5, TRBV6.5 in Donor 2, and TRBV25 in Donor 5. We next analyzed the 
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DEL-cross-reactive subset; however it was not possible to utilize a DEL-HLA-B*18:01 tetramer 
because preliminary experiments revealed that this tetramer failed to label T cells from all donors 
(data not shown), presumably due to the low avidity of some of these T cells for this self-peptide-
HLA complex, as suggested by the peptide dose-response data shown in Fig. 3. Instead, the DEL-
reactive T cells were assessed for intracellular IFN-γ following stimulation with this peptide. As 
shown in Fig. 5B, this DEL-cross-reactive subset was also surprisingly polyclonal, but with 
dominant usage of TRBV10 in Donors 1 and 2, co-dominance of TRBV25 in Donor 2, and strong 
usage of both TRBV11 and TRBV20 in Donor 5, indicating that a diverse array of TCRs have the 
capacity to cross-recognize these two peptides. 
 
The self-peptide structure is a mimic of the EBV epitope 
To have a better understanding of the cross-reactivity observed for the SEL-specific T cells we next 
crystallized the DEL self-peptide in complex with the HLA-B*18:01 molecule to compare it with 
the previously solved HLA-B*18:01-SEL complex structure [13]. The structure of the HLA-
B*18:01-DEL complex was solved at a resolution of 1.43 Å (Table 1) revealing a clear electron 
density for the peptide (Fig. 6A & 6B) in the cleft of HLA-B*18:01. We superimposed the 
structures of the self and EBV peptides in complex with the HLA-B*18:01 (Fig. 7). The HLA 
structures were very similar, with a root mean square deviation on the Cα atoms of the α1-α2 
domains of 0.143 Å between the two pHLA complexes. The peptides were also adopted a very 
similar confirmation, with a root mean square deviation on the peptide Cα atoms of 0.17 Å.  The 
major differences between the two structures occurring at the P1 and P7 where the substitutions 
between the two peptides are located (Fig. 7B). Overall the structure of HLA-B*18:01 in complex 
with the DEL self-peptide shows that the substitutions with the EBV epitope did not affect the 
structure of the pHLA complex, and that the viral epitope was a structural mimic of the self-peptide. 
We previously showed that the substitution of Ser with Ala at P1 of the EBV peptide did not 
affect recognition by a polyclonal T cell line, but that Ala substitution at P7 decreased T cell 
recognition of the EBV epitope [13].  Since the self-peptide contains a P7-Ala, it is likely that this 
substitution is the basis for the lower TCR avidity implied by the dose-response curves. The P7-Arg 
is presumably the focus of the EBV-specific T cell response in healthy virus carriers in order to 
avoid self-reactivity.  
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Discussion 
Although T cells have the capacity to discriminate between an enormous number of peptide-MHC 
complexes, there is a limit to their specificity due to the small size of the target epitope. A small, 
strongly immunogenic CD8+ T cell epitope from EBV was found to share six of its eight residues 
with a sequence from the human CPSF3L protein, including the primary anchor residues, raising 
questions on the potential of this anti-viral response to be “dangerous” or auto-reactive under 
certain circumstances. Expression of the CPSF3L protein has been shown to be upregulated by the 
HIV-1 Tat protein and disrupted by RNA interference demonstrating that CPSF3L is an important 
regulatory protein for both viral and cellular gene expression [28].  This protein also plays a critical 
role in snRNA 3’ end formation [29] and has been shown to be expressed in both LCLs and human 
osteoblasts [30].  
Our investigations first showed that this self-peptide does bind well to HLA-B*18:01, and is 
presented on human cells at levels detectable by LC-MS/MS. Furthermore, some T cells raised from 
healthy donors against this EBV peptide could recognize the human peptide. Although self-
tolerance had ensured there was a window of differential sensitivity between T cell recognition of 
the viral versus self-peptide, in some cases only 10-fold more of the self-peptide was required for 
equivalent T cell activation to that observed using the EBV peptide – a surprisingly small buffer 
zone of functional avidity to prevent autoimmunity. The TCR repertoire for the EBV peptide was 
not highly restricted by the self-peptide homology, and many different TRBV genes were also 
expressed by the subset of T cells that cross-reacted with the self-peptide. This was unexpected, 
given that structural analysis showed that the viral-peptide-HLA and self-peptide-HLA complexes 
were virtually indistinguishable, with the exception of the two mismatched peptide side-chains. 
This is the first report, to our knowledge, confirming the natural presentation on human cells 
of a self-peptide cross-recognized by EBV-reactive CD8+ T cells, for which the presenting HLA 
allele for the EBV and self-peptide is the same. Earlier work on alloantigen cross-reactivity by 
EBV-reactive CD8+ T cells demonstrated that molecular mimicry also plays a role in alloreactivity. 
In this case, EBV-reactive T cells were shown to cross-recognize an HLA-B*08:01-bound viral 
epitope and an HLA-B*44:02/5-bound peptide from a human ATP binding cassette protein [31].   
Previous studies have also described T cell cross-reactivity between EBV and peptides from the MS 
autoantigen, myelin basic protein (MBP). In one case, CD4+ T cells raised against EBV nuclear 
antigen 1 cross-reacted with MBP and other myelin proteins [32], and in another example, CD4+ T 
cells were shown to cross-react with an epitope from the DNA-polymerase protein of EBV 
(BALF5), and MBP (residues 83–99) [33].  In the latter example, the EBV peptide was presented 
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by HLA-DRB5*0101 and the MBP peptide was presented by DRB1*1501, both MS-associated 
restriction elements. 
These studies support the notion that EBV-reactive T cells could be involved in 
autoimmunity via molecular mimicry. There is now a large body of evidence that infection with 
EBV is an environmental trigger for many chronic autoimmune diseases [12, 34, 35].  Many 
observations implicate EBV in the pathogenesis of MS; for example, MS patients are almost 
universally seropositive for EBV, but not for other viruses [34, 36].  Moreover, a clinical history of 
acute infectious mononucleosis (IM) increases the risk of MS, with a relative risk of 2.3 [37].  
Patients with MS also have elevated levels of serum IgG antibodies against many EBV antigens 
[38].  EBV may also be involved in the salivary gland tissue damage leading to Sjögren’s syndrome 
[39].  Data suggesting this possibility include a higher incidence of EBV reactivation in Sjögren’s 
syndrome patients, and increased levels of EBV antigens and DNA in salivary infiltrating 
lymphocytes [40].  It has also been shown that the saliva of Sjögren’s syndrome patients can 
stimulate transactivation of BZLF1 (the viral antigen from which the SEL peptide is derived), and 
that this may be responsible for the autoimmune response in the salivary glands of Sjögren’s 
syndrome patients [41].  An increased seroprevalence of EBV has been noted in North Americans 
of different ethnicities with systemic lupus erythematosus (SLE) [42, 43].  SLE patients also have 
an increased EBV genome load in blood compared to healthy individuals [44], with viral loads 
peaking after initiation of disease flares [45].  Importantly, in the context of the present report, SLE 
patients also have aberrant expression of the BZLF1 antigen in the blood [46].  It is also relevant to 
highlight that EBV-reactive CD8+ T cells are enriched in or near the diseased organs of patients 
with rheumatoid arthritis [47, 48] and MS [49], including a high proportion of T cells specific for 
BZLF1 [50].  This could reflect a local immune response against EBV in the diseased organs, or 
non-specific homing of virus-specific T cells to inflamed sites [51]. 
It is possible that autoreactivity by EBV-reactive T cells is partly responsible for the 
immunopathology associated with acute IM following primary EBV infection. BZLF1-specific T 
cells are known to be expanded to huge numbers during acute IM, with one report of T cells 
specific for a single BZLF1 epitope accounting for 44% of the CD8+ T cells in IM blood [52].  
Indeed, an earlier study by Misko et al. demonstrated another example of T cell cross-reactivity 
between a BZLF1 octamer peptide and a self-peptide, both presented by HLA-B8, although in this 
case, the self peptide was not shown to be naturally presented [53]. Mouse studies certainly support 
the notion that autoimmunity following infection with pathogens is mediated by effector T cells 
with low avidity for self and which are not normally primed by endogenous amounts of self antigen 
[54, 55]. 
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As well as highlighting the potential danger of self-reactivity by T cells expanded in 
response to common viral infection, the present report also underscores the exquisite specificity of 
the immune system by showing that a strong T cell response, utilizing a variety of TCRs, can be 
mounted against a foreign peptide-HLA complex that is essentially identical to a self-peptide-HLA 
complex with the exception of one TCR-accessible peptide side-chain.  Although immune tolerance 
ensures that the healthy subjects examined in this study are ignorant towards their own cells, 
increasing self-peptide levels above those naturally presented (by addition of exogenous self-
peptide) leads to readily detectible T cell activation.  The functional avidity of T cells from one 
healthy subject was only 10-fold higher for the viral epitope compared to the self-peptide.  Such 
minor differences in T cell activation threshold are presumably sufficient to avoid autoreactivity in 
most individuals, as supported by previous studies showing that small avidity differences can have a 
major functional impact on T cell recognition [56, 57].  
It is difficult to establish the mechanisms behind the EBV/autoimmunity association because 
EBV does not infect animals commonly used in models of autoimmune diseases. However, it is 
notable that recent studies with a humanized mouse model of EBV infection reported the 
development of erosive arthritis resembling rheumatoid arthritis in the majority of such mice [58].  
The present study has provided support for a molecular mimicry mechanism by demonstrating that 
EBV-reactive CD8+ T cell expansions can be identified in healthy people that can cross-react with a 
naturally presented self-peptide. The potential for self-reactivity by these T cells is presumably kept 
under rigorous control by normal self-tolerance mechanisms. However, these EBV/self cross-
reactive T cells could pose an autoimmune threat if co-stimulatory adhesion molecules or HLA-
B*18:01-DEL levels increased or the T cell activation threshold was reduced as a result of cytokine 
release during inflammation or acute infections [54].  The cross-reactive T cell populations 
identified in the present report should be considered for their potential role in autoimmune diseases 
associated with HLA-B*18:01 such as type 1 diabetes [59]. 
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Table 1. Data Collection and Refinement Statistics 
Data Collection Statistics  
Space group P212121 
Cell Dimensions (a,b,c) (Å) 50.66, 80.80, 108.98 
Resolution (Å) 24.67 - 1.43 (1.50 - 1.43) 
Total number of observations 493100 (65298) 
Number of unique observations 80489 (11097) 
Multiplicity 6.1 (5.9) 
Data completeness (%) 95.8 (91.7) 
I/σI 7.7 (2.2) 
Rpima (%) 4.7 (28.3) 
Refinement Statistics  
Non-hydrogen atoms  
Protein 3265 
Water 516 
Rfactorb (%) 20.5 
Rfreeb (%) 23.5 
Rms deviations from ideality  
Bond lengths (Å) 0.006 
Bond angles (°) 1.064 
Ramachandran plot (%)  
Favored region 97.7 
Disallowed region 0 
aRp.i.m = Σhkl [1/(N-1)]1/2  Σi | Ihkl, i - <Ihkl> | / Σhkl <Ihkl>. b Rfactor = Σhkl  | | Fo | - | Fc | | / Σhkl | Fo | for all data 
except ≈ 5% which were used for Rfree calculation. 
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Figures and Figure Legends 
 
 
FIGURE 1. Thermal stability of SEL-HLA-B*18:01 and DELHLA-B*18:01 complexes. Thermal 
unfolding of peptide-HLA-B*18:01 complexes was measured by real time detection. Graph shows 
curves for the SELEIKRY peptide (dotted line) and DELEIKAY peptide (solid line) bound to HLA-
B*18:01. Tm is the melting point temperature needed to unfold 50% of the protein. 
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                                                                            Figure 2 
 
 
 
FIGURE 2. Mass spectrometry-based detection of the HLA-B*18:01-bound peptides DELEIKAY 
and DELEIKAYY. Peptides were eluted from C1R-B*18:01 cells and identified by liquid 
chromatography tandem mass spectrometry on an AB SCIEX TripleTOF® 5600+ mass 
spectrometer and data manually interrogated for the presence of the DEL 8mer and 9mer sequences. 
(A) MS1 isotope series (red) for the doubly charged ion of the 8mer DELEIKAY. (B) MS2 
fragmentation spectra of DELEIKAY, highlighting dominant fragment ions. (C) MS1 isotope series 
(red) for the doubly charged ion of the 9mer DELEIKAYY. (D) MS2 fragmentation spectra of 
DELEIKAYY, highlighting dominant fragment ions. 
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FIGURE 3. HLA-B*18:01+ individuals tested for recognition of SELEIKRY and DELEIKAY.  
IFN-γ ELISPOT assays were used to test (A) SEL-specific T cell lines from Donor 1 (HLA-A2, A3, 
B7, B18, Cw7, Cw12), Donor 2 (HLA-A2, B18, B62, Cw1, Cw5) and Donor 3 (HLA-A1, A30, B8, 
B18, Cw7, Cw7) and (B) EBV-specific T cell lines from Donor 1, Donor 3 and Donor 4 (HLA-
A23, A25, B18, B49, Cw7, Cw12) for recognition of indicated peptides at various concentrations.   
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FIGURE 4. SEL-specific T cell lines from Donor 1, Donor 2 and Donor 5 (HLA-A3, A25, B18, 
B4403) were exposed to SEL or DEL peptide (1μg/ml) and assessed for IFN-γ production by 
intracellular cytokine staining. 
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FIGURE 5.  TRBV gene usage in the recognition of the SEL and DEL peptides by EBV-exposed, 
HLA-B*1801+ individuals.  TRBV gene usage was assessed in T cell cultures using flow cytometry 
with a panel of TCR-β-chain-specific mAbs.  (A) An SEL-HLA-B*1801 tetramer was used to 
examine the SEL-reactive T cell subset, and (B) intracellular IFN-γ production following 
stimulation with the DEL peptide was used to examine the DEL-reactive T cell subset. 
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FIGURE 6. The crystal structure of HLA-B*18:01-DEL. (A) Structure of HLA-B*18:01 (white 
cartoon) in complex with the DEL peptide (cyan sticks) overlaid with the unbiased Fo-Fc density 
map for the peptide contoured at 3σ (green mesh). (B) Structure of HLA-B*18:01 (white cartoon) 
and the DEL peptide (cyan sticks) overlaid with the refined 2Fo-Fc density map contoured at 1σ 
(blue mesh).  The α2 helix has been removed for clarity in this figure. 
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FIGURE 7. Superimposition of the HLA-B*18:01-DEL (cyan) with the HLA-B*18:01-SEL 
(orange) structures (PDB: 4JQV). Superimposition of the crystal structures using main chain atoms 
from residues 1 – 181 of the heavy chain (root mean square deviation = 0.144 Å), viewed from 
above (A) or the side (B). The heavy chain atoms are shown as cartoons and the peptide atoms are 
shown as sticks.  
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7.1 Overview 
In determining the presence of novel CD8+ T cell epitopes, including noncanonical epitopes, 
the latent herpes virus EBV is a superb model due to the strong responses detected in healthy virus 
carriers.  In this thesis, eight highly immunogenic EBV antigens including four latent antigens and 
four lytic antigens were chosen to address the first of three main aims.  The initial aim was to 
determine the relative prevalence of peptide epitopes of over 10 amino acids in length in CD8+ T 
cell recognition of EBV.  This aim was achieved by investigating the CD8+ T cell responses in 
healthy virus carriers toward seven of these EBV antigens (Chapter 3).  The close examination of 
immediate early EBV antigen BZLF1 (Chapter 4) fulfilled the second aim by showing that this 
highly immunogenic antigen did indeed include novel CD8+ T cell epitopes.  The focus of the third 
aim was to determine if the peptide length preference of class I HLA influences epitope selection in 
the EBV-specific T cell response.  Chapter 5 demonstrates that HLA peptide length preferences do 
indeed control EBV–specific CD8+ T cell responses.  The fourth aim was to characterise a cross-
reactive T cell response to an EBV epitope and a self-peptide presented by HLA-B*1801.  In 
Chapter 6 it is shown that individuals with T cells cross-reactive to both the EBV epitope and the 
self-peptide express a diverse array of T cell receptors.  This thesis reports a comprehensive study 
of the CD8+ T cell response to eight EBV antigens determining novel CD8+ T cell epitopes, HLA 
peptide length preferences and cross-reactivity with a self antigen.   
 
7.2 Determine the relative prevalence of peptide epitopes of over 10 amino acids 
in length in CD8+ T cell recognition of EBV 
Class I MHC molecules present peptides derived from viral antigens on the cell surface for 
recognition by CD8+ T cells.  These peptides are generally between 8 and 10 amino acids in length.  
The breakthrough discovery enabling more efficient CTL epitope mapping was that, for most MHC 
alleles, two of the pockets within the peptide binding groove have a preference for one or two 
amino acids at certain anchor positions within the peptide.  In most cases, previous studies have 
utilised web-based algorithms designed to predict CD8+ T cell epitopes to lengths of 8, 9 or 10 
amino acids.  These widely used algorithms may be behind this bias in the literature of MHC class 
I-presented epitopes of 8 to 10 amino acids in length.  Several studies have shown noncanonical 
epitopes naturally processed and presented for CD8+ T cell recognition including a number in EBV 
(Green, Miles et al. 2004) (Tynan, Borg et al. 2005, Miles, Borg et al. 2006, Rist, Theodossis et al. 
2013).   
Thus, investigating the relative prevalence of noncanonical epitopes in EBV by utilising 
overlapping peptides from immunogenic EBV antigens as opposed to web-based algorithm 
prediction may determine natural presentation of longer epitopes.  In Chapter 3, 20-mer peptides 
 118 
 
 
(overlapping by 15 aa) corresponding to the EBV lytic antigens BRLF1, BMLF1 and BMRF1 and 
latent antigens EBNA3A, -3B, -3C and EBNA1 were assayed for CD8+ T cell recognition.  IFN-γ 
ELISpot assays shown to be the best high-throughput screening method (Tischer, Dieks et al. 2014) 
were used to test forty-one healthy virus carriers with around 1000 peptides to address this aim.  
This study provides an extensive list of novel class I EBV epitopes identified from these antigens, 
including four noncanonical epitopes.   
Results from Pudney et al suggest a focusing of CD8+ T cell responses toward epitopes from 
immediate early (IE) and early (E) proteins and a hierarchy of immunodominance amongst the EBV 
lytic cycle antigens (Pudney, Leese et al. 2005).  The findings of this study confirm the 
immunodominance pattern of IE proteins (BRLF1, in addition to BZLF1 (Chapter 4 and 5)) being 
immunodominant over E (BMLF1 and BMRF1) proteins.  Immediate early proteins BRLF1 and 
BZLF1 activate the expression of early proteins including transactivator BMLF1 (Lieberman, 
O'Hare et al. 1986) and BMRF1, involved in viral DNA replication (Pearson, Luka et al. 1987) 
among others.  Pepperl et al defined several BRLF1 epitopes including an HLA-A24-restricted 
decamer epitope 28DYCNVLNKEF37 and 134ATIGTAMYK142 restricted to HLA-A11, as well as the 
HLA-Cw4 restricted 393ERPIFPHPSKPTFLP407 epitope and HLA-B61-restricted 
529QKEEAAICGQMDLS543 peptide (Pepperl, Benninger-Doring et al. 1998).  Our results 
demonstrate five novel epitopes for the IE BRLF1 antigen and four novel epitopes from each of the 
E proteins BMLF1 and BMRF1.  Included in the novel BMRF1 CD8+ T cell epitopes is one of the 
four noncanonical epitopes, 11-mer epitope 146MPYMPPASDRL156 (Table 2, Chapter 3).   
Comparing the number of defined IE epitopes to the E epitopes there are fewer epitopes 
from the E lytic proteins BMLF1 and BMRF1.  Steven et al have defined epitopes from both of 
these proteins.  These include the HLA-A2-restricted 259GLCTLVAML267 and HLA-B18-restricted 
397DEVEFLGHY405 epitopes which are both from the BMLF1 protein (Steven, Annels et al. 1997).  
BMRF1 epitopes include the HLA-Cw6 268YRSGIIAVV276 peptide which has also been found to be 
restricted by HLA-B39 by Pudney et al and the 86FRNLAYGRTCVLGKE100 epitope with HLA-
Cw3 restriction, for which the minimal active sequence has not been precisely mapped (Steven, 
Annels et al. 1997) (Pudney, Leese et al. 2005).      
The hierarchy of immunodominance of both lytic and latent EBV antigens, however, depicts 
the latent EBNA-3A, -3B and -3C antigens as immunodominant over the lytic IE and E proteins, 
based on the total number of defined epitopes.  The relative immunodominance hierarchy in this 
study (with the exclusion of BZLF1), based on the identification of 28 latent and 13 lytic CTL 
epitopes, is EBNA3A, EBNA3C, EBNA3B, BRLF1, BMLF1 and BMRF1 and lastly EBNA1, in 
accord with the findings of Hislop et al  (Hislop, Taylor et al. 2007).  This focus of CTL epitope 
responses towards the EBNA 3 group of proteins may be a reflection of these proteins accounting 
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for >60% of the latent antigen’s coding capacity (Taylor, Long et al. 2015).  Each antigen’s position 
in the hierarchy of immunodominance likely correlates with the kinetics of the virus.  The 
development of memory responses to EBV antigens post-IM involves the maintenance of slow 
latent responses while certain lytic responses disappear (Hislop, Annels et al. 2002, Woodberry, 
Suscovich et al. 2005).  The strongest individual lytic epitope-specific responses appear to be 
directed towards epitopes that are efficiently presented on the surface of lytically infected cells 
(Pudney, Leese et al. 2005), and the CTL response becomes focused on targets expressed early in 
the lytic cycle (Hislop, Taylor et al. 2007). 
   Interestingly, an 11-mer epitope was defined in each of the EBNA3 proteins with the 
overall distribution of these noncanonical epitopes in antigens BMRF1, EBNA3A, EBNA3B and 
EBNA3C.  The extent of the abundance or prevalence of noncanonical epitopes from antigens of 
interest was determined by combining the overall numbers of novel epitopes of this study with 
defined epitopes from previous studies.  Of the 41 novel epitopes that were defined in this study, 4 
(~10%) were noncanonical 11mers (Chapter 3, Table 2).  Of note, three of these epitopes have a 
proline at the second residue and are recognised by members of the HLA–B7 supertype family 
concurring with previous findings (Burrows, Rossjohn et al. 2006, Burrows, Bell et al. 2008) and 
implicating an association between particular HLA alleles and noncanonical epitopes.  Although 
these noncanonical epitopes may not be overtly abundant they do play a significant role in the 
antiviral CD8+ T cell response.   
The greatest number of epitopes defined in these antigens of interest were from EBNA3A 
which also displayed a degree of epitope clustering and overlapping.  The RBPJκ binding activity 
region and the conserved region of all three EBNA3 proteins from amino acids 90-320 are the 
domains of epitope clustering.  Epitope overlapping was observed between residues 126 and 145 
with four epitopes contained in these 20 amino acids, in addition to residues 170 to 196 and 502 to 
517 of EBNA 3A with 3 epitopes and 2 epitopes overlapping, respectively.  Thus, these regions are 
clearly an important target of the T cell response.   
In this study, the transcription and replication factor, EBNA1 was the antigen with the least 
CD8+ T cell immune responses.  It is likely that this low level of immune recognition by CD8+ T 
cells is due to the GAr region.  Almost the entire N-terminal region of EBNA1 is composed of the 
GAr that protects against degradation by the proteasome (Levitskaya, Shapiro et al. 1997).  Of note, 
the EBNA1 CD8+ T cell epitope 72RPQKRPSCI80 is the only epitope located in the N-terminal half 
of the antigen and prior to the GAr region (Blake, Haigh et al. 2000).  The remaining epitopes, 
including the novel EBNA1 epitope 499DEGTWVAGVF508 from this study, are located in the C-
terminal half of the antigen (Chapter 1, Table 1 and Chapter 3 Table 2).  This concurs with the 
postulation of Capone and colleagues that EBNA1 contains two spatially distinct domains with the 
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N-terminal region hosting an immunotolerance function whilst the C-terminal region plays an 
antigenic role (Capone, Calabro et al. 2013).    
Another possibility is that the weak immune recognition of EBNA1 is due to this antigen 
sharing areas of sequence with a number of self proteins including myelin basic protein (MBP), 
with cross-reactive antibodies described in multiple sclerosis (MS) patients (Bray, Luka et al. 1992), 
and the Ro 60 kDa protein with cross-reactive antibodies described in systemic lupus erythematosus 
(SLE) patients (McClain, Heinlen et al. 2005).  It has recently been reported that EBNA1 shows 
significant peptide sharing with other human proteins.  Almost ninety percent of this peptide 
sharing occurs in the GAr region along the N-terminus of this antigen, supporting the suggestion of 
molecular mimicry by EBNA1 playing a role in immunoevasion (Capone, Calabro et al. 2013).  
Thus, these high levels of sequence sharing between the host and EBNA1 may create a camouflage 
affect for the virus leading to tolerance and ultimately escaping immune recognition.  Although 
current peptide elution/mass spectrometric technology is limited in its ability to detect EBV 
epitopes on LCLs, future studies could endeavour to determine if peptides from these homologous 
regions are presented by LCLs or if indeed these potentially reactive T cells have been removed 
from the repertoire.  This low CD8+ T cell response to EBNA1 may contribute to the immune 
escape of EBV-associated malignancies.   
As many studies have used IM patient samples to find new epitopes, previously defined 
epitopes will differ significantly from our findings as it has been shown that large clonal expansions 
of CD8+ T cells in acute IM do not persist following recovery (Callan, Steven et al. 1996).  Indeed, 
previous work has demonstrated a noticeable shift from lytic to latent antigen-specific responses 
between the acute and chronic stages of EBV infection (Hislop, Annels et al. 2002, Woodberry, 
Suscovich et al. 2005) with some T cell specificities emerging whilst others are lost following 
resolution of IM (Hislop, Annels et al. 2002).  Many of the novel epitopes defined in this study may 
arise from the difference in donor cohorts and account for some of the T cell specificities that 
emerge with long-term carriage of the virus.  Furthermore, the reactivities towards CTL epitopes are 
likely to reflect the donor cohort and may be quite variable between studies depending on the 
individual’s HLA type. Future studies could determine if novel epitopes found in this study elicit an 
immune response with IM samples.   
Thus, this study has shown that epitopes of over 10 amino acids in length account for ~ 10% 
CD8+ T cell epitopes as well as providing a significant list of novel epitopes from a number of 
immunogenic EBV antigens, identified from healthy virus carriers, restricted to various HLA-A, -B 
and -C alleles.  In addition, the limitations of web-based prediction algorithms including HLA 
coverage and epitope length have been highlighted.  Taken together these findings provide further 
understanding of the complex antiviral CTL immunity towards several highly immunogenic EBV 
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antigens and many new epitopes for further study and possible incorporation into peptide-based 
vaccines.    
 
7.3 Determine if the highly immunogenic BZLF1 antigen of EBV includes novel 
CD8+ T cell epitopes  
The expression of BZLF1 in association with BRLF1 plays a critical role in EBV, initiating 
lytic cycle activation (Cox, Leahy et al. 1990).  In addition to the seven highly immunogenic EBV 
antigens that were investigated in Chapter 3, the IE EBV antigen BZLF1 was closely examined in 
Chapter 4.  T cells raised from in vitro stimulation of PBMCs from thirty-six healthy virus carriers 
with their autologous LCLs were screened with the 46 overlapping peptides (20-mers overlapping 
by 15aa) covering the entire length of BZLF1 based on the B95-8 strain of EBV.  This study 
identified 11 novel CD8+ T cell epitopes restricted through a large number of HLA alleles that were 
clustered within certain domains of the protein, with many overlapping sequences. 
Importantly, this plethora of novel CD8+ T cell epitopes are located in this antigen of only 
245 residues, with almost half of these amino acids included in epitopes.  The most significant 
clustering of overlapping epitopes was evident between residues 160 and 220, exquisitely focused 
from residues 188 to 200 with three epitopes that overlap the HLA-B8-restricted 190RAKFKQLL197 
epitope, first identified 20 years ago (Bogedain, Wolf et al. 1995).  As our findings have shown 
190RAKFKQLL197 is located within an epitope cluster region of BZLF1 and is overlapped by the 
novel HLA-B7-restricted 188KCRAKFKQL196, HLA-Cw6-restricted 189CRAKFKQLL197 and HLA-
A30-restricted 192KFKQLLQHY200 epitopes.    
Previous work in healthy virus carriers by Benninger-Doring and colleagues analysed the 
frequency of CD8+ T cells specific for peptides from BZLF1, BRLF1 and EBNA3A, restricted to 
either HLA-A3 or HLA-B8.  Their findings showed that the BZLF1 HLA-B8-restricted 
190RAKFKQLL197 epitope was likely the dominant target for specific CD8+ T cells in all HLA-B8+ 
individuals tested.  Responses to EBNA3A HLA-B8-restricted 325FLRGRAYGL333 epitope were 
significantly lower and only seen in three individuals (Benninger-Doring, Pepperl et al. 1999).  
Future work incorporating tetramer labeling assays could determine if donors expressing HLA-B8 
in conjunction with the HLA alleles restricted by the other cluster epitopes highlighted above (i.e. 
HLA-B8 and HLA-B7 and/or HLA-Cw6) maintain a dominant 190RAKFKQLL197 immune 
response. 
Sequence analysis of 190RAKFKQLL197 -reactive clones from five HLA-B8+ donors showed 
individuals responded with a unique or “private” TRBV repertoire which remained unfocused after 
long-term virus exposure. Importantly, specific CD8+ T cells for this epitope have been shown to be 
present in individuals that undergo primary infection with either EBV type A or type B (Silins, 
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Cross et al. 1997).  Given the strong immune response to this epitope and its conserved sequence in 
both type A and type B virus, 190RAKFKQLL197 should be considered for inclusion in vaccine 
formulations aimed at reducing the viral load following primary EBV infection.  
Luo and colleagues investigated sequence variation in BZLF1 in EBV-associated gastric 
carcinomas and NPC in Northern China and detected 17 mutations and a deletion. Interestingly, 
seven of these mutations and a deletion are located in epitopes.  The most common of these 
mutations (73/89 samples) was the missense mutation at residue 195 resulting in Gln → His (Luo, 
Tang et al. 2011).  This mutation is within the 189CRAKFKQLL197 epitope and our assessment of T 
cell recognition of the variant 189CRAKFKHLL197 indicated that this single sequence polymorphism 
had a significant impact with approximately 10 fold reduction in T cell recognition.  It is of note, 
that this missense mutation is included within the four cluster epitopes restricted by either HLA-
A30, -B7, -B8, or -Cw6.   
This highly immunogenic antigen also appears to play a role in autoimmune disease.  Gross 
et al have shown the aberrant expression of IE EBV antigen, BZLF1 in addition to LMP1 and 
LMP2A in the peripheral blood of SLE patients.  Only a small fraction of cells expressed BZLF1, 
however, expression of BZLF1 has never been detected in the blood of healthy controls (Gross, 
Hochberg et al. 2005).  Future work could delve into the immune responses of autoimmune disease 
patients and identify if there is a pronounced immune response to BZLF1 epitopes or if indeed the 
opposite is the case and sufferers of autoimmune conditions show a significantly decreased CD8+ T 
cell response to this antigen.  The present study has significantly expanded knowledge of the 
immune response to BZLF1 adding to the current pool of CD8+ T cell epitopes that can be utilised 
in vaccine development and adoptive immunotherapy. 
 
7.4 Determine if the peptide length preferences of class I human leukocyte 
antigens influence epitope selection in the EBV-specific T cell response 
Fundamental to adaptive immunity, the HLA genes represent the greatest polymorphic 
region in the human genome culminating within the peptide-binding groove (Sette and Sidney 
1998).  This polymorphism gives rise to HLA molecules from different haplotypes with the ability 
to present an array of both self and microbial derived peptides (Doherty and Zinkernagel 1975).  
The amino acids accommodated within the six peptide-binding pockets, A to F, are distinct and 
determine the specificity of the peptide-HLA class I interaction (Clements, Dunstone et al. 2006).  
Generally HLA alleles have a preference for one or two amino acids at certain positions within the 
peptide.  Based on this, peptide-binding motifs have been identified, designating primary anchors, 
with the greatest effect on binding and to a lesser extent on auxiliary or secondary anchors.  In 
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many instances several HLA alleles share common motifs in addition to structure and are classified 
into groups or HLA supertypes accordingly (Doytchinova, Guan et al. 2004).   
One such group is the HLA-B*44 supertype consisting of some of the most common HLA 
alleles (Cao, Hollenbach et al. 2001), including HLA-B*1801 and HLA-B*4403 which share a 
preference for peptides with Glutamic Acid (E) at position 2 and Phenylalanine (F) or Tyrosine (Y) 
at the C terminus (Sidney, Southwood et al. 2003, Hillen, Mester et al. 2008).  In addition to the 11 
CD8+ T cell epitopes identified in the EBV IE BZLF1 antigen and described in Chapter 4, Chapter 
5 focuses on a further two novel overlapping peptides from this antigen of different size that both 
conform to the HLA-B*44 supertype binding motif.  These peptides are, the HLA-B*1801-
restricted octamer 173SELEIKRY180 and the HLA-B*4403-restricted noncanonical dodecamer 
169EECDSELEIKRY180, which encompasses the octamer peptide.  
Previous work of Hillen and colleagues has shown different length variants in the HLA-
B*44 supertype with the nonamer AEFKEAFQL presented by HLA-B*4001 and the decamer 
AEFKEAFQLF presented by HLA-B*4402 (Hillen, Mester et al. 2008).  Also described in their 
study was the peptide SEIEAKVRY from the TLN1 gene that encodes a cytoskeletal protein 
concentrated in areas of cell-substratum and cell to cell contacts. This peptide is presented by HLA-
B*4402 (Hillen, Mester et al. 2008) and shows striking sequence homology to the HLA-B*1801-
restricted SELEIKRY EBV epitope.  It would be interesting to determine whether the SEIEAKVRY 
peptide is also recognised by HLA-B*1801-restricted T cells reactive with the octamer EBV 
peptide.  As it has been proposed that a peptide that binds to one member of a HLA supertype could 
be capable of binding to other members of that supertype (Sidney, Southwood et al. 2003) it would 
be intriguing to assess whether healthy virus carriers with the remaining HLA allotypes of the 
HLA-B*44 supertype HLA-B37, -B40, -B41, -B45, -B47, -B49 or -B50 recognise either 
EECDSELEIKRY or SELEIKRY. 
To establish an explanation for the variable peptide length preferences of these HLA-B*44 
supertype molecules, crystal structures were solved for the viral peptide-HLA complexes.  This 
revealed that the antigen-binding cleft of HLA-B*1801 was clearly suited to bind shorter length 
peptides, whilst HLA-B*4403 was more suited to presenting longer peptides with a bulged 
conformation.  It is predicted that binding of HLA-B*4403 to SELEIKRY is likely to lead to steric 
clashes as the peptide would be forced to sit flat in the binding cleft and the depth of the HLA-
B*4403 is shallow compared to the depth of the central region of HLA-B*1801.  Differences have 
been observed in the antigen presentation pathway and structure between members of the HLA-
B*44 supertype.  HLA-B*4402 and HLA-B*4405, which differ by a single residue alteration at 
position 116 (Asp→Tyr) were shown to present unique peptides as a result of the change in the F 
pocket of the binding cleft (Zernich, Purcell et al. 2004).  Although this work gives no indication as 
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to peptide length preference of these HLA alleles, another study into HLA-B*4402 has shown this 
allele to have an intolerance for presenting 8 aa peptides (Hillen, Mester et al. 2008) in concordance 
with HLA-B*4403.                
Thermal stability analysis provided further proof of the epitope selection differences 
between HLA-B*1801 and HLA-B*4403.  Data for each of the HLA-peptide complexes indicated 
an observable preference for HLA-B*1801 and the shorter peptide SELEIKRY and HLA-B*4403 
and the longer peptide EECDSELEIKRY.  Most notable was the instability of the HLA-B*4403-
SELEIKRY complex.  Furthermore, mass spectrometry data confirmed these findings showing the 
natural ligands of cells expressing HLA-B*1801 or HLA-B*4403. Results showed 18% of peptides 
presented by HLA-B*1801 were octamers compared to 0.8% eluted off HLA-B*4403.  In contrast, 
longer length peptides > 10aa were dominantly presented by HLA-B*4403 with 18.5% compared to 
2.3% by HLA-B*1801.   
Our work has recently been cited by Motozono and colleagues whose findings also portray 
overlapping peptides eliciting CTL responses.  Their study investigating the highly immunogenic 
viral protein, HIV-1 Nef demonstrates overlapping peptides of different lengths (8mer, 9mer and 
11mer) presented by the same HLA-molecule, HLA-B*3501 (Motozono, Yokoyama et al. 2014).  It 
was shown that the TCR reactivity toward these peptide length variants was either mutually 
exclusive toward the 11mer or the 8mer or cross-reactive toward the 9mer and 11mer.  Of note, the 
8mer VY8 (VPLRPMTY) is a dominant epitope in the early phase of HIV-1 infection, while the 
overlapping 11mer RY11 (RPQVPLRPMTY) becomes the dominant epitope in the chronic phase 
(Ueno, Idegami et al. 2007).  Interestingly, the presenting allele, HLA-B*3501, a member of the 
HLA-B7 supertype, has previously been associated with recognition of noncanonical 11mer 
epitopes (Burrows, Rossjohn et al. 2006, Bell, Brennan et al. 2008) making this allele an ideal 
candidate for future studies into peptide length preferences.    
To our knowledge the present report is the first to show peptide length preference among 
MHC molecules and provide a structural mechanism for the phenomenon.  Future work needs to 
expand on this knowledge and study other class I MHC molecules to determine peptide length 
preferences and enhance the quality of predictive algorithms ensuring more accurate peptide 
prediction tools.  
 
7.5 T cell cross-reactivity between an EBV epitope and an abundant self-peptide 
presented by HLA-B*1801+ cells 
The fourth aim of characterising a cross-reactive T cell response to an HLA-B*1801-
restricted epitope, derived from the BZLF1 antigen of EBV (SELEIKRY) and an HLA-B*1801-
bound self-peptide, from the cleavage and polyadenylation specific factor 3-like protein 
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(DELEIKAY) was addressed in Chapter 6.  This study has provided support for a molecular 
mimicry mechanism in autoimmunity by showing that EBV-reactive CD8+ T cell expansions can be 
identified in healthy HLA-B*1801+ individuals that can cross-react with a naturally presented self-
peptide.   
  Thymic clonal deletion is the most efficient mechanism for the removal of clones that have a 
high affinity for self antigens, although this process cannot eliminate all self-reactive lymphocytes 
(Hogquist, Baldwin et al. 2005).  Recently it has been suggested that a crippling of the CD8+ T cell 
repertoire and domination by T cells with a high affinity to self antigens can result from interference 
in antigen processing in the cortical thymic epithelial cell-specific pathway that diversifies the T 
cell repertoire (Klein, Kyewski et al. 2014).  Another recent study has shown that mechanisms exist 
that allow T cells with low affinity for self ligands to avoid clonal deletion and apoptosis (Hogquist 
and Jameson 2014).  It has also been suggested that nonstimulatory self peptide-MHC complexes 
may assist the reactivity of T cells to foreign peptide-MHC antigen (Krogsgaard, Juang et al. 2007).   
Klein and colleagues postulate the beneficial aspects of having T cells with a range of both 
high and low affinities for self antigens and the role these may play in the response to infection with 
pathogens.  T cells with high affinity for self may provide initial, rapid response whilst T cells with 
low self affinity maintain a sustained response (Klein, Kyewski et al. 2014).  These studies were 
undertaken using transgenic mice and it remains to be determined how these observations correlate 
with the adaptive immune response in humans. Interestingly, the three HLA-B*1801+ donors with 
cross-reactive CD8+ T cells to both the EBV SEL epitope and the self-peptide DEL are also the 
donors that displayed the strongest CTL responses to the SEL epitope.  TCR repertoire analysis of 
the cross-reactive T cells depicted a polyclonal population of T cells from all three donors as many 
different Vβ genes were expressed by these subsets of T cells.    
Molecular mimicry is the mechanism by which it is hypothesized that an immune response 
by the host mounted against a specific determinant of an infectious microbial agent may cross-react 
with a mimicked self sequence and lead to autoimmunity and/or disease (Oldstone 1987).  T cell 
cross-reactivity to viral antigens of EBV and self-antigens has been shown for autoimmune diseases 
including multiple sclerosis (MS), systemic lupus erythematosus (SLE) and rheumatoid arthritis 
(RA) (Niller, Wolf et al. 2008).  Cross-reactivity has been shown previously between peptides from 
EBV antigen BALF5 (627-641) and MBP (85-99).  Although these peptides have different 
sequences, there are structural similarities and these peptides are recognised by the same TCR.  
Interestingly, recognition is through two different MHC class II alleles, HLA-DRB1*1501 (the 
strongest genetic risk to MS) presenting the MBP peptide and HLA-DRB5*0101 the BALF5 
peptide (Lang, Jacobsen et al. 2002).  Structural similarities of charge and overall shape between 
SEL and DEL indicate that molecular mimicry is the underlying mechanism for the observed cross-
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reactivity. Crystal structures revealed that HLA-B*1801 in complex with the EBV epitope was a 
structural mimic of the self-peptide.  
Malissen and colleagues first identified in clones originating from a B10.A mouse, dual 
reactivity resulting from the cross-reactive recognition of an allogeneic MHC product by a self 
MHC-restricted αβ TCR (Malissen, Trucy et al. 1988).  Transgenic mice studies have demonstrated 
that low-avidity CD8+ T cells are largely spared from elimination by central and peripheral 
tolerance mechanisms.  These low-avidity self-reactive CD8+ T cells were shown to have the ability 
to make IFN-γ following brief in vitro restimulation with high concentrations of peptide and be 
mediators of autoimmunity in the system (Zehn and Bevan 2006).  This study correlates with our 
findings that the self-peptide DEL was recognised by cross-reactive CD8+ T cells albeit requiring a 
higher concentration than the EBV SEL epitope.  Further studies have shown that challenge with 
lymphocytic choriomeningitis virus (LCMV) following insertion of the LCMV NP (nucleoprotein) 
or GP (glycoprotein) genes in the germline of transgenic mice leads to the generation of an antiviral 
response that is anti-self, leading to Insulin-dependent diabetes mellitus (IDDM) (Oldstone, 
Nerenberg et al. 1991). 
It has been suggested that the autoimmune disease IDDM might be the culmination of a 
series of inflammatory “hits”, that affect particular areas of the pancreas in a relapsing-remitting 
cycle, and viruses, including Herpesviridae, may play a role in this (Schneider and von Herrath 
2013).   IDDM has been associated with host genes, autoimmune responses and environmental 
triggers including viral infection with  coxsackie virus B (Bach 2002) and cytomegalovirus (Richer 
and Horwitz 2008).  In addition, viruses that induce cross-reactivity and/or molecular mimicry are 
likely to be involved in the induction of autoimmunity which may ultimately end in autoimmune 
disease e.g. IDDM (Schneider and von Herrath 2014).  It is reasonable to propose, therefore, that 
these EBV/self cross-reactive T cell populations identified in this study may potentially play a role 
in autoimmune disease associated with HLA-B*1801 such as type 1 diabetes (Nejentsev, Howson et 
al. 2007).   
 
7.6 Conclusions 
This thesis reports the comprehensive study of eight highly immunogenic EBV antigens to 
assess the adaptive immune response to this virus.  Aim one (Chapter 3) focused on the relative 
prevalence of peptide epitopes of over 10 amino acids in length in CD8+ T cell recognition of EBV.  
The hypothesis was that indeed peptide epitopes of over 10 amino acids in length are abundant in 
antiviral CD8+ T cell responses.  What has been determined is that there are various factors which 
influence epitope selection including the virus’s interaction with the host and the role that each 
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antigen plays in that.  Five noncanonical epitopes were identified and shown to account for ~10% of 
CD8+ T cell epitopes.  This study has also provided an expansive list of novel EBV CTL epitopes, 
demonstrating a hierarchy of immunodominance between the EBV antigens, as well as highly 
immunogenic regions within several of the antigens including epitope clustering.  The relative 
immunodominance hierarchy (with the exclusion of BZLF1), based on the identification of 28 latent 
and 13 lytic epitopes, including four noncanonical epitopes, was EBNA3A, EBNA3C, EBNA3B, 
BRLF1, BMLF1, BMRF1 and lastly EBNA1.  The limited number of CD8+ T cell epitopes 
identified in EBNA1 is likely a result of the GAr region and the immunoevasion quality this 
presents.   
The focus of the second aim was the detailed investigation of the IE EBV antigen BZLF1 
identified 11 novel CD8+ T cell epitopes, many presented by common HLA alleles (Chapter 4).  
Interestingly, these epitopes have a clustered distribution along the length of this highly 
immunogenic antigen, with many overlapping sequences.  As BZLF1 has shown itself to elicit a 
strong CD8+ T cell response in many individuals, this antigen would make an ideal candidate in the 
development of an EBV vaccine.  Although it is unlikely that any EBV vaccine would provide 
prevention from primary infection, a more realistic approach may focus on a reduction in viral load, 
which could in turn reduce the incidence of IM, Hodgkin’s lymphoma, PTLD and possibly other 
EBV-associated malignancies.  For immunotherapeutic purposes the EBV-BZLF1 peptide pool may 
be a potential candidate as it is available commercially in GMP-grade and we have shown that this 
diminutive antigen is highly immunogenic and induces immune responses through a wide range of 
HLA alleles.  Thus, these results can be widely used in future studies focused on manipulating the 
immune system and targeting EBV and its associated diseases.   
The third objective (Chapter 5) was to determine if the peptide length preference of class I 
HLA influences epitope selection in the EBV-specific T cell response.  In addition to the 11 novel 
BZLF1 CD8+ T cell epitopes identified in Chapter 4, a further two novel epitopes were identified, 
the HLA-B*1801-restricted octamer 173SELEIKRY180 and the HLA-B*4403-restricted 
noncanonical dodecamer 169EECDSELEIKRY180, which encompasses the octamer epitope.  The 
common alleles HLA-B*1801 and HLA-B*4403 are members of the HLA-B*44 supertype which 
share a preference for peptides with Glu at position 2 and Phe or Tyr at the C terminus (Sidney, 
Southwood et al. 2003, Hillen, Mester et al. 2008).  Findings of this study indicate that class I MHC 
polymorphism influences not only amino acid preferences at certain positions within the peptide, 
but in addition, a preference for particular lengths of presented peptides.  Structural studies of these 
viral pMHC complexes depict the binding clefts of these two HLA-B*44 supertype members 
favouring peptides of different lengths.  This was evident with the more “shallow” groove of HLA-
B*4403 leading to steric clashes with octamer peptides, whilst the deep groove of HLA-B*1801 is 
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perfectly suited to these shorter epitopes.  The peptide length preference was further confirmed with 
the results of mass spectrometry analysis showing a bias of HLA-B*1801 presenting peptides <10 
aa, whereas HLA-B*4403 more frequently presented peptides >10 aa.   In summary, this study 
highlights a novel mechanism through which MHC class I polymorphism can diversify the immune 
response, influencing epitope selection in an antigen specific T cell response.  Future studies in this 
area are required to determine the peptide length preference of other HLA alleles which may be 
used to improve web-based algorithms for epitope prediction, in addition to assisting strategies for 
peptide-based vaccine design.  
The final objective was to characterise a cross-reactive T cell response to an HLA-B*1801-
bound EBV epitope and a self-peptide (Chapter 6).  The hypothesis was that some healthy 
individuals carry T cells that cross-react with these two closely related peptides and that the T cell 
receptor repertoire that cross-reacts with an EBV epitope and a self-peptide is similar between 
individuals.  The data confirmed that a significant minority of individuals carry T cells that can 
cross-recognise the viral and self-peptide but unexpectedly, a diverse array of T cell receptors was 
expressed by these cross-reactive T cells.  11 HLA-B*1801+ healthy virus carriers were screened 
for cross-reactive responses to the HLA-B*1801-restricted epitope, SEL and HLA-B*1801-
restricted self-peptide, DEL, and interestingly, only 3 of these individuals were shown to elicit a 
CTL immune response to both SEL and DEL (all donors recognised SEL).  The self-peptide DEL 
has been shown to share substantial sequence and structural homology with the HLA-B*1801-
bound EBV peptide.  The self-peptide was only recognised in vitro at relatively high concentrations, 
which explains how these auto-reactive T cells have evaded tolerance.  To our knowledge, this 
report is the first showing the natural presentation on human cells of a self-peptide cross-recognized 
by EBV-reactive CD8+ T cells and presented by a self-HLA antigen.  In future studies it will be 
important to establish if this cross-reactive T cell population plays a role in patients with IDDM, 
given the association of HLA-B*1801 with this autoimmune disease (Nejentsev, Howson et al. 
2007).        
It has been proposed that a peptide that binds to one member of a HLA supertype should, 
reasonably be capable of binding to other members of that supertype (Sidney, Southwood et al. 
2003), and therefore epitopes that fit into this category would make ideal vaccine and/ or 
immunotherapy candidates.  A number of epitopes that are presented by more than one HLA 
antigen have been identified in this study including BRLF1 101IACPIVMRY109 presented by HLA-
A*24 and HLA-A*29, members of the HLA-A*24 supertype, and BMRF1 286LPLDLSVI/LF295 
presented by HLA-B*35 and HLA-B*53, members of the HLA-B*07 supertype, and BZLF1 
209SENDRLRLL217 presented by the HLA-B*44 supertype members HLA-B*60 and HLA-B*49.  
This study has contributed a significant list of novel CD8+ T cell EBV epitopes as well as 
 129 
 
 
highlighting a novel mechanism through which MHC class I polymorphism can further diversify 
immune responses.  Together the findings of this study will impact EBV vaccine and 
immunotherapy development, improve web-based algorithms for epitope prediction, and highlights 
a potential mechanism by which EBV infection could trigger autoimmune disease.     
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Supplementary Data 
Chapter 5: 
 
Aim Three: 
Determine if the peptide length preferences of class I human leukocyte antigens influence epitope 
selection in the EBV-specific T cell response. 
 
Hypothesis Three: 
Different class I human leukocyte antigens have distinct peptide length preferences, and this 
influences epitope selection in the EBV-specific T cell response. 
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